AVR_I_SSAP_ID,Entry_type,Peptide_name,Sequence,Length,Source,Source_organism,Taxonomy,Validation,Target_organism,Inhibition_concentration,Toxicity_&_hemolytic_activity,PubMed_ID,PDB_ID,UniProt_ID,DrugBank_ID
AVR/I/SSAP1,Clinical,Melittin,GIGAVLKVLTTGLPALISWIKRKRQQ,26,Bee venom,Apis mellifera,Animalia (Insect),Experimentally validated,VISA-9 (clinical isolate collected from burn wound infections),MIC = 2 microM,High toxicity to erythrocytes and other human cells,"34087287, 34360692","3QRX_B, 1BH1_A","P68407, P01501, Q8LW54",DB10955
AVR/I/SSAP2,Clinical,Magainin-2,GIGKFLHSAKKFGKAFVGEIMNS,23,Not available,Xenopus laevis,Animalia (Frog),Experimentally validated,"VISA-8 (clinical specimen from the Institute of Infectious Diseases and Public Health, Polytechnic University of Marche, Ancona, Italy)",MIC = 16 microG/ML,Not available,"16797106, 34360692","2LSA_A, 2MAG_A","C0HKN6, P11006",Not available
AVR/I/SSAP3,Clinical,Temporin-CPa,IPPFIKKVLTTVF,13,Not available,Lithobates capito,Animalia (Frog),Experimentally validated,VISA-28 (clinical strain),MIC => 25 microM,Hemolysis of human erythrocytes at high concentrations,"29842923, 34360692",Not available,Not available,Not available
AVR/I/SSAP4,Clinical,Temporin-CPb,FLPIVGRLISGIL,13,Not available,Lithobates capito,Animalia (Frog),Experimentally validated,VISA-28 (clinical strain),MIC = 12.5 microM,Hemolysis of human erythrocytes at high concentrations,"29842923, 34360692",Not available,Not available,Not available
AVR/I/SSAP5,Clinical,Temporin-1Ga,SILPTIVSFLSKVF,14,Not available,Rana grylio,Animalia (Frog),Experimentally validated,VISA-28 (clinical strain),MIC = 6.2 microM,Strong hemolytic effect on human erythrocytes,"29842923, 34360692",Not available,Not available,Not available
AVR/I/SSAP6,Clinical,Temporin-1OLa,FLPFLKSILGKIL,13,Not available,Rana okaloosae,Animalia (Frog),Experimentally validated,VISA-28 (clinical strain),MIC = 3.1 microM,Strong hemolytic effect on human erythrocytes,"29842923, 34360692",Not available,Not available,Not available
AVR/I/SSAP7,Clinical,Temporin-1SPa,FLSAITSILGKIL,13,Not available,Rana septentrionalis,Animalia (Frog),Experimentally validated,VISA-28 (clinical strain),MIC = 12.5 microM,Moderate hemolytic effect on human erythrocytes,"29842923, 34360692",Not available,Not available,Not available
AVR/I/SSAP8,Clinical,Temporin-1Oc,FLPLLASLFRLF,12,Not available,Rana ornativentris,Animalia (Frog),Experimentally validated,VISA-28 (clinical strain),MIC = 1.6 microM,Strong hemolytic effect on human erythrocytes,"29842923, 34360692",Not available,Not available,Not available
AVR/I/SSAP9,Clinical,WR12,RWWRWWRRWWRR,12,Not available,Synthetic peptide,Not available,Experimentally validated,VRSA-6 (clinical isolate of multi-drug resistant S. aureus were provided by Network of Antimicrobial Resistance in Staphylococcus aureus (NARSA) program supported under NIAID/NIH Contract # HHSN272200700055C),MIC = 4 microM,Not available,"27405275, 34360692",Not available,Not available,Not available
AVR/I/SSAP10,Clinical,WR12,RWWRWWRRWWRR,12,Not available,Synthetic peptide,Not available,Experimentally validated,VRSA-7 (clinical isolate of multi-drug resistant S. aureus were provided by Network of Antimicrobial Resistance in Staphylococcus aureus (NARSA) program supported under NIAID/NIH Contract # HHSN272200700055C),MIC = 8 microM,Not available,"27405275, 34360692",Not available,Not available,Not available
AVR/I/SSAP11,Clinical,WR12,RWWRWWRRWWRR,12,Not available,Synthetic peptide,Not available,Experimentally validated,VRSA-8 (clinical isolate of multi-drug resistant S. aureus were provided by Network of Antimicrobial Resistance in Staphylococcus aureus (NARSA) program supported under NIAID/NIH Contract # HHSN272200700055C),MIC = 8 microM,Not available,"27405275, 34360692",Not available,Not available,Not available
AVR/I/SSAP12,Clinical,WR12,RWWRWWRRWWRR,12,Not available,Synthetic peptide,Not available,Experimentally validated,VRSA-9 (clinical isolate of multi-drug resistant S. aureus were provided by Network of Antimicrobial Resistance in Staphylococcus aureus (NARSA) program supported under NIAID/NIH Contract # HHSN272200700055C),MIC = 4 microM,Not available,"27405275, 34360692",Not available,Not available,Not available
AVR/I/SSAP13,Clinical,WR12,RWWRWWRRWWRR,12,Not available,Synthetic peptide,Not available,Experimentally validated,VRSA-10 (clinical isolate of multi-drug resistant S. aureus were provided by Network of Antimicrobial Resistance in Staphylococcus aureus (NARSA) program supported under NIAID/NIH Contract # HHSN272200700055C),MIC = 4 microM,Not available,"27405275, 34360692",Not available,Not available,Not available
AVR/I/SSAP14,Clinical,WR12,RWWRWWRRWWRR,12,Not available,Synthetic peptide,Not available,Experimentally validated,VRSA-11 (clinical isolate of multi-drug resistant S. aureus were provided by Network of Antimicrobial Resistance in Staphylococcus aureus (NARSA) program supported under NIAID/NIH Contract # HHSN272200700055C),MIC = 8 microM,Not available,"27405275, 34360692",Not available,Not available,Not available
AVR/I/SSAP15,Clinical,WR12,RWWRWWRRWWRR,12,Not available,Synthetic peptide,Not available,Experimentally validated,VRSA-12 (clinical isolate of multi-drug resistant S. aureus were provided by Network of Antimicrobial Resistance in Staphylococcus aureus (NARSA) program supported under NIAID/NIH Contract # HHSN272200700055C),MIC = 4 microM,Not available,"27405275, 34360692",Not available,Not available,Not available
AVR/I/SSAP16,Clinical,WR12,RWWRWWRRWWRR,12,Not available,Synthetic peptide,Not available,Experimentally validated,VISA-4 (clinical isolate of multi-drug resistant S. aureus were provided by Network of Antimicrobial Resistance in Staphylococcus aureus (NARSA) program supported under NIAID/NIH Contract # HHSN272200700055C),MIC = 1 microM,Not available,"27405275, 34360692",Not available,Not available,Not available
AVR/I/SSAP17,Clinical,WR12,RWWRWWRRWWRR,12,Not available,Synthetic peptide,Not available,Experimentally validated,VISA-5 (clinical isolate of multi-drug resistant S. aureus were provided by Network of Antimicrobial Resistance in Staphylococcus aureus (NARSA) program supported under NIAID/NIH Contract # HHSN272200700055C),MIC = 1 microM,Not available,"27405275, 34360692",Not available,Not available,Not available
AVR/I/SSAP18,Clinical,WR12,RWWRWWRRWWRR,12,Not available,Synthetic peptide,Not available,Experimentally validated,VISA-6 (clinical isolate of multi-drug resistant S. aureus were provided by Network of Antimicrobial Resistance in Staphylococcus aureus (NARSA) program supported under NIAID/NIH Contract # HHSN272200700055C),MIC = 1 microM,Not available,"27405275, 34360692",Not available,Not available,Not available
AVR/I/SSAP19,Clinical,DIK-8,IRIKIRIK,8,Not available,Synthetic peptide,Not available,Experimentally validated,VRSA-6 (clinical isolate of multi-drug resistant S. aureus were provided by Network of Antimicrobial Resistance in Staphylococcus aureus (NARSA) program supported under NIAID/NIH Contract # HHSN272200700055C),MIC = 8 microM,Not available,"27405275, 34360692",Not available,Not available,Not available
AVR/I/SSAP20,Clinical,DIK-8,IRIKIRIK,8,Not available,Synthetic peptide,Not available,Experimentally validated,VRSA-7 (clinical isolate of multi-drug resistant S. aureus were provided by Network of Antimicrobial Resistance in Staphylococcus aureus (NARSA) program supported under NIAID/NIH Contract # HHSN272200700055C),MIC = 16 microM,Not available,"27405275, 34360692",Not available,Not available,Not available
AVR/I/SSAP21,Clinical,DIK-8,IRIKIRIK,8,Not available,Synthetic peptide,Not available,Experimentally validated,VRSA-8 (clinical isolate of multi-drug resistant S. aureus were provided by Network of Antimicrobial Resistance in Staphylococcus aureus (NARSA) program supported under NIAID/NIH Contract # HHSN272200700055C),MIC = 16 microM,Not available,"27405275, 34360692",Not available,Not available,Not available
AVR/I/SSAP22,Clinical,DIK-8,IRIKIRIK,8,Not available,Synthetic peptide,Not available,Experimentally validated,VRSA-9 (clinical isolate of multi-drug resistant S. aureus were provided by Network of Antimicrobial Resistance in Staphylococcus aureus (NARSA) program supported under NIAID/NIH Contract # HHSN272200700055C),MIC = 16 microM,Not available,"27405275, 34360692",Not available,Not available,Not available
AVR/I/SSAP23,Clinical,DIK-8,IRIKIRIK,8,Not available,Synthetic peptide,Not available,Experimentally validated,VRSA-10 (clinical isolate of multi-drug resistant S. aureus were provided by Network of Antimicrobial Resistance in Staphylococcus aureus (NARSA) program supported under NIAID/NIH Contract # HHSN272200700055C),MIC = 16 microM,Not available,"27405275, 34360692",Not available,Not available,Not available
AVR/I/SSAP24,Clinical,DIK-8,IRIKIRIK,8,Not available,Synthetic peptide,Not available,Experimentally validated,VRSA-11 (clinical isolate of multi-drug resistant S. aureus were provided by Network of Antimicrobial Resistance in Staphylococcus aureus (NARSA) program supported under NIAID/NIH Contract # HHSN272200700055C),MIC = 16 microM,Not available,"27405275, 34360692",Not available,Not available,Not available
AVR/I/SSAP25,Clinical,DIK-8,IRIKIRIK,8,Not available,Synthetic peptide,Not available,Experimentally validated,VRSA-12 (clinical isolate of multi-drug resistant S. aureus were provided by Network of Antimicrobial Resistance in Staphylococcus aureus (NARSA) program supported under NIAID/NIH Contract # HHSN272200700055C),MIC = 16 microM,Not available,"27405275, 34360692",Not available,Not available,Not available
AVR/I/SSAP26,Clinical,DIK-8,IRIKIRIK,8,Not available,Synthetic peptide,Not available,Experimentally validated,VISA-4 (clinical isolate of multi-drug resistant S. aureus were provided by Network of Antimicrobial Resistance in Staphylococcus aureus (NARSA) program supported under NIAID/NIH Contract # HHSN272200700055C),MIC = 8 microM,Not available,"27405275, 34360692",Not available,Not available,Not available
AVR/I/SSAP27,Clinical,DIK-8,IRIKIRIK,8,Not available,Synthetic peptide,Not available,Experimentally validated,VISA-5 (clinical isolate of multi-drug resistant S. aureus were provided by Network of Antimicrobial Resistance in Staphylococcus aureus (NARSA) program supported under NIAID/NIH Contract # HHSN272200700055C),MIC = 8 microM,Not available,"27405275, 34360692",Not available,Not available,Not available
AVR/I/SSAP28,Clinical,DIK-8,IRIKIRIK,8,Not available,Synthetic peptide,Not available,Experimentally validated,VISA-6 (clinical isolate of multi-drug resistant S. aureus were provided by Network of Antimicrobial Resistance in Staphylococcus aureus (NARSA) program supported under NIAID/NIH Contract # HHSN272200700055C),MIC = 8 microM,Not available,"27405275, 34360692",Not available,Not available,Not available
AVR/I/SSAP29,Clinical,Fl-PRPRPL-5,FLPRPRPLPQ,10,Not available,Synthetic peptide,Not available,Experimentally validated,VRSA 5 (clinical isolate),"MIC = 16 microM, MBC = 16 microM",Not available,26543355,Not available,Not available,Not available
AVR/I/SSAP30,Clinical,Mersacidin,A-Abu-I-Abu-L-P-C-G-G-G-V-A-Abu-L-Abu-Dha-E-A-I,15,Not available,"Bacillus sp. strain HIL Y-85, 54728",Bacteria,Experimentally validated,VISA strain SA137/93A (clinical isolate),MIC = 35 microG/ML,Not available,18947397,Not available,Not available,Not available
AVR/I/SSAP31,Clinical,Mersacidin,A-Abu-I-Abu-L-P-C-G-G-G-V-A-Abu-L-Abu-Dha-E-A-I,15,Not available,"Bacillus sp. strain HIL Y-85, 54729",Bacteria,Experimentally validated,VISA strain SA137/ 93G (clinical isolate),MIC = 30 microG/ML,Not available,18947397,Not available,Not available,Not available
AVR/I/SSAP32,Clinical,Lipopeptide 1,Cyclo(-D-Leu-D-Leu-D-Tyr-D-Phe-D-Ser-D-Thr-),6,Not available,Synthetic peptide,Not available,Experimentally validated,VRSA (NARSA VRS 4) (clinical isolate from the University of Queensland Centre for Clinical Research (UQCCR)),MIC = 0.5 microM,Not available,27048775,Not available,Not available,Not available
AVR/I/SSAP33,Clinical,Lipopeptide 1,Cyclo(-D-Leu-D-Leu-D-Tyr-D-Phe-D-Ser-D-Thr-),6,Not available,Synthetic peptide,Not available,Experimentally validated,VRSA (NARSA VRS 1) (clinical isolate from the University of Queensland Centre for Clinical Research (UQCCR)),MIC = 0.7 microM,Not available,27048775,Not available,Not available,Not available
AVR/I/SSAP34,Clinical,Lipopeptide 1,Cyclo(-D-Leu-D-Leu-D-Tyr-D-Phe-D-Ser-D-Thr-),6,Not available,Synthetic peptide,Not available,Experimentally validated,VRSA (NARSA VRS 10) (clinical isolate from the University of Queensland Centre for Clinical Research (UQCCR)),MIC = 0.9 microM,Not available,27048775,Not available,Not available,Not available
AVR/I/SSAP35,Clinical,Lipopeptide 2,Cyclo(LLYFSTD),6,Not available,Synthetic peptide,Not available,Experimentally validated,VRSA (NARSA VRS 4) (clinical isolate from the University of Queensland Centre for Clinical Research (UQCCR)),MIC = 2.8 microM,Lipopeptide 2 showed no cytotoxic activity at concentrations up to 15microM against HEK293 and HepG2 cell lines and did not induce significant hemolysis even at 100microM.,27048775,Not available,Not available,Not available
AVR/I/SSAP36,Clinical,Lipopeptide 2,Cyclo(LLYFSTD),6,Not available,Synthetic peptide,Not available,Experimentally validated,VRSA (NARSA VRS 1) (clinical isolate from the University of Queensland Centre for Clinical Research (UQCCR)),MIC = 1.9 microM,Lipopeptide 2 showed no cytotoxic activity at concentrations up to 15microM against HEK293 and HepG2 cell lines and did not induce significant hemolysis even at 100microM.,27048775,Not available,Not available,Not available
AVR/I/SSAP37,Clinical,Lipopeptide 2,Cyclo(LLYFSTD),6,Not available,Synthetic peptide,Not available,Experimentally validated,VRSA (NARSA VRS 10) (clinical isolate from the University of Queensland Centre for Clinical Research (UQCCR)),MIC = 2.8 microM,Lipopeptide 2 showed no cytotoxic activity at concentrations up to 15microM against HEK293 and HepG2 cell lines and did not induce significant hemolysis even at 100microM.,27048775,Not available,Not available,Not available
AVR/I/SSAP38,Clinical,Lipopeptide 3,Cyclo(-D-Phe-D-Leu-D-Phe-D-Leu-),4,Not available,Synthetic peptide,Not available,Experimentally validated,VRSA (NARSA VRS 4) (clinical isolate from the University of Queensland Centre for Clinical Research (UQCCR)),MIC = 30 microM,Lipopeptides 3 did not exhibit cytotoxic activity at concentrations up to 15 microM against the tested mammalian cell lines (HEK293 and HepG2) and did not induce significant hemolytic effects even at high concentrations of 100 microM.,27048775,Not available,Not available,Not available
AVR/I/SSAP39,Clinical,Lipopeptide 3,Cyclo(-D-Phe-D-Leu-D-Phe-D-Leu-),4,Not available,Synthetic peptide,Not available,Experimentally validated,VRSA (NARSA VRS 1) (clinical isolate from the University of Queensland Centre for Clinical Research (UQCCR)),MIC = 30 microM,Lipopeptides 3 did not exhibit cytotoxic activity at concentrations up to 15 microM against the tested mammalian cell lines (HEK293 and HepG2) and did not induce significant hemolytic effects even at high concentrations of 100 microM.,27048775,Not available,Not available,Not available
AVR/I/SSAP40,Clinical,Lipopeptide 3,Cyclo(-D-Phe-D-Leu-D-Phe-D-Leu-),4,Not available,Synthetic peptide,Not available,Experimentally validated,VRSA (NARSA VRS 10) (clinical isolate from the University of Queensland Centre for Clinical Research (UQCCR)),MIC = 30 microM,Lipopeptides 3 did not exhibit cytotoxic activity at concentrations up to 15 microM against the tested mammalian cell lines (HEK293 and HepG2) and did not induce significant hemolytic effects even at high concentrations of 100 microM.,27048775,Not available,Not available,Not available
AVR/I/SSAP41,Clinical,Lipopeptide 4,Cyclo(-D-Phe-D-Val-L-Thr-D-Leu-),4,Not available,Synthetic peptide,Not available,Experimentally validated,VRSA (NARSA VRS 4) (clinical isolate from the University of Queensland Centre for Clinical Research (UQCCR)),MIC = 30 microM,Lipopeptides 4 did not exhibit cytotoxic activity at concentrations up to 15 microM against the tested mammalian cell lines (HEK293 and HepG2) and did not induce significant hemolytic effects even at high concentrations of 100 microM.,27048775,Not available,Not available,Not available
AVR/I/SSAP42,Clinical,Lipopeptide 4,Cyclo(-D-Phe-D-Val-L-Thr-D-Leu-),4,Not available,Synthetic peptide,Not available,Experimentally validated,VRSA (NARSA VRS 1) (clinical isolate from the University of Queensland Centre for Clinical Research (UQCCR)),MIC = 30 microM,Lipopeptides 4 did not exhibit cytotoxic activity at concentrations up to 15 microM against the tested mammalian cell lines (HEK293 and HepG2) and did not induce significant hemolytic effects even at high concentrations of 100 microM.,27048775,Not available,Not available,Not available
AVR/I/SSAP43,Clinical,Lipopeptide 4,Cyclo(-D-Phe-D-Val-L-Thr-D-Leu-),4,Not available,Synthetic peptide,Not available,Experimentally validated,VRSA (NARSA VRS 10) (clinical isolate from the University of Queensland Centre for Clinical Research (UQCCR)),MIC = 30 microM,Lipopeptides 4 did not exhibit cytotoxic activity at concentrations up to 15 microM against the tested mammalian cell lines (HEK293 and HepG2) and did not induce significant hemolytic effects even at high concentrations of 100 microM.,27048775,Not available,Not available,Not available
AVR/I/SSAP44,Clinical,Lipopeptide 5,Cyclo(-D-Leu-D-Tyr-D-Leu-D-Phe-D-Pro-D-Val-),6,Not available,Synthetic peptide,Not available,Experimentally validated,VRSA (NARSA VRS 4) (clinical isolate from the University of Queensland Centre for Clinical Research (UQCCR)),MIC = 0.2 microM,Lipopeptides 5 did not exhibit cytotoxic activity at concentrations up to 15 microM against the tested mammalian cell lines (HEK293 and HepG2) and did not induce significant hemolytic effects even at high concentrations of 100 microM.,27048775,Not available,Not available,Not available
AVR/I/SSAP45,Clinical,Lipopeptide 5,Cyclo(-D-Leu-D-Tyr-D-Leu-D-Phe-D-Pro-D-Val-),6,Not available,Synthetic peptide,Not available,Experimentally validated,VRSA (NARSA VRS 1) (clinical isolate from the University of Queensland Centre for Clinical Research (UQCCR)),MIC = 0.1 microM,Lipopeptides 5 did not exhibit cytotoxic activity at concentrations up to 15 microM against the tested mammalian cell lines (HEK293 and HepG2) and did not induce significant hemolytic effects even at high concentrations of 100 microM.,27048775,Not available,Not available,Not available
AVR/I/SSAP46,Clinical,Lipopeptide 5,Cyclo(-D-Leu-D-Tyr-D-Leu-D-Phe-D-Pro-D-Val-),6,Not available,Synthetic peptide,Not available,Experimentally validated,VRSA (NARSA VRS 10) (clinical isolate from the University of Queensland Centre for Clinical Research (UQCCR)),MIC = 0.1 microM,Lipopeptides 5 did not exhibit cytotoxic activity at concentrations up to 15 microM against the tested mammalian cell lines (HEK293 and HepG2) and did not induce significant hemolytic effects even at high concentrations of 100 microM.,27048775,Not available,Not available,Not available
AVR/I/SSAP47,Clinical,Lipopeptide 6,Cyclo(-D-Phe-D-Val-L-Thr-D-Leu-D-Leu-),5,Not available,Synthetic peptide,Not available,Experimentally validated,VRSA (NARSA VRS 4) (clinical isolate from the University of Queensland Centre for Clinical Research (UQCCR)),MIC = 2.8 microM,Lipopeptides 6 did not exhibit cytotoxic activity at concentrations up to 15 microM against the tested mammalian cell lines (HEK293 and HepG2) and did not induce significant hemolytic effects even at high concentrations of 100 microM.,27048775,Not available,Not available,Not available
AVR/I/SSAP48,Clinical,Lipopeptide 6,Cyclo(-D-Phe-D-Val-L-Thr-D-Leu-D-Leu-),5,Not available,Synthetic peptide,Not available,Experimentally validated,VRSA (NARSA VRS 1) (clinical isolate from the University of Queensland Centre for Clinical Research (UQCCR)),MIC = 1.9 microM,Lipopeptides 6 did not exhibit cytotoxic activity at concentrations up to 15 microM against the tested mammalian cell lines (HEK293 and HepG2) and did not induce significant hemolytic effects even at high concentrations of 100 microM.,27048775,Not available,Not available,Not available
AVR/I/SSAP49,Clinical,Lipopeptide 6,Cyclo(-D-Phe-D-Val-L-Thr-D-Leu-D-Leu-),5,Not available,Synthetic peptide,Not available,Experimentally validated,VRSA (NARSA VRS 10) (clinical isolate from the University of Queensland Centre for Clinical Research (UQCCR)),MIC = 1.9 microM,Lipopeptides 6 did not exhibit cytotoxic activity at concentrations up to 15 microM against the tested mammalian cell lines (HEK293 and HepG2) and did not induce significant hemolytic effects even at high concentrations of 100 microM.,27048775,Not available,Not available,Not available
AVR/I/SSAP50,Clinical,MP196,RWRWRW-NH2,6,Not available,Synthetic peptide,Not available,Experimentally validated,"SG511 (VISA) (clinical isolate provided by Hans-Georg Sahl, University of Bonn, Germany, and Keiichi Hiramatsu, Juntendo University, Bunkyo, Japan)",MIC = 16 microG/ML,"MP196 was only slightly hemolytic at high concentrations and not significantly cytotoxic to various human and animal cell lines, but it caused erythrocyte shrinking at 250microg/mL and severe morphological changes and lysis at 500microg/mL in murine red blood cells. In mice, intravenous doses of MP196 led to acute toxicity, including symptoms like excitement, indisposition, hind leg paralysis, and eventual death at higher concentrations.",27617260,Not available,Not available,Not available
AVR/I/SSAP51,Clinical,MP196,RWRWRW-NH2,6,Not available,Synthetic peptide,Not available,Experimentally validated,"Mu50 (VISA) (clinical isolate provided by Hans-Georg Sahl, University of Bonn, Germany, and Keiichi Hiramatsu, Juntendo University, Bunkyo, Japan)",MIC = 64 microG/ML,"MP196 was only slightly hemolytic at high concentrations and not significantly cytotoxic to various human and animal cell lines, but it caused erythrocyte shrinking at 250microg/mL and severe morphological changes and lysis at 500microg/mL in murine red blood cells. In mice, intravenous doses of MP196 led to acute toxicity, including symptoms like excitement, indisposition, hind leg paralysis, and eventual death at higher concentrations.",27617260,Not available,Not available,Not available
AVR/I/SSAP52,Clinical,Cecropin A,GIGKFLHSAKKFGKAFVGEIMNS,23,Not available,Hyalophora cecropi,Animalia (Insect),Experimentally validated,"VISA (the VISA strain was isolated from a clinical specimen submitted for routine bacteriological investigation to the Institute of Infectious Diseases and Public Health, Polytechnic University of Marche, Ancona, Italy)",FIC = 0.312,Cecropin A exhibits low cytotoxicity towards mammalian cells at certain concentrations,16797106,"2LSA_A, 2MAG_A","C0HKN6, P11006",Not available
AVR/I/SSAP53,Clinical,Magainin-2,GIGKFLHSAKKFGKAFVGEIMNS,23,Not available,Xenopus laevis,Animalia (Frog),Experimentally validated,"VISA (the VISA strain was isolated from a clinical specimen submitted for routine bacteriological investigation to the Institute of Infectious Diseases and Public Health, Polytechnic University of Marche, Ancona, Italy)",FIC = 0.458,"Magainin II exhibits low cytotoxicity towards mammalian cells, is non-hemolytic, and selectively disrupts bacterial membranes, demonstrating a favorable safety profile and broad antimicrobial activity.",16797106,"2LSA_A, 2MAG_A","C0HKN6, P11006",Not available
AVR/I/SSAP54,Clinical,Smp24,IWSFLIKAATKLLP--SLFGGG-KKDS,24,Not available,Scorpio maurus palmatus,Animalia (Scorpion),Experimentally validated,VISA MU50 (clinical isolate from Sheffield Hallam University),MIC = 32 microG/ML,"Smp24, a broad-spectrum antimicrobial peptide from Scorpio maurus palmatus venom, disrupts membranes and causes hemolysis, unlike the non-hemolytic Smp43, with its hemolytic and cytotoxic effects influenced by modifications like truncation and the addition of a Gly-Val-Gly hinge.",27019370,Not available,Not available,Not available
AVR/I/SSAP55,Clinical,Smp24,IWSFLIKAATKLLP--SLFGGG-KKDS,24,Not available,Scorpio maurus palmatus,Animalia (Scorpion),Experimentally validated,VISA KM126 (clinical isolate from Sheffield Hallam University),MIC = 64 microG/ML,"Smp24, a broad-spectrum antimicrobial peptide from Scorpio maurus palmatus venom, disrupts membranes and causes hemolysis, unlike the non-hemolytic Smp43, with its hemolytic and cytotoxic effects influenced by modifications like truncation and the addition of a Gly-Val-Gly hinge.",27019370,Not available,Not available,Not available
AVR/I/SSAP56,Clinical,Smp24GVG,IWSFLIKAATKLLGVGSLFGGG-KKDS,26,Not available,Scorpio maurus palmatus,Animalia (Scorpion),Experimentally validated,VISA MU50 (clinical isolate from Sheffield Hallam University),MIC = 32 microG/ML,"The addition of a Gly-Val-Gly hinge to Smp24, resulting in Smp24GVG, did not alter its hemolytic activity or significantly change its cytotoxicity in HepG2 cells compared to the parent peptide.",27019370,Not available,Not available,Not available
AVR/I/SSAP57,Clinical,Smp24GVG,IWSFLIKAATKLLGVGSLFGGG-KKDS,26,Not available,Scorpio maurus palmatus,Animalia (Scorpion),Experimentally validated,VISA KM126 (clinical isolate from Sheffield Hallam University),MIC = 64 microG/ML,"The addition of a Gly-Val-Gly hinge to Smp24, resulting in Smp24GVG, did not alter its hemolytic activity or significantly change its cytotoxicity in HepG2 cells compared to the parent peptide.",27019370,Not available,Not available,Not available
AVR/I/SSAP58,Clinical,Smp24T,IWSFLIKAATKLL--PSLFGG,19,Not available,Scorpio maurus palmatus,Animalia (Scorpion),Experimentally validated,VISA MU50 (clinical isolate from Sheffield Hallam University),MIC = 32 microG/ML,Not available,27019370,Not available,Not available,Not available
AVR/I/SSAP59,Clinical,Smp24T,IWSFLIKAATKLL--PSLFGG,19,Not available,Scorpio maurus palmatus,Animalia (Scorpion),Experimentally validated,VISA KM126 (clinical isolate from Sheffield Hallam University),MIC = 64 microG/ML,Not available,27019370,Not available,Not available,Not available
AVR/I/SSAP60,Clinical,Smp43,G-VWDWIKKTAGKIWNSEPVKALKSQALNAAKNFVAEKIGATPS,43,Not available,Scorpio maurus palmatus,Animalia (Scorpion),Experimentally validated,VISA MU50 (clinical isolate from Sheffield Hallam University),MIC = 32 microG/ML,"Unlike the haemolytic Smp24, Smp43 was non-haemolytic but exhibited concentration-dependent cytotoxicity in HepG2 cells, as indicated by ATP release.",27019370,Not available,Not available,Not available
AVR/I/SSAP61,Clinical,Smp43,G-VWDWIKKTAGKIWNSEPVKALKSQALNAAKNFVAEKIGATPS,43,Not available,Scorpio maurus palmatus,Animalia (Scorpion),Experimentally validated,VISA KM126 (clinical isolate from Sheffield Hallam University),MIC = 64 microG/ML,"Unlike the haemolytic Smp24, Smp43 was non-haemolytic but exhibited concentration-dependent cytotoxicity in HepG2 cells, as indicated by ATP release.",27019370,Not available,Not available,Not available
AVR/I/SSAP62,Clinical,Melittin,GIGAVLKVLTTGLPALISWIKRKRQQ,26,Bee venom,Apis mellifera,Animalia (Insect),Experimentally validated,VRSA (clinical isolate from burn-associated infections at Laboratory of Shahid Motahari Hospital),MBC = 0.125-2 microG/ML,"Melittin was evaluated for dermal toxicity on burned and normal skin at various time points (2, 24, 48, and 72 hours), showing no morphological changes in both test and normal groups. An in vivo hemolysis assay in mice revealed no hemolysis in the test groups compared to controls. These results indicate that melittin at the tested concentration did not cause dermal toxicity or hemolysis.",34087287,"3QRX_B, 1BH1_A","P68407, P01501, Q8LW55",DB10955
AVR/I/SSAP63,Clinical,Persulcatusin(IP),GFGCPFNQGACHRHCRSIGRRGGYCAGLFKQTCTCYSR,38,Midgut,Ixodes persulcatus ,Animalia (Insect),Experimentally validated,"Mu50 (VISA) (clinical isolate stored at TS; Nissui, Tokyo, Japan))",MIC(90%) = 8 microG/ML− 1 microG/ML,Not available,27531221,Not available,Not available,Not available
AVR/I/SSAP64,Clinical,IR,GGYYCPFFQDKCHRHCR SFGRKAGYCGGFLKKTCICV,37,Not available,Ixodes ricinus,Animalia (Insect),Experimentally validated,"Mu50 (VISA) (clinical isolate stored at TS; Nissui, Tokyo, Japan))",MIC(90%) = 32 microG/ML,Not available,27531221,Not available,Not available,Not available
AVR/I/SSAP65,Clinical,HAE,GCPLNQGACHNHCRSIGRRGGYCAGIIKQTCTCYRK,36,Not available,Haemaphysalis longicornis,Animalia (Insect),Experimentally validated,"Mu50 (VISA) (clinical isolate stored at TS; Nissui, Tokyo, Japan))",MIC(90%) = 32 microG/ML,Not available,27531221,Not available,Not available,Not available
AVR/I/SSAP66,Clinical,OMBAC,GFGCPFNQ YECHAHCSGVPGYKGGYCKGLFKQTCNCY,37,Not available,Ornithodoros moubata,Animalia (Insect),Experimentally validated,"Mu50 (VISA) (clinical isolate stored at TS; Nissui, Tokyo, Japan))",MIC(90%) = 32 microG/ML,Not available,27531221,Not available,Not available,Not available
AVR/I/SSAP67,Clinical,BMAP28,GGLRSLGKKILRAWKKYGPIIVPIIRI,27,Bovine Myeloid ,Bos taurus,Animalia (Cow),Experimentally validated,"Mu50 (VISA) (clinical isolate stored at TS; Nissui, Tokyo, Japan))",MIC(90%) = 32 microG/ML,Not available,27531221,Not available,Not available,Not available
AVR/I/SSAP68,Clinical,Persulcatusin(IP),GFGCPFNQGACHRHCRSIGRRGGYCAGLFKQTCTCYSR,38,Midgut,Ixodes persulcatus ,Animalia (Insect),Experimentally validated,"VRS1 (VRSA) (clinical isolate stored at TS; Nissui, Tokyo, Japan))",MIC(90%) = 2 microG/ML,Not available,27531221,Not available,Not available,Not available
AVR/I/SSAP69,Clinical,IR,GGYYCPFFQDKCHRHCR SFGRKAGYCGGFLKKTCICV,37,Not available,Ixodes ricinus,Animalia (Insect),Experimentally validated,"VRS1 (VRSA) (clinical isolate stored at TS; Nissui, Tokyo, Japan))",MIC(90%) = 32 microG/ML,Not available,27531221,Not available,Not available,Not available
AVR/I/SSAP70,Clinical,HAE,GCPLNQGACHNHCRSIGRRGGYCAGIIKQTCTCYRK,36,Not available,Haemaphysalis longicornis,Animalia (Insect),Experimentally validated,"VRS1 (VRSA) (clinical isolate stored at TS; Nissui, Tokyo, Japan))",MIC(90%) = 32 microG/ML,Not available,27531221,Not available,Not available,Not available
AVR/I/SSAP71,Clinical,OMBAC,GFGCPFNQ YECHAHCSGVPGYKGGYCKGLFKQTCNCY,37,Not available,Ornithodoros moubata,Animalia (Insect),Experimentally validated,"VRS1 (VRSA) (clinical isolate stored at TS; Nissui, Tokyo, Japan))",MIC(90%) = 8 microG/ML,Not available,27531221,Not available,Not available,Not available
AVR/I/SSAP72,Clinical,BMAP28,GGLRSLGKKILRAWKKYGPIIVPIIRI,27,Bovine Myeloid ,Bos taurus,Animalia (Cow),Experimentally validated,"VRS1 (VRSA) (clinical isolate stored at TS; Nissui, Tokyo, Japan))",MIC(90%) = 32 microG/ML,Not available,27531221,Not available,Not available,Not available
AVR/I/SSAP73,Clinical,Daptomycin,Thr-D-Asn-Glu-Tyr-Asn-Pro-L-Asn-Gly-L-Thr-L-Ser-D-Asn-Gly-L-Thr-L-Thr-L-Cys-L-Thr,16,Not available,Streptomyces roseosporus,Bacteria,Experimentally validated,VRSA HMC3 (clinical strain isolated at the Hershey Medical Center),MIC = 0.5 mg/L,Not available,14563898,Not available,Not available,DB00080
AVR/I/SSAP74,Clinical,WR12,RWWRWWRRWWRR,12,Not available,Synthetic peptide,Not available,Experimentally validated,VISA (NRS19) (clinical isolate),EC50 = 1 microM,"The MTS assay on HaCat cells revealed that WR12 have EC50 value of 128microM, indicating low toxicity to mammalian cells relative to their antimicrobial potency, which suggests a favorable drug safety profile and selective action against bacterial membranes.",27405275,Not available,Not available,Not available
AVR/I/SSAP75,Clinical,WR12,RWWRWWRRWWRR,12,Not available,Synthetic peptide,Not available,Experimentally validated,VISA (NRS37) (clinical isolate),EC50 = 1 microM,"The MTS assay on HaCat cells revealed that WR12 have EC50 value of 128microM, indicating low toxicity to mammalian cells relative to their antimicrobial potency, which suggests a favorable drug safety profile and selective action against bacterial membranes.",27405275,Not available,Not available,Not available
AVR/I/SSAP76,Clinical,WR12,RWWRWWRRWWRR,12,Not available,Synthetic peptide,Not available,Experimentally validated,VISA (NRS1) (clinical isolate),EC50 = 1 microM,"The MTS assay on HaCat cells revealed that WR12 have EC50 value of 128microM, indicating low toxicity to mammalian cells relative to their antimicrobial potency, which suggests a favorable drug safety profile and selective action against bacterial membranes.",27405275,Not available,Not available,Not available
AVR/I/SSAP77,Clinical,WR12,RWWRWWRRWWRR,12,Not available,Synthetic peptide,Not available,Experimentally validated,VRSA (VRS4) (clinical isolate),EC50 = 4 microM,"The MTS assay on HaCat cells revealed that WR12 have EC50 value of 128microM, indicating low toxicity to mammalian cells relative to their antimicrobial potency, which suggests a favorable drug safety profile and selective action against bacterial membranes.",27405275,Not available,Not available,Not available
AVR/I/SSAP78,Clinical,WR12,RWWRWWRRWWRR,12,Not available,Synthetic peptide,Not available,Experimentally validated,VRSA (VRS5) (clinical isolate),EC50 = 8 microM,"The MTS assay on HaCat cells revealed that WR12 have EC50 value of 128microM, indicating low toxicity to mammalian cells relative to their antimicrobial potency, which suggests a favorable drug safety profile and selective action against bacterial membranes.",27405275,Not available,Not available,Not available
AVR/I/SSAP79,Clinical,WR12,RWWRWWRRWWRR,12,Not available,Synthetic peptide,Not available,Experimentally validated,VRSA (VRS10) (clinical isolate),EC50 = 8 microM,"The MTS assay on HaCat cells revealed that WR12 have EC50 value of 128microM, indicating low toxicity to mammalian cells relative to their antimicrobial potency, which suggests a favorable drug safety profile and selective action against bacterial membranes.",27405275,Not available,Not available,Not available
AVR/I/SSAP80,Clinical,WR12,RWWRWWRRWWRR,12,Not available,Synthetic peptide,Not available,Experimentally validated,VRSA (VRS11a) (clinical isolate),EC50 = 4 microM,"The MTS assay on HaCat cells revealed that WR12 have EC50 value of 128microM, indicating low toxicity to mammalian cells relative to their antimicrobial potency, which suggests a favorable drug safety profile and selective action against bacterial membranes.",27405275,Not available,Not available,Not available
AVR/I/SSAP81,Clinical,WR12,RWWRWWRRWWRR,12,Not available,Synthetic peptide,Not available,Experimentally validated,VRSA (VRS11b) (clinical isolate),EC50 = 4 microM,"The MTS assay on HaCat cells revealed that WR12 have EC50 value of 128microM, indicating low toxicity to mammalian cells relative to their antimicrobial potency, which suggests a favorable drug safety profile and selective action against bacterial membranes.",27405275,Not available,Not available,Not available
AVR/I/SSAP82,Clinical,WR12,RWWRWWRRWWRR,12,Not available,Synthetic peptide,Not available,Experimentally validated,VRSA (VRS12) (clinical isolate),EC50 = 8 microM,"The MTS assay on HaCat cells revealed that WR12 have EC50 value of 128microM, indicating low toxicity to mammalian cells relative to their antimicrobial potency, which suggests a favorable drug safety profile and selective action against bacterial membranes.",27405275,Not available,Not available,Not available
AVR/I/SSAP83,Clinical,WR12,RWWRWWRRWWRR,12,Not available,Synthetic peptide,Not available,Experimentally validated,VRSA (VRS13) (clinical isolate),EC50 = 4 microM,"The MTS assay on HaCat cells revealed that WR12 have EC50 value of 128microM, indicating low toxicity to mammalian cells relative to their antimicrobial potency, which suggests a favorable drug safety profile and selective action against bacterial membranes.",27405275,Not available,Not available,Not available
AVR/I/SSAP84,Clinical,D-IK8,IRIKIRIK,8,Not available,Synthetic peptide,Not available,Experimentally validated,VISA (NRS19) (clinical isolate),EC50 = 8 microM,"The MTS assay on HaCat cells revealed that D-IK8 have EC50 value of > 256microM, indicating low toxicity to mammalian cells relative to their antimicrobial potency, which suggests a favorable drug safety profile and selective action against bacterial membranes.",27405275,Not available,Not available,Not available
AVR/I/SSAP85,Clinical,D-IK8,IRIKIRIK,8,Not available,Synthetic peptide,Not available,Experimentally validated,VISA (NRS37) (clinical isolate),EC50 = 8 microM,"The MTS assay on HaCat cells revealed that D-IK8 have EC50 value of > 256microM, indicating low toxicity to mammalian cells relative to their antimicrobial potency, which suggests a favorable drug safety profile and selective action against bacterial membranes.",27405275,Not available,Not available,Not available
AVR/I/SSAP86,Clinical,D-IK8,IRIKIRIK,8,Not available,Synthetic peptide,Not available,Experimentally validated,VISA (NRS1) (clinical isolate),EC50 = 8 microM,"The MTS assay on HaCat cells revealed that D-IK8 have EC50 value of > 256microM, indicating low toxicity to mammalian cells relative to their antimicrobial potency, which suggests a favorable drug safety profile and selective action against bacterial membranes.",27405275,Not available,Not available,Not available
AVR/I/SSAP87,Clinical,D-IK8,IRIKIRIK,8,Not available,Synthetic peptide,Not available,Experimentally validated,VRSA (VRS4) (clinical isolate),EC50 = 8 microM,"The MTS assay on HaCat cells revealed that D-IK8 have EC50 value of > 256microM, indicating low toxicity to mammalian cells relative to their antimicrobial potency, which suggests a favorable drug safety profile and selective action against bacterial membranes.",27405275,Not available,Not available,Not available
AVR/I/SSAP88,Clinical,D-IK8,IRIKIRIK,8,Not available,Synthetic peptide,Not available,Experimentally validated,VRSA (VRS5) (clinical isolate),EC50 = 16 microM,"The MTS assay on HaCat cells revealed that D-IK8 have EC50 value of > 256microM, indicating low toxicity to mammalian cells relative to their antimicrobial potency, which suggests a favorable drug safety profile and selective action against bacterial membranes.",27405275,Not available,Not available,Not available
AVR/I/SSAP89,Clinical,D-IK8,IRIKIRIK,8,Not available,Synthetic peptide,Not available,Experimentally validated,VRSA (VRS10) (clinical isolate),EC50 = 16 microM,"The MTS assay on HaCat cells revealed that D-IK8 have EC50 value of > 256microM, indicating low toxicity to mammalian cells relative to their antimicrobial potency, which suggests a favorable drug safety profile and selective action against bacterial membranes.",27405275,Not available,Not available,Not available
AVR/I/SSAP90,Clinical,D-IK8,IRIKIRIK,8,Not available,Synthetic peptide,Not available,Experimentally validated,VRSA (VRS11a) (clinical isolate),EC50 = 16 microM,"The MTS assay on HaCat cells revealed that D-IK8 have EC50 value of > 256microM, indicating low toxicity to mammalian cells relative to their antimicrobial potency, which suggests a favorable drug safety profile and selective action against bacterial membranes.",27405275,Not available,Not available,Not available
AVR/I/SSAP91,Clinical,D-IK8,IRIKIRIK,8,Not available,Synthetic peptide,Not available,Experimentally validated,VRSA (VRS11b) (clinical isolate),EC50 = 16 microM,"The MTS assay on HaCat cells revealed that D-IK8 have EC50 value of > 256microM, indicating low toxicity to mammalian cells relative to their antimicrobial potency, which suggests a favorable drug safety profile and selective action against bacterial membranes.",27405275,Not available,Not available,Not available
AVR/I/SSAP92,Clinical,D-IK8,IRIKIRIK,8,Not available,Synthetic peptide,Not available,Experimentally validated,VRSA (VRS12) (clinical isolate),EC50 = 16 microM,"The MTS assay on HaCat cells revealed that D-IK8 have EC50 value of > 256microM, indicating low toxicity to mammalian cells relative to their antimicrobial potency, which suggests a favorable drug safety profile and selective action against bacterial membranes.",27405275,Not available,Not available,Not available
AVR/I/SSAP93,Clinical,D-IK8,IRIKIRIK,8,Not available,Synthetic peptide,Not available,Experimentally validated,VRSA (VRS13) (clinical isolate),EC50 = 16 microM,"The MTS assay on HaCat cells revealed that D-IK8 have EC50 value of > 256microM, indicating low toxicity to mammalian cells relative to their antimicrobial potency, which suggests a favorable drug safety profile and selective action against bacterial membranes.",27405275,Not available,Not available,Not available
AVR/I/SSAP94,Clinical,LL-37,LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES,37,Human skin,Homo sapiens,Animalia (Human),Experimentally validated,VISA (NRS19) (clinical isolate),EC50 = 128 microM,Low toxicity and hemolytic activity.,27405275,2K6O_A,"Q1KLX1, P49913",DB16532
AVR/I/SSAP95,Clinical,LL-37,LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES,37,Human skin,Homo sapiens,Animalia (Human),Experimentally validated,VISA (NRS37) (clinical isolate),EC50 = 128 microM,Low toxicity and hemolytic activity.,27405275,2K6O_A,"Q1KLX1, P49913",DB16532
AVR/I/SSAP96,Clinical,LL-37,LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES,37,Human skin,Homo sapiens,Animalia (Human),Experimentally validated,VISA (NRS1) (clinical isolate),EC50 = 128 microM,Low toxicity and hemolytic activity.,27405275,2K6O_A,"Q1KLX1, P49913",DB16532
AVR/I/SSAP97,Clinical,LL-37,LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES,37,Human skin,Homo sapiens,Animalia (Human),Experimentally validated,VRSA (VRS4) (clinical isolate),EC50 = 128 microM,Low toxicity and hemolytic activity.,27405275,2K6O_A,"Q1KLX1, P49913",DB16532
AVR/I/SSAP98,Clinical,LL-37,LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES,37,Human skin,Homo sapiens,Animalia (Human),Experimentally validated,VRSA (VRS5) (clinical isolate),EC50 = 128 microM,Low toxicity and hemolytic activity.,27405275,2K6O_A,"Q1KLX1, P49913",DB16532
AVR/I/SSAP99,Clinical,LL-37,LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES,37,Human skin,Homo sapiens,Animalia (Human),Experimentally validated,VRSA (VRS10) (clinical isolate),EC50 = 128 microM,Low toxicity and hemolytic activity.,27405275,2K6O_A,"Q1KLX1, P49913",DB16532
AVR/I/SSAP100,Clinical,LL-37,LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES,37,Human skin,Homo sapiens,Animalia (Human),Experimentally validated,VRSA (VRS11a) (clinical isolate),EC50 = 128 microM,Low toxicity and hemolytic activity.,27405275,2K6O_A,"Q1KLX1, P49913",DB16532
AVR/I/SSAP101,Clinical,LL-37,LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES,37,Human skin,Homo sapiens,Animalia (Human),Experimentally validated,VRSA (VRS11b) (clinical isolate),EC50 = 128 microM,Low toxicity and hemolytic activity.,27405275,2K6O_A,"Q1KLX1, P49913",DB16532
AVR/I/SSAP102,Clinical,LL-37,LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES,37,Human skin,Homo sapiens,Animalia (Human),Experimentally validated,VRSA (VRS12) (clinical isolate),EC50 = 128 microM,Low toxicity and hemolytic activity.,27405275,2K6O_A,"Q1KLX1, P49913",DB16532
AVR/I/SSAP103,Clinical,LL-37,LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES,37,Human skin,Homo sapiens,Animalia (Human),Experimentally validated,VRSA (VRS13) (clinical isolate),EC50 = 128 microM,Low toxicity and hemolytic activity.,27405275,2K6O_A,"Q1KLX1, P49913",DB16532
AVR/I/SSAP104,Clinical,Nisin,I-Dhb-A-I-Dhb-I-A-Abu-P-G-A-K-Abu-G-A-L-M-G-A-N-M-K-Abu-A-Abu-A-H-A-S-I-H-V-Dha-K,27,Not available,Lactococcus lactis,Bacteria,Experimentally validated,VRS1(VRSA) (clinical isolate),MIC = 16 microM,Not available,27531221,Not available,Not available,Not available
AVR/I/SSAP105,Clinical,Nisin,I-Dhb-A-I-Dhb-I-A-Abu-P-G-A-K-Abu-G-A-L-M-G-A-N-M-K-Abu-A-Abu-A-H-A-S-I-H-V-Dha-K,27,Not available,Lactococcus lactis,Bacteria,Experimentally validated,Mu50(VISA) (clinical isolate),MIC = 16 microM,Not available,27531221,Not available,Not available,Not available
AVR/I/SSAP106,Clinical,Ramoplanin,Ac-D-Tyr-D-Tyr-D-4Cl-Phe-L-Ser-D-Hpg-D-Orn-D-Leu-D-Arg-D-Asn-NH2,7,Not available,glycolipodepsipeptide,Not available,Experimentally validated,VRSA HMC3 (clinical strain isolated at the Hershey Medical Center),MIC = 0.125-0.5 mg/L,Not available,14563898,Not available,Not available,DB04952
AVR/I/SSAP107,Clinical,Cryptdin-4 (Crp-4),GLLCYCRKGHCKRGERVRGTC---GIRFLYCCPRR,32,a-defensin,Mouse,Animalia (Mouse),Experimentally validated,"Mu50 (VISA) (clinical bacterial isolate obtained from hospitalized patients at Huntington Hospital (Pasadena, CA, USA))",MBC = 3 microM,"Crp-4, along with RMAD-4 and RTD-1, are non-hemolytic peptides. Systemic administration of RTD-1 to BALB/c mice was non-toxic, stable in serum and plasma, and significantly improved survival in mice with E. coli peritonitis and sepsis induced by cecal ligation-and-puncture.",24345876,1TV0_A,P28311,Not available
AVR/I/SSAP108,Clinical,Cryptdin-4 (Crp-4),GLLCYCRKGHCKRGERVRGTC---GIRFLYCCPRR,32,a-defensin,Mouse,Animalia (Mouse),Experimentally validated,"Mu3 (hVISA) (clinical bacterial isolate obtained from hospitalized patients at Huntington Hospital (Pasadena, CA, USA))",MBC = 1.5 microM,"Crp-4, along with RMAD-4 and RTD-1, are non-hemolytic peptides. Systemic administration of RTD-1 to BALB/c mice was non-toxic, stable in serum and plasma, and significantly improved survival in mice with E. coli peritonitis and sepsis induced by cecal ligation-and-puncture.",24345876,1TV0_A,P28311,Not available
AVR/I/SSAP109,Clinical,Cryptdin-4 (Crp-4),GLLCYCRKGHCKRGERVRGTC---GIRFLYCCPRR,32,a-defensin,Mouse,Animalia (Mouse),Experimentally validated,"DH 290 (hVISA) (clinical bacterial isolate obtained from hospitalized patients at Huntington Hospital (Pasadena, CA, USA))",MBC = 3 microM,"Crp-4, along with RMAD-4 and RTD-1, are non-hemolytic peptides. Systemic administration of RTD-1 to BALB/c mice was non-toxic, stable in serum and plasma, and significantly improved survival in mice with E. coli peritonitis and sepsis induced by cecal ligation-and-puncture.",24345876,1TV0_A,P28311,Not available
AVR/I/SSAP110,Clinical,Cryptdin-4 (Crp-4),GLLCYCRKGHCKRGERVRGTC---GIRFLYCCPRR,32,a-defensin,Mouse,Animalia (Mouse),Experimentally validated,"DH280 (hVISA) (clinical bacterial isolate obtained from hospitalized patients at Huntington Hospital (Pasadena, CA, USA))",MBC = 3 microM,"Crp-4, along with RMAD-4 and RTD-1, are non-hemolytic peptides. Systemic administration of RTD-1 to BALB/c mice was non-toxic, stable in serum and plasma, and significantly improved survival in mice with E. coli peritonitis and sepsis induced by cecal ligation-and-puncture.",24345876,1TV0_A,P28311,Not available
AVR/I/SSAP111,Clinical,RMAD-4,RRTCRCRFGRCFRRESYGSCNINGRIFSLCCR,32,myeloid a-defensin,Rhesus macaque,Animalia (Rhesus monkey),Experimentally validated,"Mu50 (VISA) (clinical bacterial isolate obtained from hospitalized patients at Huntington Hospital (Pasadena, CA, USA))",MBC = 1.5 microM,"RMAD-4, along with Crp-4 and RTD-1, are non-hemolytic peptides. Systemic administration of RMAD-4 to BALB/c mice was non-toxic and stable in serum and plasma, indicating its safety profile in vivo.",24345876,Not available,Not available,Not available
AVR/I/SSAP112,Clinical,RMAD-4,RRTCRCRFGRCFRRESYGSCNINGRIFSLCCR,32,myeloid a-defensin,Rhesus macaque,Animalia (Rhesus monkey),Experimentally validated,"Mu3 (hVISA) (clinical bacterial isolate obtained from hospitalized patients at Huntington Hospital (Pasadena, CA, USA))",MBC = 3 microM,"RMAD-4, along with Crp-4 and RTD-1, are non-hemolytic peptides. Systemic administration of RMAD-4 to BALB/c mice was non-toxic and stable in serum and plasma, indicating its safety profile in vivo.",24345876,Not available,Not available,Not available
AVR/I/SSAP113,Clinical,RMAD-4,RRTCRCRFGRCFRRESYGSCNINGRIFSLCCR,32,myeloid a-defensin,Rhesus macaque,Animalia (Rhesus monkey),Experimentally validated,"DH 290 (hVISA) (clinical bacterial isolate obtained from hospitalized patients at Huntington Hospital (Pasadena, CA, USA))",MBC = 1.5 microM,"RMAD-4, along with Crp-4 and RTD-1, are non-hemolytic peptides. Systemic administration of RMAD-4 to BALB/c mice was non-toxic and stable in serum and plasma, indicating its safety profile in vivo.",24345876,Not available,Not available,Not available
AVR/I/SSAP114,Clinical,RMAD-4,RRTCRCRFGRCFRRESYGSCNINGRIFSLCCR,32,myeloid a-defensin,Rhesus macaque,Animalia (Rhesus monkey),Experimentally validated,"DH280 (hVISA) (clinical bacterial isolate obtained from hospitalized patients at Huntington Hospital (Pasadena, CA, USA))",MBC = 1.5 microM,"RMAD-4, along with Crp-4 and RTD-1, are non-hemolytic peptides. Systemic administration of RMAD-4 to BALB/c mice was non-toxic and stable in serum and plasma, indicating its safety profile in vivo.",24345876,Not available,Not available,Not available
AVR/I/SSAP115,Clinical,RTD-1,GFCRCLCRRGVCRCICTR,18,Theta-defensin,rhesus macaque (Macaca mulatta) ,Animalia (Rhesus monkey),Experimentally validated,"Mu50 (VISA) (clinical bacterial isolate obtained from hospitalized patients at Huntington Hospital (Pasadena, CA, USA))",MBC = 3 microM,"RTD-1, along with Crp-4 and RMAD-4, are non-hemolytic peptides. Systemic administration of RTD-1 to BALB/c mice was non-toxic and stable in serum and plasma, and it significantly improved survival in mice with E. coli peritonitis and sepsis induced by cecal ligation-and-puncture.",24345876,1HVZ_A,Not available,Not available
AVR/I/SSAP116,Clinical,RTD-1,GFCRCLCRRGVCRCICTR,18,Theta-defensin,rhesus macaque (Macaca mulatta) ,Animalia (Rhesus monkey),Experimentally validated,"Mu3 (hVISA) (clinical bacterial isolate obtained from hospitalized patients at Huntington Hospital (Pasadena, CA, USA))",MBC = 1.5 microM,"RTD-1, along with Crp-4 and RMAD-4, are non-hemolytic peptides. Systemic administration of RTD-1 to BALB/c mice was non-toxic and stable in serum and plasma, and it significantly improved survival in mice with E. coli peritonitis and sepsis induced by cecal ligation-and-puncture.",24345876,1HVZ_A,Not available,Not available
AVR/I/SSAP117,Clinical,RTD-1,GFCRCLCRRGVCRCICTR,18,Theta-defensin,rhesus macaque (Macaca mulatta) ,Animalia (Rhesus monkey),Experimentally validated,"DH 290 (hVISA) (clinical bacterial isolate obtained from hospitalized patients at Huntington Hospital (Pasadena, CA, USA))",MBC = 3 microM,"RTD-1, along with Crp-4 and RMAD-4, are non-hemolytic peptides. Systemic administration of RTD-1 to BALB/c mice was non-toxic and stable in serum and plasma, and it significantly improved survival in mice with E. coli peritonitis and sepsis induced by cecal ligation-and-puncture.",24345876,1HVZ_A,Not available,Not available
AVR/I/SSAP118,Clinical,RTD-1,GFCRCLCRRGVCRCICTR,18,Theta-defensin,rhesus macaque (Macaca mulatta) ,Animalia (Rhesus monkey),Experimentally validated,"DH280 (hVISA) (clinical bacterial isolate obtained from hospitalized patients at Huntington Hospital (Pasadena, CA, USA))",MBC = 1.5 microM,"RTD-1, along with Crp-4 and RMAD-4, are non-hemolytic peptides. Systemic administration of RTD-1 to BALB/c mice was non-toxic and stable in serum and plasma, and it significantly improved survival in mice with E. coli peritonitis and sepsis induced by cecal ligation-and-puncture.",24345876,1HVZ_A,Not available,Not available
AVR/I/SSAP119,Clinical,P-113,Ac- A K R His His G Y K R K F His -NH2,12,Not available,Synthetic peptide,Not available,Experimentally validated,"VISA01 (clinical MDR strain isolate provided by Tsai-Ling Yang, National Health Research Institutes (Miaoli, Taiwan))",MIC = 64 microG/ML,"P-113 exhibited increased toxicity at concentrations greater than 25 microG/mL, causing 10-20% cell death and hemolysis.",32605123,Not available,Not available,DB06763
AVR/I/SSAP120,Clinical,P-113,Ac- A K R His His G Y K R K F His -NH2,12,Not available,Synthetic peptide,Not available,Experimentally validated,"VISA02 (clinical MDR strain isolate provided by Tsai-Ling Yang, National Health Research Institutes (Miaoli, Taiwan))",MIC = 64 microG/ML,"P-113 exhibited increased toxicity at concentrations greater than 25 microG/mL, causing 10-20% cell death and hemolysis.",32605123,Not available,Not available,DB06763
AVR/I/SSAP121,Clinical,P-113,Ac- A K R His His G Y K R K F His -NH2,12,Not available,Synthetic peptide,Not available,Experimentally validated,"VISA03 (clinical MDR strain isolate provided by Tsai-Ling Yang, National Health Research Institutes (Miaoli, Taiwan))",MIC = 64 microG/ML,"P-113 exhibited increased toxicity at concentrations greater than 25 microG/mL, causing 10-20% cell death and hemolysis.",32605123,Not available,Not available,DB06763
AVR/I/SSAP122,Clinical,Phe-P-113,Ac- A K R Phe Phe G Y K R K F Phe -NH2,12,Not available,Synthetic peptide,Not available,Experimentally validated,"VISA01 (clinical MDR strain isolate provided by Tsai-Ling Yang, National Health Research Institutes (Miaoli, Taiwan))",MIC = 64 microG/ML,"Phe-P-113 exhibited low toxicity and hemolytic activity. It caused minimal cell death and hemolysis, indicating a favorable safety profile compared to other peptides with bulkier hydrophobic side chains.",32605123,Not available,Not available,Not available
AVR/I/SSAP123,Clinical,Phe-P-113,Ac- A K R Phe Phe G Y K R K F Phe -NH2,12,Not available,Synthetic peptide,Not available,Experimentally validated,"VISA02 (clinical MDR strain isolate provided by Tsai-Ling Yang, National Health Research Institutes (Miaoli, Taiwan))",MIC = 64 microG/ML,"Phe-P-113 exhibited low toxicity and hemolytic activity. It caused minimal cell death and hemolysis, indicating a favorable safety profile compared to other peptides with bulkier hydrophobic side chains.",32605123,Not available,Not available,Not available
AVR/I/SSAP124,Clinical,Phe-P-113,Ac- A K R Phe Phe G Y K R K F Phe -NH2,12,Not available,Synthetic peptide,Not available,Experimentally validated,"VISA03 (clinical MDR strain isolate provided by Tsai-Ling Yang, National Health Research Institutes (Miaoli, Taiwan))",MIC = 64 microG/ML,"Phe-P-113 exhibited low toxicity and hemolytic activity. It caused minimal cell death and hemolysis, indicating a favorable safety profile compared to other peptides with bulkier hydrophobic side chains.",32605123,Not available,Not available,Not available
AVR/I/SSAP125,Clinical,"beta-(4, 4'-biphenyl)alanine (Bip-P-113)",Ac- A K R Bip Bip G Y K R K F Bip -NH2,9,Not available,Synthetic peptide,Not available,Experimentally validated,"VISA01 (clinical MDR strain isolate provided by Tsai-Ling Yang, National Health Research Institutes (Miaoli, Taiwan))",MIC = 16 microG/ML,"At concentrations higher than 25 microG/mL, Bip-P-113 caused increased toxicity, 10-20% cell death and hemolysis. However, in an in vivo endotoxemia mouse model, no adverse effects were observed at a dose of 10 mg/kg (0.2 mg/mouse).",32605123,Not available,Not available,Not available
AVR/I/SSAP126,Clinical,"beta-(4, 4'-biphenyl)alanine (Bip-P-113)",Ac- A K R Bip Bip G Y K R K F Bip -NH2,9,Not available,Synthetic peptide,Not available,Experimentally validated,"VISA02 (clinical MDR strain isolate provided by Tsai-Ling Yang, National Health Research Institutes (Miaoli, Taiwan))",MIC = 16 microG/ML,"At concentrations higher than 25 microG/mL, Bip-P-113 caused increased toxicity, 10-20% cell death and hemolysis. However, in an in vivo endotoxemia mouse model, no adverse effects were observed at a dose of 10 mg/kg (0.2 mg/mouse).",32605123,Not available,Not available,Not available
AVR/I/SSAP127,Clinical,"beta-(4, 4'-biphenyl)alanine (Bip-P-113)",Ac- A K R Bip Bip G Y K R K F Bip -NH2,9,Not available,Synthetic peptide,Not available,Experimentally validated,"VISA03 (clinical MDR strain isolate provided by Tsai-Ling Yang, National Health Research Institutes (Miaoli, Taiwan))",MIC = 8 microG/ML,"At concentrations higher than 25 microG/mL, Bip-P-113 caused increased toxicity, 10-20% cell death and hemolysis. However, in an in vivo endotoxemia mouse model, no adverse effects were observed at a dose of 10 mg/kg (0.2 mg/mouse).",32605123,Not available,Not available,DB10955
AVR/I/SSAP128,Clinical,beta-diphenylalanine (Dip-P-113),Ac- A K R Dip Dip G Y K R K F Dip -NH2,9,Not available,Synthetic peptide,Not available,Experimentally validated,"VISA01 (clinical MDR strain isolate provided by Tsai-Ling Yang, National Health Research Institutes (Miaoli, Taiwan))",MIC = 16 microG/ML,"Dip-P-113 with bulky hydrophobic side chains caused 10-20% cell death and hemolysis at concentrations above 25microg/mL, but no adverse effects were observed in an in vivo endotoxemia mouse model treated with 10 mg/kg of Dip-P-113.",32605123,Not available,Not available,Not available
AVR/I/SSAP129,Clinical,beta-diphenylalanine (Dip-P-113),Ac- A K R Dip Dip G Y K R K F Dip -NH2,9,Not available,Synthetic peptide,Not available,Experimentally validated,"VISA02 (clinical MDR strain isolate provided by Tsai-Ling Yang, National Health Research Institutes (Miaoli, Taiwan))",MIC = 16 microG/ML,"Dip-P-113 with bulky hydrophobic side chains caused 10-20% cell death and hemolysis at concentrations above 25microg/mL, but no adverse effects were observed in an in vivo endotoxemia mouse model treated with 10 mg/kg of Dip-P-113.",32605123,Not available,Not available,Not available
AVR/I/SSAP130,Clinical,beta-diphenylalanine (Dip-P-113),Ac- A K R Dip Dip G Y K R K F Dip -NH2,9,Not available,Synthetic peptide,Not available,Experimentally validated,"VISA03 (clinical MDR strain isolate provided by Tsai-Ling Yang, National Health Research Institutes (Miaoli, Taiwan))",MIC = 16 microG/ML,"Dip-P-113 with bulky hydrophobic side chains caused 10-20% cell death and hemolysis at concentrations above 25microg/mL, but no adverse effects were observed in an in vivo endotoxemia mouse model treated with 10 mg/kg of Dip-P-113.",32605123,Not available,Not available,Not available
AVR/I/SSAP131,Clinical,beta-naphthylalanine (Nal-P-113),Ac- A K R Nal Nal G Y K R K F Nal -NH2,9,Not available,Synthetic peptide,Not available,Experimentally validated,"VISA01 (clinical MDR strain isolate provided by Tsai-Ling Yang, National Health Research Institutes (Miaoli, Taiwan))",MIC = 16 microG/ML,"Nal-P-113, a peptide with bulky hydrophobic side chains, exhibited increased cell toxicity and hemolytic activity at higher concentrations (> 25 microG/mL), causing 10-20% cell death and hemolysis. This was in comparison to controls, indicating a potential concern for toxicity at elevated doses.",32605123,Not available,Not available,Not available
AVR/I/SSAP132,Clinical,beta-naphthylalanine (Nal-P-113),Ac- A K R Nal Nal G Y K R K F Nal -NH2,9,Not available,Synthetic peptide,Not available,Experimentally validated,"VISA02 (clinical MDR strain isolate provided by Tsai-Ling Yang, National Health Research Institutes (Miaoli, Taiwan))",MIC = 16 microG/ML,"Nal-P-113, a peptide with bulky hydrophobic side chains, exhibited increased cell toxicity and hemolytic activity at higher concentrations (> 25 microG/mL), causing 10-20% cell death and hemolysis. This was in comparison to controls, indicating a potential concern for toxicity at elevated doses.",32605123,Not available,Not available,Not available
AVR/I/SSAP133,Clinical,beta-naphthylalanine (Nal-P-113),Ac- A K R Nal Nal G Y K R K F Nal -NH2,9,Not available,Synthetic peptide,Not available,Experimentally validated,"VISA03 (clinical MDR strain isolate provided by Tsai-Ling Yang, National Health Research Institutes (Miaoli, Taiwan))",MIC = 16 microG/ML,"Nal-P-113, a peptide with bulky hydrophobic side chains, exhibited increased cell toxicity and hemolytic activity at higher concentrations (> 25 microG/mL), causing 10-20% cell death and hemolysis. This was in comparison to controls, indicating a potential concern for toxicity at elevated doses.",32605123,Not available,Not available,Not available
AVR/I/SSAP134,Non-clinical,Hec,FALALKALKKALKKLKKALKKAL,23,Bee venom,Apis mellifera,Animalia (Insect),Experimentally validated,VRSA-4,MIC = 80 microM,Moderate toxic effect at high concentrations,"30349337, 34360692",Not available,Not available,Not available
AVR/I/SSAP135,Non-clinical,Cecropin A,GIGKFLHSAKKFGKAFVGEIMNS,23,Not available,Hyalophora cecropi,Animalia (Insect),Experimentally validated,VISA-8,MIC = 64 microG/ML,Low cytotoxic effect on human lung carcinoma,"16797106, 34360692","2LSA_A, 2MAG_A","C0HKN6, P11006",Not available
AVR/I/SSAP136,Non-clinical,Agelaia-MPI,INWLKLGKAIIDAL,14,Not available,Parachartergus fraternus,Animalia (Insect),Experimentally validated,VRSA-33,MIC = 4-8 microG/ML,Strong hemolytic effect on human erythrocytes,"33244888, 34360692",Not available,P0DRA8,Not available
AVR/I/SSAP137,Non-clinical,Protonectin,ILGTILGLLKGL,12,Not available,Agelaia pallipes pallipes,Animalia (Insect),Experimentally validated,VRSA-33,MIC = 16 microG/ML,"Toxic to cancerous and non-cancerous cell lines, but moderated hemolytic effect against human erythrocytes","33244888, 34360692",6N68_A,P0C1R1,Not available
AVR/I/SSAP138,Non-clinical,NeuroVAL,ILE-PHE-TRP-LEU-PHE-ARG-GLY-LYS-ALA-ASP-VAL-ALA-LEU-NH2,13,Agelaia-MPI analog,Parachartergus fraternus,Animalia (Insect),Experimentally validated,VRSA-33,MIC = 128 microG/ML,"Non toxic to human erythrocytes, and cancerous and non-cancerous cells lines.","33244888, 34360692",Not available,Not available,Not available
AVR/I/SSAP139,Non-clinical,Protonectin-F,IFGTILGFLKGL,12,Protonectin Analog,Agelaia pallipes pallipes,Animalia (Insect),Experimentally validated,VRSA-33,MIC = 16 microG/ML,"Toxic to cancerous and non-cancerous cell lines, but moderated hemolytic effect against human erythrocytes","33244888, 34360692",Not available,Not available,Not available
AVR/I/SSAP140,Non-clinical,Ctriporin,FLWGLIPGAVTSLIAISKK,19,Not available,Chaerilus tricostatus,Animalia (Scorpion),Experimentally validated,VRSA-1,MIC = 10 microG/ML,Histological results showed recovery of the skin,"21876042, 34360692",Not available,Not available,Not available
AVR/I/SSAP141,Non-clinical,Ctriporin,FLWGLIPGAVTSLIAISKK,19,Not available,Chaerilus tricostatus,Animalia (Scorpion),Experimentally validated,VRSA-2,MIC = 10 microG/ML,Histological results showed recovery of the skin,"21876042, 34360692",Not available,Not available,Not available
AVR/I/SSAP142,Non-clinical,Ctriporin,FLWGLIPGAVTSLIAISKK,19,Not available,Chaerilus tricostatus,Animalia (Scorpion),Experimentally validated,VISA-1,MIC = 10 microG/ML,Histological results showed recovery of the skin,"21876042, 34360692",Not available,Not available,Not available
AVR/I/SSAP143,Non-clinical,Smp24,IWSFLIKAATKLLPSLFGGG-KKDS,24,Not available,Scorpio maurus palmatus,Animalia (Scorpion),Experimentally validated,VISA-25,MIC = 32 microG/ML,Toxic to sheep erythrocytes,"27019370, 34360692",Not available,Not available,Not available
AVR/I/SSAP144,Non-clinical,Smp24,IWSFLIKAATKLLPSLFGGG-KKDS,24,Not available,Scorpio maurus palmatus,Animalia (Scorpion),Experimentally validated,VISA-26,MIC = 64 microG/ML,Toxic to sheep erythrocytes,"27019370, 34360692",Not available,Not available,Not available
AVR/I/SSAP145,Non-clinical,Persulcatusin (IP),GFGCPFNQGACHRHCRSIGRRGGYCAGLFKQTCTCYSR,38,Not available,Ixodes persulcatus,Animalia (Insect),Experimentally validated,VRSA-3,MIC = 2 microG/ML,"Non toxic to fibroblasts, colon, epithelial cells, and erythrocytes","27531221, 34360692",Not available,Not available,Not available
AVR/I/SSAP146,Non-clinical,Persulcatusin (IP),GFGCPFNQGACHRHCRSIGRRGGYCAGLFKQTCTCYSR,38,Not available,Ixodes persulcatus,Animalia (Insect),Experimentally validated,VISA-2,MIC = 8 microG/ML,"Non toxic to fibroblasts, colon, epithelial cells, and erythrocytes","27531221, 34360692",Not available,Not available,Not available
AVR/I/SSAP147,Non-clinical,IR,GGYYCPFFQDKCHRHCRSFGRKAGYCGGFLKKTCICV,37,Not available,Ixodes ricinus,Animalia (Insect),Experimentally validated,VRSA-3,MIC = 32 microG/ML,Not available,"27531221, 34360692",Not available,Not available,Not available
AVR/I/SSAP148,Non-clinical,IR,GGYYCPFFQDKCHRHCRSFGRKAGYCGGFLKKTCICV,37,Not available,Ixodes ricinus,Animalia (Insect),Experimentally validated,VISA-2,MIC = 32 microG/ML,Not available,"27531221, 34360692",Not available,Not available,Not available
AVR/I/SSAP149,Non-clinical,HAE,GCPLNQGACHNHCRSIGRRGGYCAGIKQTCTCYRK,35,Not available,Haemaphysalis longicornis,Animalia (Insect),Experimentally validated,VRSA-3,MIC = 32 microG/ML,Not available,"27531221, 34360692",Not available,Not available,Not available
AVR/I/SSAP150,Non-clinical,HAE,GCPLNQGACHNHCRSIGRRGGYCAGIKQTCTCYRK,35,Not available,Haemaphysalis longicornis,Animalia (Insect),Experimentally validated,VISA-2,MIC = 32 microG/ML,Not available,"27531221, 34360692",Not available,Not available,Not available
AVR/I/SSAP151,Non-clinical,OMBAC,GFGCPFNQYECHAHCSGVPGYPGYKGGYCKGLFKQTCNCY,40,Not available,Ornithodoros moubata,Animalia (Insect),Experimentally validated,VRSA-3,MIC = 8 microG/ML,Not available,"27531221, 34360692",Not available,Not available,Not available
AVR/I/SSAP152,Non-clinical,OMBAC,GFGCPFNQYECHAHCSGVPGYPGYKGGYCKGLFKQTCNCY,40,Not available,Ornithodoros moubata,Animalia (Insect),Experimentally validated,VISA-2,MIC => 32 microG/ML,Not available,"27531221, 34360692",Not available,Not available,Not available
AVR/I/SSAP153,Non-clinical,FL10,GVVDILKGALKDIAGHLASKVMNKL,25,Not available,Fallaxin analogs,Not available,Experimentally validated,VISA-32,MIC = 50 microM,High hemolytic effect on human erythrocytes,"17766389, 34360692",Not available,Not available,Not available
AVR/I/SSAP154,Non-clinical,FL9,GVVDILKGLAKDIAGHLASKVMNKL,25,Not available,Fallaxin analogs,Not available,Experimentally validated,VISA-32,MIC = 50 microM,Moderate hemolytic effect on human erythrocytes,"17766389, 34360692",Not available,Not available,Not available
AVR/I/SSAP155,Non-clinical,FA12,GVVDILKGAAKAIAGHLASKVMNKL,25,Not available,Fallaxin analogs,Not available,Experimentally validated,VISA-32,MIC = 50 microM,High hemolytic effect on human erythrocytes,"17766389, 34360692",Not available,Not available,Not available
AVR/I/SSAP156,Non-clinical,FL14,GVVDILKGAAKDILGHLASKVMNKL,25,Not available,Fallaxin analogs,Not available,Experimentally validated,VISA-32,MIC = 50 microM,High hemolytic effect on human erythrocytes,"17766389, 34360692",Not available,Not available,Not available
AVR/I/SSAP157,Non-clinical,LL-37,LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES,37,Not available,Homo sapiens,Animalia (Human),Experimentally validated,VRSA-18,MIC = 64 microG/ML,Low cytotoxic effect,"30120393, 34360692",2K6O_A,"Q1KLX1, P49913",DB16532
AVR/I/SSAP158,Non-clinical,LL-37,LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES,37,Not available,Homo sapiens,Animalia (Human),Experimentally validated,VISA-7,MIC = 64 microG/ML,Low cytotoxic effect,"30120393, 34360692",2K6O_A,"Q1KLX1, P49913",DB16532
AVR/I/SSAP159,Non-clinical,LL-13,IGKEFKRIVQRIKDFLRNLVPRTES,25,Not available,Derived from LL-37,Not available,Experimentally validated,VRSA-18,MIC = 512 microG/ML,Not available,"30120393, 34360692","2FCG_F, 2K6O_A","Q1KLX1, P49913",Not available
AVR/I/SSAP160,Non-clinical,LL-13,IGKEFKRIVQRIKDFLRNLVPRTES,25,Not available,Derived from LL-37,Not available,Experimentally validated,VRSA-7,MIC = 1024 microG/ML,Not available,"30120393, 34360692","2FCG_F, 2K6O_A","Q1KLX1, P49913",Not available
AVR/I/SSAP161,Non-clinical,LL-17,LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES,37,Not available,Derived from LL-37,Not available,Experimentally validated,VRSA-18,MIC = 512 microG/ML,Not available,"30120393, 34360692",2K6O_A,"Q1KLX1, P49913",Not available
AVR/I/SSAP162,Non-clinical,LL-17,LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES,37,Not available,Derived from LL-37,Not available,Experimentally validated,VRSA-7,MIC = 1024 microG/ML,Not available,"30120393, 34360692",2K6O_A,"Q1KLX1, P49913",Not available
AVR/I/SSAP163,Non-clinical,Nisin,I-Dhb-A-I-Dhb-I-A-Abu-P-G-A-K-Abu-G-A-L-M-G-A-N-M-K-Abu-A-Abu-A-H-A-S-I-H-V-Dha-K,27,Not available,Lactococcus lactis,Bacteria,Experimentally validated,VISA-19,MIC = 4.1 mg/L,Hemolytic effect on sheep erythrocytes,"19561147, 34360692",Not available,Not available,Not available
AVR/I/SSAP164,Non-clinical,Nisin,I-Dhb-A-I-Dhb-I-A-Abu-P-G-A-K-Abu-G-A-L-M-G-A-N-M-K-Abu-A-Abu-A-H-A-S-I-H-V-Dha-K,27,Not available,Lactococcus lactis,Bacteria,Experimentally validated,VISA-20,MIC = 8.3 mg/L,Hemolytic effect on sheep erythrocytes,"19561147, 34360692",Not available,Not available,Not available
AVR/I/SSAP165,Non-clinical,Nisin,I-Dhb-A-I-Dhb-I-A-Abu-P-G-A-K-Abu-G-A-L-M-G-A-N-M-K-Abu-A-Abu-A-H-A-S-I-H-V-Dha-K,27,Not available,Lactococcus lactis,Bacteria,Experimentally validated,VISA-21,MIC = 4.1 mg/L,Hemolytic effect on sheep erythrocytes,"19561147, 34360692",Not available,Not available,Not available
AVR/I/SSAP166,Non-clinical,Nisin,I-Dhb-A-I-Dhb-I-A-Abu-P-G-A-K-Abu-G-A-L-M-G-A-N-M-K-Abu-A-Abu-A-H-A-S-I-H-V-Dha-K,27,Not available,Lactococcus lactis,Bacteria,Experimentally validated,VISA-22,MIC = 8.3 mg/L,Hemolytic effect on sheep erythrocytes,"19561147, 34360692",Not available,Not available,Not available
AVR/I/SSAP167,Non-clinical,Nisin,I-Dhb-A-I-Dhb-I-A-Abu-P-G-A-K-Abu-G-A-L-M-G-A-N-M-K-Abu-A-Abu-A-H-A-S-I-H-V-Dha-K,27,Not available,Lactococcus lactis,Bacteria,Experimentally validated,VISA-23,MIC = 4.1 mg/L,Hemolytic effect on sheep erythrocytes,"19561147, 34360692",Not available,Not available,Not available
AVR/I/SSAP168,Non-clinical,Nisin,I-Dhb-A-I-Dhb-I-A-Abu-P-G-A-K-Abu-G-A-L-M-G-A-N-M-K-Abu-A-Abu-A-H-A-S-I-H-V-Dha-K,27,Not available,Lactococcus lactis,Bacteria,Experimentally validated,VISA-24,MIC = 8.3 mg/L,Hemolytic effect on sheep erythrocytes,"19561147, 34360692",Not available,Not available,Not available
AVR/I/SSAP169,Non-clinical,Hominicin,Dmlle-Dhb-P-A-Dhb-P-F-Dhb-P-A-I-T-E-I-Dhb-A-A-V-I-A-Dmp,15,Not available,Staphylococcus hominis,Bacteria,Experimentally validated,VISA-18,MIC = 3.82 microG/ML,Not available,"20654578, 34360692",Not available,Not available,Not available
AVR/I/SSAP170,Non-clinical,Mutacin 1140,F-K-A-W-Dha-L-A-Abu-P-G-A-A-R-Dhb-G-A-F-N-A-Y-A,18,Not available,Streptococcus mutans,Bacteria,Experimentally validated,VRSA-23,MIC = 4-8 microG/ML,Not available,"20039385, 34360692",Not available,Not available,Not available
AVR/I/SSAP171,Non-clinical,Mutacin 1140,F-K-A-W-Dha-L-A-Abu-P-G-A-A-R-Dhb-G-A-F-N-A-Y-A,18,Not available,Streptococcus mutans,Bacteria,Experimentally validated,VISA-15,MIC = 4 microG/ML,Not available,"20039385, 34360692",Not available,Not available,Not available
AVR/I/SSAP172,Non-clinical,Bactofencin A (analog 5),KRKKHRCRVWNNGLPTGLYRWC,22,Not available,Lactobacillus salivarius,Bacteria,Experimentally validated,VRSA-25,MIC = 4.3 microM,Not available,"30540905, 34360692",Not available,Not available,Not available
AVR/I/SSAP173,Non-clinical,Bactofencin A (analog 5),KRKKHRCRVWNNGLPTGLYRWC,22,Not available,Lactobacillus salivarius,Bacteria,Experimentally validated,VRSA-26,MIC = 100 microM,Not available,"30540905, 34360692",Not available,Not available,Not available
AVR/I/SSAP174,Non-clinical,Lugdunin,Thiazolidine-Val-Trp-Leu-Val-Val,5,Not available,Staphylococcus lugdunensis,Bacteria,Experimentally validated,VISA-30,MIC = 3 microG/ML,No lysis of primary human erythrocytes or neutrophils.,"27466123, 34360692",Not available,Not available,Not available
AVR/I/SSAP175,Non-clinical,P138-C,Gly-Leu-Glu-Glu-Thr-Val-Tyr-Ile-Tyr-Gly-Ala-Asn-Met-X-Ser,14,Not available,Bacillus subtilis subsp. inaquosorum,Bacteria,Experimentally validated,VRSA-14,MIC = 20 microG/ML,Not available,"28581021, 34360692",Not available,Not available,Not available
AVR/I/SSAP176,Non-clinical,CSPK14,HYDPGDDSGNTG,12,Not available,Bacillus amyloliquefaciens,Bacteria,Experimentally validated,VRSA-13,MIC = 64 microG/ML,Not available,"27787755, 34360692",Not available,Not available,Not available
AVR/I/SSAP177,Non-clinical,LI-F04a analog 5,Thr-Val-Val-Thr-Asn-Ala,6,Not available,Fusaricidin analogs,Not available,Experimentally validated,VISA-29,MIC = 16 microG/ML,Hemolysis on human erythrocytes,"22392790, 34360692",Not available,Not available,Not available
AVR/I/SSAP178,Non-clinical,LI-F04a analog 6,Thr-Val-Val-Thr-Asn-Ala,6,Not available,Fusaricidin analogs,Not available,Experimentally validated,VISA-29,MIC = 16 microG/ML,Hemolysis on human erythrocytes,"22392790, 34360692",Not available,Not available,Not available
AVR/I/SSAP179,Non-clinical,LI-F04a analog 8,Thr-Val-Ala-Thr-Asn-Ala,6,Not available,Fusaricidin analogs,Not available,Experimentally validated,VISA-29,MIC = 16 microG/ML,Hemolysis on human erythrocytes,"22392790, 34360692",Not available,Not available,Not available
AVR/I/SSAP180,Non-clinical,LI-F04a analog 11,Thr-Val-Phe-Thr-Asn-Ala,6,Not available,Fusaricidin analogs,Not available,Experimentally validated,VISA-29,MIC = 16 microG/ML,Hemolysis on human erythrocytes,"22392790, 34360692",Not available,Not available,Not available
AVR/I/SSAP181,Non-clinical,LTX-109,Gly-Gly-Glu-Phe-Ile-Lys-Arg-Ile-Lys-Ile-Arg-Gly-Gly,12,Not available,Synthetic peptide,Not available,Experimentally validated,VRSA-5,MIC = 2-4 microG/ML,Phase III of a clinical trial,"22585222, 34360692",Not available,Not available,DB12711
AVR/I/SSAP182,Non-clinical,LTX-109,Gly-Gly-Glu-Phe-Ile-Lys-Arg-Ile-Lys-Ile-Arg-Gly-Gly,12,Not available,Synthetic peptide,Not available,Experimentally validated,VISA-3,MIC = 2-4 microG/ML,Phase III of a clinical trial,"22585222, 34360692",Not available,Not available,DB12711
AVR/I/SSAP183,Non-clinical,Omiganan (Indolicidin analog),ILRWPWWPWRRK-amide,12,Not available,Synthetic peptide,Not available,Experimentally validated,VRSA-19,MIC = 16 microG/ML,Topical antimicrobial agent in phase III of a clinical trial,"18178361, 34360692",Not available,Not available,DB06610
AVR/I/SSAP184,Non-clinical,Omiganan (Indolicidin analog),ILRWPWWPWRRK-amide,12,Not available,Synthetic peptide,Not available,Experimentally validated,VISA-10,MIC = 16 microG/ML,Topical antimicrobial agent in phase III of a clinical trial,"18178361, 34360692",Not available,Not available,DB06610
AVR/I/SSAP185,Non-clinical,Omiganan (Indolicidin analog),ILRWPWWPWRRK-amide,12,Not available,Synthetic peptide,Not available,Experimentally validated,VISA-11,MIC = 16 microG/ML,Topical antimicrobial agent in phase III of a clinical trial,"18178361, 34360692",Not available,Not available,DB06610
AVR/I/SSAP186,Non-clinical,MP196,RWRWRW-NH2,6,Not available,Synthetic peptide,Not available,Experimentally validated,VISA-16,MIC = 16 microM,Light hemolytic effect on cell lines of breast cancer. Acute toxicity in mice cells,"27617260, 34360692",Not available,Not available,Not available
AVR/I/SSAP187,Non-clinical,MP196,RWRWRW-NH2,6,Not available,Synthetic peptide,Not available,Experimentally validated,VISA-17,MIC = 64 microG/ML,Light hemolytic effect on cell lines of breast cancer. Acute toxicity in mice cells,"27617260, 34360692",Not available,Not available,Not available
AVR/I/SSAP188,Non-clinical,P-113,Ac-A-K-R-H-H-G-Y-K-R-K-F-H-NH2,12,Not available,Synthetic peptide,Not available,Experimentally validated,VRSA-20,MIC = 64 microG/ML,Not available,"32605123, 34360692",Not available,Not available,DB06763
AVR/I/SSAP189,Non-clinical,P-113,Ac-A-K-R-H-H-G-Y-K-R-K-F-H-NH2,12,Not available,Synthetic peptide,Not available,Experimentally validated,VRSA-21,MIC = 64 microG/ML,Not available,"32605123, 34360692",Not available,Not available,DB06763
AVR/I/SSAP190,Non-clinical,P-113,Ac-A-K-R-H-H-G-Y-K-R-K-F-H-NH2,12,Not available,Synthetic peptide,Not available,Experimentally validated,VRSA-22,MIC = 64 microG/ML,Not available,"32605123, 34360692",Not available,Not available,DB06763
AVR/I/SSAP191,Non-clinical,P-113,Ac-A-K-R-H-H-G-Y-K-R-K-F-H-NH2,12,Not available,Synthetic peptide,Not available,Experimentally validated,VISA-12,MIC = 64 microG/ML,Not available,"32605123, 34360692",Not available,Not available,DB06763
AVR/I/SSAP192,Non-clinical,P-113,Ac-A-K-R-H-H-G-Y-K-R-K-F-H-NH2,12,Not available,Synthetic peptide,Not available,Experimentally validated,VISA-13,MIC = 64 microG/ML,Not available,"32605123, 34360692",Not available,Not available,DB06763
AVR/I/SSAP193,Non-clinical,P-113,Ac-A-K-R-H-H-G-Y-K-R-K-F-H-NH2,12,Not available,Synthetic peptide,Not available,Experimentally validated,VISA-14,MIC = 64 microG/ML,Not available,"32605123, 34360692",Not available,Not available,DB06763
AVR/I/SSAP194,Non-clinical,Phe-P-113,Ac-A-K-R-F-F-G-Y-K-R-K-F-F-NH2,12,Not available,Synthetic peptide,Not available,Experimentally validated,VRSA-20,MIC = 64 microG/ML,Not available,"32605123, 34360692",Not available,Not available,Not available
AVR/I/SSAP195,Non-clinical,Phe-P-113,Ac-A-K-R-F-F-G-Y-K-R-K-F-F-NH2,12,Not available,Synthetic peptide,Not available,Experimentally validated,VRSA-21,MIC = 64 microG/ML,Not available,"32605123, 34360692",Not available,Not available,Not available
AVR/I/SSAP196,Non-clinical,Phe-P-113,Ac-A-K-R-F-F-G-Y-K-R-K-F-F-NH2,12,Not available,Synthetic peptide,Not available,Experimentally validated,VRSA-22,MIC = 64 microG/ML,Not available,"32605123, 34360692",Not available,Not available,Not available
AVR/I/SSAP197,Non-clinical,Phe-P-113,Ac-A-K-R-F-F-G-Y-K-R-K-F-F-NH2,12,Not available,Synthetic peptide,Not available,Experimentally validated,VISA-12,MIC = 64 microG/ML,Not available,"32605123, 34360692",Not available,Not available,Not available
AVR/I/SSAP198,Non-clinical,Phe-P-113,Ac-A-K-R-F-F-G-Y-K-R-K-F-F-NH2,12,Not available,Synthetic peptide,Not available,Experimentally validated,VISA-13,MIC = 64 microG/ML,Not available,"32605123, 34360692",Not available,Not available,Not available
AVR/I/SSAP199,Non-clinical,Phe-P-113,Ac-A-K-R-F-F-G-Y-K-R-K-F-F-NH2,12,Not available,Synthetic peptide,Not available,Experimentally validated,VISA-14,MIC = 64 microG/ML,Not available,"32605123, 34360692",Not available,Not available,Not available
AVR/I/SSAP200,Non-clinical,Bip-P-113,Ac-A-K-R-Bip-Bip-G-Y-K-R-K-F-Bip-NH2,9,Not available,Synthetic peptide,Not available,Experimentally validated,VRSA-20,MIC = 16 microG/ML,Not available,"32605123, 34360692",Not available,Not available,Not available
AVR/I/SSAP201,Non-clinical,Bip-P-113,Ac-A-K-R-Bip-Bip-G-Y-K-R-K-F-Bip-NH2,9,Not available,Synthetic peptide,Not available,Experimentally validated,VRSA-21,MIC = 16 microG/ML,Not available,"32605123, 34360692",Not available,Not available,Not available
AVR/I/SSAP202,Non-clinical,Bip-P-113,Ac-A-K-R-Bip-Bip-G-Y-K-R-K-F-Bip-NH2,9,Not available,Synthetic peptide,Not available,Experimentally validated,VRSA-22,MIC = 8 microG/ML,Not available,"32605123, 34360692",Not available,Not available,Not available
AVR/I/SSAP203,Non-clinical,Bip-P-113,Ac-A-K-R-Bip-Bip-G-Y-K-R-K-F-Bip-NH2,9,Not available,Synthetic peptide,Not available,Experimentally validated,VISA-12,MIC = 16 microG/ML,Not available,"32605123, 34360692",Not available,Not available,Not available
AVR/I/SSAP204,Non-clinical,Bip-P-113,Ac-A-K-R-Bip-Bip-G-Y-K-R-K-F-Bip-NH2,9,Not available,Synthetic peptide,Not available,Experimentally validated,VISA-13,MIC = 16 microG/ML,Not available,"32605123, 34360692",Not available,Not available,Not available
AVR/I/SSAP205,Non-clinical,Bip-P-113,Ac-A-K-R-Bip-Bip-G-Y-K-R-K-F-Bip-NH2,9,Not available,Synthetic peptide,Not available,Experimentally validated,VISA-14,MIC = 8 microG/ML,Not available,"32605123, 34360692",Not available,Not available,Not available
AVR/I/SSAP206,Non-clinical,Dip-P-113,Ac-A-K-R-Dip-Dip-G-Y-K-R-K-F-Dip-NH2,9,Not available,Synthetic peptide,Not available,Experimentally validated,VRSA-20,MIC = 32 microG/ML,Not available,"32605123, 34360692",Not available,Not available,Not available
AVR/I/SSAP207,Non-clinical,Dip-P-113,Ac-A-K-R-Dip-Dip-G-Y-K-R-K-F-Dip-NH2,9,Not available,Synthetic peptide,Not available,Experimentally validated,VRSA-21,MIC = 32 microG/ML,Not available,"32605123, 34360692",Not available,Not available,Not available
AVR/I/SSAP208,Non-clinical,Dip-P-113,Ac-A-K-R-Dip-Dip-G-Y-K-R-K-F-Dip-NH2,9,Not available,Synthetic peptide,Not available,Experimentally validated,VRSA-22,MIC = 32 microG/ML,Not available,"32605123, 34360692",Not available,Not available,Not available
AVR/I/SSAP209,Non-clinical,Dip-P-113,Ac-A-K-R-Dip-Dip-G-Y-K-R-K-F-Dip-NH2,9,Not available,Synthetic peptide,Not available,Experimentally validated,VISA-12,MIC = 16 microG/ML,Not available,"32605123, 34360692",Not available,Not available,Not available
AVR/I/SSAP210,Non-clinical,Dip-P-113,Ac-A-K-R-Dip-Dip-G-Y-K-R-K-F-Dip-NH2,9,Not available,Synthetic peptide,Not available,Experimentally validated,VISA-13,MIC = 16 microG/ML,Not available,"32605123, 34360692",Not available,Not available,Not available
AVR/I/SSAP211,Non-clinical,Dip-P-113,Ac-A-K-R-Dip-Dip-G-Y-K-R-K-F-Dip-NH2,9,Not available,Synthetic peptide,Not available,Experimentally validated,VISA-14,MIC = 16 microG/ML,Not available,"32605123, 34360692",Not available,Not available,Not available
AVR/I/SSAP212,Non-clinical,Nal-P-113,Ac-AKR-Nal-Nal-GYKRKF-Nal-NH2,9,Not available,Synthetic peptide,Not available,Experimentally validated,VRSA-20,MIC = 8 microG/ML,Not available,"32605123, 34360692",Not available,Not available,Not available
AVR/I/SSAP213,Non-clinical,Nal-P-113,Ac-AKR-Nal-Nal-GYKRKF-Nal-NH2,9,Not available,Synthetic peptide,Not available,Experimentally validated,VRSA-21,MIC = 8 microG/ML,Not available,"32605123, 34360692",Not available,Not available,Not available
AVR/I/SSAP214,Non-clinical,Nal-P-113,Ac-AKR-Nal-Nal-GYKRKF-Nal-NH2,9,Not available,Synthetic peptide,Not available,Experimentally validated,VRSA-22,MIC = 16 microG/ML,Not available,"32605123, 34360692",Not available,Not available,Not available
AVR/I/SSAP215,Non-clinical,Nal-P-113,Ac-AKR-Nal-Nal-GYKRKF-Nal-NH2,9,Not available,Synthetic peptide,Not available,Experimentally validated,VISA-12,MIC = 8 microG/ML,Not available,"32605123, 34360692",Not available,Not available,Not available
AVR/I/SSAP216,Non-clinical,Nal-P-113,Ac-AKR-Nal-Nal-GYKRKF-Nal-NH2,9,Not available,Synthetic peptide,Not available,Experimentally validated,VISA-13,MIC = 8 microG/ML,Not available,"32605123, 34360692",Not available,Not available,Not available
AVR/I/SSAP217,Non-clinical,Nal-P-113,Ac-AKR-Nal-Nal-GYKRKF-Nal-NH2,9,Not available,Synthetic peptide,Not available,Experimentally validated,VISA-14,MIC = 8 microG/ML,Not available,"32605123, 34360692",Not available,Not available,Not available
AVR/I/SSAP218,Non-clinical,Lipopeptide 1,Cyclo(-D-Leu-D-Leu-D-Tyr-D-Phe-D-Ser-D-Thr-),6,Not available,Synthetic peptide,Not available,Experimentally validated,VRSA-15,MIC = 0.5 microM,Low toxicity in human embryonic and kidney cells,"27048775, 34360692",Not available,Not available,Not available
AVR/I/SSAP219,Non-clinical,Lipopeptide 1,Cyclo(-D-Leu-D-Leu-D-Tyr-D-Phe-D-Ser-D-Thr-),6,Not available,Synthetic peptide,Not available,Experimentally validated,VRSA-16,MIC = 0.6 microM,Low toxicity in human embryonic and kidney cells,"27048775, 34360692",Not available,Not available,Not available
AVR/I/SSAP220,Non-clinical,Lipopeptide 1,Cyclo(-D-Leu-D-Leu-D-Tyr-D-Phe-D-Ser-D-Thr-),6,Not available,Synthetic peptide,Not available,Experimentally validated,VRSA-17,MIC = 0.7 microM,Low toxicity in human embryonic and kidney cells,"27048775, 34360692",Not available,Not available,Not available
AVR/I/SSAP221,Non-clinical,Lipopeptide 2,Cyclo(LLYFSTD),6,Not available,Synthetic peptide,Not available,Experimentally validated,VRSA-15,MIC = 2.8 microM,Low toxicity in human embryonic and kidney cells,"27048775, 34360692",Not available,Not available,Not available
AVR/I/SSAP222,Non-clinical,Lipopeptide 2,Cyclo(LLYFSTD),6,Not available,Synthetic peptide,Not available,Experimentally validated,VRSA-16,MIC = 1.9 microM,Low toxicity in human embryonic and kidney cells,"27048775, 34360692",Not available,Not available,Not available
AVR/I/SSAP223,Non-clinical,Lipopeptide 2,Cyclo(LLYFSTD),6,Not available,Synthetic peptide,Not available,Experimentally validated,VRSA-17,MIC = 2.8 microM,Low toxicity in human embryonic and kidney cells,"27048775, 34360692",Not available,Not available,Not available
AVR/I/SSAP224,Non-clinical,Lipopeptide 3,Cyclo(-D-Phe-D-Leu-D-Phe-D-Leu-),4,Not available,Synthetic peptide,Not available,Experimentally validated,VRSA-15,MIC = 30 microM,Low toxicity in human embryonic and kidney cells,"27048775, 34360692",Not available,Not available,Not available
AVR/I/SSAP225,Non-clinical,Lipopeptide 3,Cyclo(-D-Phe-D-Leu-D-Phe-D-Leu-),4,Not available,Synthetic peptide,Not available,Experimentally validated,VRSA-16,MIC = 30 microM,Low toxicity in human embryonic and kidney cells,"27048775, 34360692",Not available,Not available,Not available
AVR/I/SSAP226,Non-clinical,Lipopeptide 3,Cyclo(-D-Phe-D-Leu-D-Phe-D-Leu-),4,Not available,Synthetic peptide,Not available,Experimentally validated,VRSA-17,MIC = 30 microM,Low toxicity in human embryonic and kidney cells,"27048775, 34360692",Not available,Not available,Not available
AVR/I/SSAP227,Non-clinical,Lipopeptide 4,Cyclo(-D-Phe-D-Val-L-Thr-D-Leu-),4,Not available,Synthetic peptide,Not available,Experimentally validated,VRSA-15,MIC = 30 microM,Low toxicity in human embryonic and kidney cells,"27048775, 34360692",Not available,Not available,Not available
AVR/I/SSAP228,Non-clinical,Lipopeptide 4,Cyclo(-D-Phe-D-Val-L-Thr-D-Leu-),4,Not available,Synthetic peptide,Not available,Experimentally validated,VRSA-16,MIC = 30 microM,Low toxicity in human embryonic and kidney cells,"27048775, 34360692",Not available,Not available,Not available
AVR/I/SSAP229,Non-clinical,Lipopeptide 4,Cyclo(-D-Phe-D-Val-L-Thr-D-Leu-),4,Not available,Synthetic peptide,Not available,Experimentally validated,VRSA-17,MIC = 30 microM,Low toxicity in human embryonic and kidney cells,"27048775, 34360692",Not available,Not available,Not available
AVR/I/SSAP230,Non-clinical,Lipopeptide 5,Cyclo(-D-Leu-D-Tyr-D-Leu-D-Phe-D-Pro-D-Val-),6,Not available,Synthetic peptide,Not available,Experimentally validated,VRSA-15,MIC = 0.2 microM,Low toxicity in human embryonic and kidney cells,"27048775, 34360692",Not available,Not available,Not available
AVR/I/SSAP231,Non-clinical,Lipopeptide 5,Cyclo(-D-Leu-D-Tyr-D-Leu-D-Phe-D-Pro-D-Val-),6,Not available,Synthetic peptide,Not available,Experimentally validated,VRSA-16,MIC = 0.1 microM,Low toxicity in human embryonic and kidney cells,"27048775, 34360692",Not available,Not available,Not available
AVR/I/SSAP232,Non-clinical,Lipopeptide 5,Cyclo(-D-Leu-D-Tyr-D-Leu-D-Phe-D-Pro-D-Val-),6,Not available,Synthetic peptide,Not available,Experimentally validated,VRSA-17,MIC = 0.1 microM,Low toxicity in human embryonic and kidney cells,"27048775, 34360692",Not available,Not available,Not available
AVR/I/SSAP233,Non-clinical,Lipopeptide 6,Cyclo(-D-Phe-D-Val-L-Thr-D-Leu-D-Leu-),5,Not available,Synthetic peptide,Not available,Experimentally validated,VRSA-15,MIC = 2.8 microM,Low toxicity in human embryonic and kidney cells,"27048775, 34360692",Not available,Not available,Not available
AVR/I/SSAP234,Non-clinical,Lipopeptide 6,Cyclo(-D-Phe-D-Val-L-Thr-D-Leu-D-Leu-),5,Not available,Synthetic peptide,Not available,Experimentally validated,VRSA-16,MIC = 1.9 microM,Low toxicity in human embryonic and kidney cells,"27048775, 34360692",Not available,Not available,Not available
AVR/I/SSAP235,Non-clinical,Lipopeptide 6,Cyclo(-D-Phe-D-Val-L-Thr-D-Leu-D-Leu-),5,Not available,Synthetic peptide,Not available,Experimentally validated,VRSA-17,MIC = 1.9 microM,Low toxicity in human embryonic and kidney cells,"27048775, 34360692",Not available,Not available,Not available
AVR/I/SSAP236,Non-clinical,C14-KK,C14-KK,16,Not available,Synthetic peptide,Not available,Experimentally validated,VISA-31,MIC = 12.5 microM,Strong hemolytic effect on human erythrocytes,"26257894, 34360692",Not available,Not available,Not available
AVR/I/SSAP237,Non-clinical,C14-RRR,C14-RRR,17,Not available,Synthetic peptide,Not available,Experimentally validated,VISA-31,MIC = 3.1 microM,Strong hemolytic effect on human erythrocytes,"26257894, 34360692",Not available,Not available,Not available
AVR/I/SSAP238,Non-clinical,C14-LK,C14-LK,16,Not available,Synthetic peptide,Not available,Experimentally validated,VISA-31,MIC = 1.56 microM,Strong hemolytic effect on human erythrocytes,"26257894, 34360692",Not available,Not available,Not available
AVR/I/SSAP239,Non-clinical,C14-LK,C14-RW,16,Not available,Synthetic peptide,Not available,Experimentally validated,VISA-31,MIC = 12.5 microM,Strong hemolytic effect on human erythrocytes,"26257894, 34360692",Not available,Not available,Not available
AVR/I/SSAP240,Non-clinical,C14-WR,C14-WR,16,Not available,Synthetic peptide,Not available,Experimentally validated,VISA-31,MIC = 3.1 microM,Strong hemolytic effect on human erythrocytes,"26257894, 34360692",Not available,Not available,Not available
AVR/I/SSAP241,Non-clinical,C14-KWI,C14-KWI,17,Not available,Synthetic peptide,Not available,Experimentally validated,VISA-31,MIC = 12.5 microM,Strong hemolytic effect on human erythrocytes,"26257894, 34360692",Not available,Not available,Not available
AVR/I/SSAP242,Non-clinical,C14-LKK,C14-LKK,17,Not available,Synthetic peptide,Not available,Experimentally validated,VISA-31,MIC = 3.1 microM,Strong hemolytic effect on human erythrocytes,"26257894, 34360692",Not available,Not available,Not available
AVR/I/SSAP243,Non-clinical,RRIKA,WLRRIKAWLRRIKA,14,Not available,Synthetic peptide,Not available,Experimentally validated,VISA-33,MIC = 2 microM,"Low hemolytic activity, but show toxicity in mammalian cell lines","24798285, 34360692",7YSS_A,Not available,Not available
AVR/I/SSAP244,Non-clinical,RRIKA,WLRRIKAWLRRIKA,14,Not available,Synthetic peptide,Not available,Experimentally validated,VRSA-29,MIC = 4 microM,"Low hemolytic activity, but show toxicity in mammalian cell lines","24798285, 34360692",7YSS_A,Not available,Not available
AVR/I/SSAP245,Non-clinical,RRIKA,WLRRIKAWLRRIKA,14,Not available,Synthetic peptide,Not available,Experimentally validated,VRSA-30,MIC = 4 microM,"Low hemolytic activity, but show toxicity in mammalian cell lines","24798285, 34360692",7YSS_A,Not available,Not available
AVR/I/SSAP246,Non-clinical,RRIKA,WLRRIKAWLRRIKA,14,Not available,Synthetic peptide,Not available,Experimentally validated,VRSA-31,MIC = 4 microM,"Low hemolytic activity, but show toxicity in mammalian cell lines","24798285, 34360692",7YSS_A,Not available,Not available
AVR/I/SSAP247,Non-clinical,RRIKA,WLRRIKAWLRRIKA,14,Not available,Synthetic peptide,Not available,Experimentally validated,VRSA-32,MIC = 4 microM,"Low hemolytic activity, but show toxicity in mammalian cell lines","24798285, 34360692",7YSS_A,Not available,Not available
AVR/I/SSAP248,Non-clinical,RRIKA,WLRRIKAWLRRIKA,14,Not available,Synthetic peptide,Not available,Experimentally validated,VRSA-33,MIC = 4 microM,"Low hemolytic activity, but show toxicity in mammalian cell lines","24798285, 34360692",7YSS_A,Not available,Not available
AVR/I/SSAP249,Non-clinical,RR,WLRRIKAWLRR,11,Not available,Synthetic peptide,Not available,Experimentally validated,VISA-33,MIC = 16 microM,"Low hemolytic activity, but show toxicity in mammalian cell lines","24798285, 34360692",7YSS_A,Not available,Not available
AVR/I/SSAP250,Non-clinical,RR,WLRRIKAWLRR,11,Not available,Synthetic peptide,Not available,Experimentally validated,VRSA-29,MIC = 32 microM,"Low hemolytic activity, but show toxicity in mammalian cell lines","24798285, 34360692",7YSS_A,Not available,Not available
AVR/I/SSAP251,Non-clinical,RR,WLRRIKAWLRR,11,Not available,Synthetic peptide,Not available,Experimentally validated,VRSA-30,MIC = 16 microM,"Low hemolytic activity, but show toxicity in mammalian cell lines","24798285, 34360692",7YSS_A,Not available,Not available
AVR/I/SSAP252,Non-clinical,RR,WLRRIKAWLRR,11,Not available,Synthetic peptide,Not available,Experimentally validated,VRSA-31,MIC = 16 microM,"Low hemolytic activity, but show toxicity in mammalian cell lines","24798285, 34360692",7YSS_A,Not available,Not available
AVR/I/SSAP253,Non-clinical,RR,WLRRIKAWLRR,11,Not available,Synthetic peptide,Not available,Experimentally validated,VRSA-32,MIC = 32 microM,"Low hemolytic activity, but show toxicity in mammalian cell lines","24798285, 34360692",7YSS_A,Not available,Not available
AVR/I/SSAP254,Non-clinical,RR,WLRRIKAWLRR,11,Not available,Synthetic peptide,Not available,Experimentally validated,VRSA-33,MIC = 32 microM,"Low hemolytic activity, but show toxicity in mammalian cell lines","24798285, 34360692",7YSS_A,Not available,Not available
AVR/I/SSAP255,Non-clinical,Mersacidin,A-Abu-I-Abu-L-P-C-G-G-G-V-A-Abu-L-Abu-Dha-E-A-I,15,Not available,"Bacillus sp. strain HIL Y-85, 54728",Bacteria,Experimentally validated,VSSA strain SG511,MIC = 1 microG/ML,Not available,18947397,Not available,Not available,Not available
AVR/I/SSAP256,Non-clinical,BCP61,AINCDAAYL,9,Not available,Bacillus sp.,Bacteria,Experimentally validated,VRSA-24,MIC = 10 microG/ML,Not available,"22578764, 34360692",Not available,Not available,Not available
AVR/I/SSAP257,Non-clinical,AgkTx-II (PLA2),GIDCGKAGKPCPCKKPCKKSCRFSFAYPFCGRGKQYRKMKADCCSCK,47,Agelena orientalis venom,Agelena orientalis,Animalia (Insect),Experimentally validated,VRSA,"MIC = 21.25 (83.6%) microG/ML, MBC (Colony forming units/ML) = (6) 80%",Not available,22050758,Not available,Not available,Not available
AVR/I/SSAP258,Non-clinical,Crotoxin B ,MSPDFYAYFKILKVKEEYGPCGVSNPWCYCTSSDNEIVCKKNGNACIEGCEPYCRGRGAAGTCRDSGKPKDATCDAVLKCYKSGKRCLPTKYGFGGFYNRPDDYFKDPKTMGAVCGEMFRKDLVKWCKKGCKKP,134,Crotalus durissus terrificus venom,Crotalus durissus terrificus,Animalia (Snake),Experimentally validated,VRSA,"MIC = nt, MBC = nt",Not available,22050758,Not available,Not available,Not available
AVR/I/SSAP259,Non-clinical,Daboiatoxin (DbTx),MDFPYAFKCM KDVVYTAAQY KKWVRYRAGC CGGNTADSYC NAICTNRRIC FSDECQRFNP DCQS,64,Daboia russelii venom,Daboia russelii,Animalia (Snake),Experimentally validated,VRSA,"MIC = nt, MBC = nt",Not available,22050758,Not available,Not available,Not available
AVR/I/SSAP260,Non-clinical,Mulgatoxin,MKLFWLLVVG AFLGLVQGPH RIGGQNIEKT IENLKNETAE ALKWNAKQEK VDEIIAIKEK AEELKEAFGK YAKSSS,76,Pseudechis australis venom,Pseudechis australis,Animalia (Snake),Experimentally validated,VRSA,"MIC = nt, MBC = nt",Not available,22050758,Not available,Not available,Not available
AVR/I/SSAP261,Non-clinical,Metalloproteinases (AHM),MIQVLLVTICLAVFPYQGSSIILES,25,"Agkistrodon halys (pallas, Chinese viper) snake venom","Agkistrodon halys (pallas, Chinese viper) snake ",Animalia (Snake),Experimentally validated,VRSA,"MIC = 7.5 (80.9%) microG/ML, MBC = (7) 83.7% ",Not available,22050758,Not available,"P83253, C9E1S2, Q805F5, Q2LD49, P20164, Q90ZI3, Q8AWI5, Q8AWX7, J9Z332, J3SBP9, C9E1R7, P83912, E9NW27, P0C6B6, P18619, P17349, Q90YA6, Q7ZZS9, E9NW26, C9E1R9",Not available
AVR/I/SSAP262,Non-clinical,Bactofencin A,GKGLVAKGALSKVKAGVGAGKAGVVKALPAAKAVKVLAAKAA,42,Not available,"Gram-positive bacteria, such as those from lactic acid bacteria",Bacteria,Experimentally validated,VRSA 40410425,MIC = 100 microM,Not available,30540905,Not available,Not available,Not available
AVR/I/SSAP263,Non-clinical,Bactofencin A,GKGLVAKGALSKVKAGVGAGKAGVVKALPAAKAVKVLAAKAA,42,Not available,"Gram-positive bacteria, such as those from lactic acid bacteria",Bacteria,Experimentally validated,VRSA 40413389,MIC = 4.3 microM,Not available,30540905,Not available,Not available,Not available
AVR/I/SSAP264,Non-clinical,BCP61,A-I-N-X-D-A-A-Y-L,9,Not available,Bacillus subtilis BSn5,Bacteria,Experimentally validated,VRSA,MIC = 10 microG/ML,Not available,22578764,Not available,Not available,Not available
AVR/I/SSAP265,Non-clinical,Fallaxin,GVVDILKGAAKDIAGHLASKVMNKL-NH2,25,Not available,West Indian mountain chicken frog Leptodactylus fallax,Animalia (Frog),Experimentally validated,VISA,MIC = 100 microM,0% hemolytic activity found at the tested concentration for VISA.,17766389,5U9S_A,C0HKF0,Not available
AVR/I/SSAP266,Non-clinical,FA25,GVVDILKGAAKDIAGHLASKVMNKA-NH2,25,Not available,West Indian mountain chicken frog Leptodactylus fallax,Animalia (Frog),Experimentally validated,VISA,MIC = 100 microM,0% hemolytic activity found at the tested concentration for VISA.,17766389,Not available,Not available,Not available
AVR/I/SSAP267,Non-clinical,FA24,GVVDILKGAAKDIAGHLASKVMNAL-NH2,25,Not available,West Indian mountain chicken frog Leptodactylus fallax,Animalia (Frog),Experimentally validated,VISA,MIC = 100 microM,2% hemolytic activity found at the tested concentration for VISA.,17766389,Not available,Not available,Not available
AVR/I/SSAP268,Non-clinical,FA23,GVVDILKGAAKDIAGHLASKVMAKL-NH2,25,Not available,West Indian mountain chicken frog Leptodactylus fallax,Animalia (Frog),Experimentally validated,VISA,MIC = 100 microM,0% hemolytic activity found at the tested concentration for VISA.,17766389,Not available,Not available,Not available
AVR/I/SSAP269,Non-clinical,FA22,GVVDILKGAAKDIAGHLASKVANKL-NH2,25,Not available,West Indian mountain chicken frog Leptodactylus fallax,Animalia (Frog),Experimentally validated,VISA,MIC = 100 microM,0% hemolytic activity found at the tested concentration for VISA.,17766389,Not available,Not available,Not available
AVR/I/SSAP270,Non-clinical,FA21,GVVDILKGAAKDIAGHLASKAMNKL-NH2,25,Not available,West Indian mountain chicken frog Leptodactylus fallax,Animalia (Frog),Experimentally validated,VISA,MIC = 100 microM,0% hemolytic activity found at the tested concentration for VISA.,17766389,Not available,Not available,Not available
AVR/I/SSAP271,Non-clinical,FA20,GVVDILKGAAKDIAGHLASAVMNKL-NH2,25,Not available,West Indian mountain chicken frog Leptodactylus fallax,Animalia (Frog),Experimentally validated,VISA,MIC = 100 microM,2% hemolytic activity found at the tested concentration for VISA.,17766389,Not available,Not available,Not available
AVR/I/SSAP272,Non-clinical,FA19,GVVDILKGAAKDIAGHLAAKVMNKL-NH2,25,Not available,West Indian mountain chicken frog Leptodactylus fallax,Animalia (Frog),Experimentally validated,VISA,MIC = 100 microM,2% hemolytic activity found at the tested concentration for VISA.,17766389,Not available,Not available,Not available
AVR/I/SSAP273,Non-clinical,FA18,GVVDILKGAAKDIAGHLLSKVMNKL-NH2,25,Not available,West Indian mountain chicken frog Leptodactylus fallax,Animalia (Frog),Experimentally validated,VISA,MIC = 100 microM,38% hemolytic activity found at the tested concentration for VISA.,17766389,Not available,Not available,Not available
AVR/I/SSAP274,Non-clinical,FA17,GVVDILKGAAKDIAGHASKVMNKL-NH2,24,Not available,West Indian mountain chicken frog Leptodactylus fallax,Animalia (Frog),Experimentally validated,VISA,MIC = 100 microM,0% hemolytic activity found at the tested concentration for VISA.,17766389,Not available,Not available,Not available
AVR/I/SSAP275,Non-clinical,FA16,GVVDILKGAAKDIAGALASKVMNKL-NH2,25,Not available,West Indian mountain chicken frog Leptodactylus fallax,Animalia (Frog),Experimentally validated,VISA,MIC = 100 microM,0% hemolytic activity found at the tested concentration for VISA.,17766389,Not available,Not available,Not available
AVR/I/SSAP276,Non-clinical,FA15,GVVDILKGAAKDIAAHLASKVMNKL-NH2,25,Not available,West Indian mountain chicken frog Leptodactylus fallax,Animalia (Frog),Experimentally validated,VISA,MIC = 100 microM,14% hemolytic activity found at the tested concentration for VISA.,17766389,Not available,Not available,Not available
AVR/I/SSAP277,Non-clinical,FA14,GVVDILKGAAKDILGHLASKVMNKL-NH2,25,Not available,West Indian mountain chicken frog Leptodactylus fallax,Animalia (Frog),Experimentally validated,VISA,MIC = 50 microM,55% hemolytic activity found at the tested concentration for VISA.,17766389,Not available,Not available,Not available
AVR/I/SSAP278,Non-clinical,FA13,GVVDILKGAAKDAAGHLASKVMNKL-NH2,25,Not available,West Indian mountain chicken frog Leptodactylus fallax,Animalia (Frog),Experimentally validated,VISA,MIC = 100 microM,0% hemolytic activity found at the tested concentration for VISA.,17766389,Not available,Not available,Not available
AVR/I/SSAP279,Non-clinical,FA12,GVVDILKGAAKAIAGHLASKVMNKL-NH2,25,Not available,West Indian mountain chicken frog Leptodactylus fallax,Animalia (Frog),Experimentally validated,VISA,MIC = 50 microM,32% hemolytic activity found at the tested concentration for VISA.,17766389,Not available,Not available,Not available
AVR/I/SSAP280,Non-clinical,FA11,GVVDILKGAAADIAGHLASKVMNKL-NH2,25,Not available,West Indian mountain chicken frog Leptodactylus fallax,Animalia (Frog),Experimentally validated,VISA,MIC = 100 microM,5% hemolytic activity found at the tested concentration for VISA.,17766389,Not available,Not available,Not available
AVR/I/SSAP281,Non-clinical,FA10,GVVDILKGALKDIAGHLASKVMNKL-NH2,25,Not available,West Indian mountain chicken frog Leptodactylus fallax,Animalia (Frog),Experimentally validated,VISA,MIC = 50 microM,43% hemolytic activity found at the tested concentration for VISA.,17766389,Not available,Not available,Not available
AVR/I/SSAP282,Non-clinical,FA9,GVVDILKGLAKDIAGHLASKVMNKL-NH2,25,Not available,West Indian mountain chicken frog Leptodactylus fallax,Animalia (Frog),Experimentally validated,VISA,MIC = 50 microM,27% hemolytic activity found at the tested concentration for VISA.,17766389,Not available,Not available,Not available
AVR/I/SSAP283,Non-clinical,FA8,GVVDILKAAAKDIAGHLASKVMNKL-NH2,25,Not available,West Indian mountain chicken frog Leptodactylus fallax,Animalia (Frog),Experimentally validated,VISA,MIC = 100 microM,11% hemolytic activity found at the tested concentration for VISA.,17766389,Not available,Not available,Not available
AVR/I/SSAP284,Non-clinical,FA7,GVVDILAGAAKDIAGHLASKVMNKL-NH2,25,Not available,West Indian mountain chicken frog Leptodactylus fallax,Animalia (Frog),Experimentally validated,VISA,MIC = 100 microM,0% hemolytic activity found at the tested concentration for VISA.,17766389,Not available,Not available,Not available
AVR/I/SSAP285,Non-clinical,FA6,GVVDIAKGAAKDIAGHLASKVMNKL-NH2,25,Not available,West Indian mountain chicken frog Leptodactylus fallax,Animalia (Frog),Experimentally validated,VISA,MIC = 100 microM,0% hemolytic activity found at the tested concentration for VISA.,17766389,Not available,Not available,Not available
AVR/I/SSAP286,Non-clinical,FA5,GVVDALKGAAKDIAGHLASKVMNKL-NH2,25,Not available,West Indian mountain chicken frog Leptodactylus fallax,Animalia (Frog),Experimentally validated,VISA,MIC = 100 microM,0% hemolytic activity found at the tested concentration for VISA.,17766389,Not available,Not available,Not available
AVR/I/SSAP287,Non-clinical,FA4,GVVAILKGAAKDIAGHLASKVMNKL-NH2,25,Not available,West Indian mountain chicken frog Leptodactylus fallax,Animalia (Frog),Experimentally validated,VISA,MIC = 100 microM,1% hemolytic activity found at the tested concentration for VISA.,17766389,Not available,Not available,Not available
AVR/I/SSAP288,Non-clinical,FA3,GVADILKGAAKDIAGHLASKVMNKL-NH2,25,Not available,West Indian mountain chicken frog Leptodactylus fallax,Animalia (Frog),Experimentally validated,VISA,MIC = 100 microM,0% hemolytic activity found at the tested concentration for VISA.,17766389,Not available,Not available,Not available
AVR/I/SSAP289,Non-clinical,FA2,GAVDILKGAAKDIAGHLASKVMNKL-NH2,25,Not available,West Indian mountain chicken frog Leptodactylus fallax,Animalia (Frog),Experimentally validated,VISA,MIC = 100 microM,0% hemolytic activity found at the tested concentration for VISA.,17766389,Not available,Not available,Not available
AVR/I/SSAP290,Non-clinical,FA1,AVVDILKGAAKDIAGHLASKVMNKL-NH2,25,Not available,West Indian mountain chicken frog Leptodactylus fallax,Animalia (Frog),Experimentally validated,VISA,MIC = 100 microM,0% hemolytic activity found at the tested concentration for VISA.,17766389,Not available,Not available,Not available
AVR/I/SSAP291,Non-clinical,FNt17-25,LASKVMNKL-NH2,9,Not available,West Indian mountain chicken frog Leptodactylus fallax,Animalia (Frog),Experimentally validated,VISA ATCC 700699 MU50,MIC = 100 microM,Not available,17766389,Not available,Not available,Not available
AVR/I/SSAP292,Non-clinical,FCt1-11,GVVDILKGAAK-NH2,11,Not available,West Indian mountain chicken frog Leptodactylus fallax,Animalia (Frog),Experimentally validated,VISA ATCC 700699MU50,MIC = 100 microM,Not available,17766389,Not available,Not available,Not available
AVR/I/SSAP293,Non-clinical,FCt1-16,GVVDILKGAAKDIAGH-NH2,16,Not available,West Indian mountain chicken frog Leptodactylus fallax,Animalia (Frog),Experimentally validated,VISA ATCC 700699MU50,MIC = 100 microM,Not available,17766389,"5U9S_A, 5U9R_A, 5U9Q_A",C0HKF0,Not available
AVR/I/SSAP294,Non-clinical,Daptomycin,Thr-D-Asn-Glu-Tyr-Asn-Pro-L-Asn-Gly-L-Thr-L-Ser-D-Asn-Gly-L-Thr-L-Thr-L-Cys-L-Thr,19,Not available,Streptomyces roseosporus,Bacteria,Experimentally validated,VRSA,"MIC(90%) = NA, MIC RANGE = 0.25 to 1 microG/ML","Daptomycin has demonstrated a favorable safety profile in both animal toxicology studies and clinical trials, including a Phase I trial assessing its tolerability and pharmacokinetics in hemodialysis patients with end-stage renal disease. Daptomycin also can cause dose-dependent hemolysis, especially in patients with renal impairment or on high doses, necessitating monitoring for anemia or hemoglobin changes during therapy.",15330747,Not available,Not available,DB00080
AVR/I/SSAP295,Non-clinical,Daptomycin,Thr-D-Asn-Glu-Tyr-Asn-Pro-L-Asn-Gly-L-Thr-L-Ser-D-Asn-Gly-L-Thr-L-Thr-L-Cys-L-Thr,19,Not available,Streptomyces roseosporus,Bacteria,Experimentally validated,VISA,"MIC(90%) = 1 microG/ML, MIC RANGE = 0.0625 to 2 microG/ML","Daptomycin has demonstrated a favorable safety profile in both animal toxicology studies and clinical trials, including a Phase I trial assessing its tolerability and pharmacokinetics in hemodialysis patients with end-stage renal disease. Daptomycin also can cause dose-dependent hemolysis, especially in patients with renal impairment or on high doses, necessitating monitoring for anemia or hemoglobin changes during therapy.",15330747,Not available,Not available,DB00080
AVR/I/SSAP296,Non-clinical,Phormicin C,ATCDLLSGTGVGHSACAAHCLLRGNRGGYCNGKGVCVCRN,40,Not available,Musca domestica,Animalia (Insect),Experimentally validated,VRSA-27,MIC = 32 microG/ML,Not available,"33202277, 34360692",Not available,Not available,Not available
AVR/I/SSAP297,Non-clinical,Nisin,I-Dhb-A-I-Dhb-I-A-Abu-P-G-A-K-Abu-G-A-L-M-G-A-N-M-K-Abu-A-Abu-A-H-A-S-I-H-V-Dha-K,27,Not available,Lactococcus lactis,Bacteria,Experimentally validated,hVISA 32679,MIC = 4.1 mg/L,Not available,19561147,Not available,Not available,Not available
AVR/I/SSAP298,Non-clinical,Nisin,I-Dhb-A-I-Dhb-I-A-Abu-P-G-A-K-Abu-G-A-L-M-G-A-N-M-K-Abu-A-Abu-A-H-A-S-I-H-V-Dha-K,27,Not available,Lactococcus lactis,Bacteria,Experimentally validated,hVISA 35197,MIC = 8.3 mg/L,Not available,19561147,Not available,Not available,Not available
AVR/I/SSAP299,Non-clinical,Nisin,I-Dhb-A-I-Dhb-I-A-Abu-P-G-A-K-Abu-G-A-L-M-G-A-N-M-K-Abu-A-Abu-A-H-A-S-I-H-V-Dha-K,27,Not available,Lactococcus lactis,Bacteria,Experimentally validated,hVISA 32652,MIC = 4.1 mg/L,Not available,19561147,Not available,Not available,Not available
AVR/I/SSAP300,Non-clinical,Nisin,I-Dhb-A-I-Dhb-I-A-Abu-P-G-A-K-Abu-G-A-L-M-G-A-N-M-K-Abu-A-Abu-A-H-A-S-I-H-V-Dha-K,27,Not available,Lactococcus lactis,Bacteria,Experimentally validated,hVISA 32675,MIC = 4.1 mg/L,Not available,19561147,Not available,Not available,Not available
AVR/I/SSAP301,Non-clinical,Nisin,I-Dhb-A-I-Dhb-I-A-Abu-P-G-A-K-Abu-G-A-L-M-G-A-N-M-K-Abu-A-Abu-A-H-A-S-I-H-V-Dha-K,27,Not available,Lactococcus lactis,Bacteria,Experimentally validated,hVISA 32681,MIC = 2 mg/L,Not available,19561147,Not available,Not available,Not available
AVR/I/SSAP302,Non-clinical,Nisin,I-Dhb-A-I-Dhb-I-A-Abu-P-G-A-K-Abu-G-A-L-M-G-A-N-M-K-Abu-A-Abu-A-H-A-S-I-H-V-Dha-K,27,Not available,Lactococcus lactis,Bacteria,Experimentally validated,VISA 22783,MIC = 8.3 mg/L,Not available,19561147,Not available,Not available,Not available
AVR/I/SSAP303,Non-clinical,Nisin,I-Dhb-A-I-Dhb-I-A-Abu-P-G-A-K-Abu-G-A-L-M-G-A-N-M-K-Abu-A-Abu-A-H-A-S-I-H-V-Dha-K,27,Not available,Lactococcus lactis,Bacteria,Experimentally validated,VISA 24764,MIC = 8.3 mg/L,Not available,19561147,Not available,Not available,Not available
AVR/I/SSAP304,Non-clinical,Nisin,I-Dhb-A-I-Dhb-I-A-Abu-P-G-A-K-Abu-G-A-L-M-G-A-N-M-K-Abu-A-Abu-A-H-A-S-I-H-V-Dha-K,27,Not available,Lactococcus lactis,Bacteria,Experimentally validated,VISA 22796,MIC = 4.1 mg/L,Not available,19561147,Not available,Not available,Not available
AVR/I/SSAP305,Non-clinical,Nisin,I-Dhb-A-I-Dhb-I-A-Abu-P-G-A-K-Abu-G-A-L-M-G-A-N-M-K-Abu-A-Abu-A-H-A-S-I-H-V-Dha-K,27,Not available,Lactococcus lactis,Bacteria,Experimentally validated,VISA 25949,MIC = 8.3 mg/L,Not available,19561147,Not available,Not available,Not available
AVR/I/SSAP306,Non-clinical,Nisin,I-Dhb-A-I-Dhb-I-A-Abu-P-G-A-K-Abu-G-A-L-M-G-A-N-M-K-Abu-A-Abu-A-H-A-S-I-H-V-Dha-K,27,Not available,Lactococcus lactis,Bacteria,Experimentally validated,VISA 29369,MIC = 8.3 mg/L,Not available,19561147,Not available,Not available,Not available
AVR/I/SSAP307,Non-clinical,Nisin,I-Dhb-A-I-Dhb-I-A-Abu-P-G-A-K-Abu-G-A-L-M-G-A-N-M-K-Abu-A-Abu-A-H-A-S-I-H-V-Dha-K,27,Not available,Lactococcus lactis,Bacteria,Experimentally validated,VISA 22797,MIC = 8.3 mg/L,Not available,19561147,Not available,Not available,Not available
AVR/I/SSAP308,Non-clinical,Lacticin 3147,NH2-Ala-Ala-Dhb-Asn-Dhb-Phe-D Ala-Leu-Ala-Asp-Tyr-Trp-Gly-Asn-Asn-Gly-Ala-Trp-Ala-Abu-Leu-Abu-His-Glu-Ala-Met-Ala-Trp-Ala-Lys-COOH + Dhb-Pro-Ala-Dhb-Pro-Ala-Ile-D Ala-Ile-Leu-D Ala-Ala-Tyr-Ile-Ala-Thr-Asn-Thr-Ala-Pro-Abu-Thr-Lys-Ala-Abu-Arg-Ala-Ala,50,Not available,Lactococcus lactis,Bacteria,Experimentally validated,hVISA 32679,MIC = 15.4 mg/L,Not available,19561147,Not available,Not available,Not available
AVR/I/SSAP309,Non-clinical,Lacticin 3147,NH2-Ala-Ala-Dhb-Asn-Dhb-Phe-D Ala-Leu-Ala-Asp-Tyr-Trp-Gly-Asn-Asn-Gly-Ala-Trp-Ala-Abu-Leu-Abu-His-Glu-Ala-Met-Ala-Trp-Ala-Lys-COOH + Dhb-Pro-Ala-Dhb-Pro-Ala-Ile-D Ala-Ile-Leu-D Ala-Ala-Tyr-Ile-Ala-Thr-Asn-Thr-Ala-Pro-Abu-Thr-Lys-Ala-Abu-Arg-Ala-Ala,50,Not available,Lactococcus lactis,Bacteria,Experimentally validated,hVISA 35197,MIC = 30.9 mg/L,Not available,19561147,Not available,Not available,Not available
AVR/I/SSAP310,Non-clinical,Lacticin 3147,NH2-Ala-Ala-Dhb-Asn-Dhb-Phe-D Ala-Leu-Ala-Asp-Tyr-Trp-Gly-Asn-Asn-Gly-Ala-Trp-Ala-Abu-Leu-Abu-His-Glu-Ala-Met-Ala-Trp-Ala-Lys-COOH + Dhb-Pro-Ala-Dhb-Pro-Ala-Ile-D Ala-Ile-Leu-D Ala-Ala-Tyr-Ile-Ala-Thr-Asn-Thr-Ala-Pro-Abu-Thr-Lys-Ala-Abu-Arg-Ala-Ala,50,Not available,Lactococcus lactis,Bacteria,Experimentally validated,hVISA 32652,MIC = 15.4 mg/L,Not available,19561147,Not available,Not available,Not available
AVR/I/SSAP311,Non-clinical,Lacticin 3147,NH2-Ala-Ala-Dhb-Asn-Dhb-Phe-D Ala-Leu-Ala-Asp-Tyr-Trp-Gly-Asn-Asn-Gly-Ala-Trp-Ala-Abu-Leu-Abu-His-Glu-Ala-Met-Ala-Trp-Ala-Lys-COOH + Dhb-Pro-Ala-Dhb-Pro-Ala-Ile-D Ala-Ile-Leu-D Ala-Ala-Tyr-Ile-Ala-Thr-Asn-Thr-Ala-Pro-Abu-Thr-Lys-Ala-Abu-Arg-Ala-Ala,50,Not available,Lactococcus lactis,Bacteria,Experimentally validated,hVISA 32675,MIC = 30.9 mg/L,Not available,19561147,Not available,Not available,Not available
AVR/I/SSAP312,Non-clinical,Lacticin 3147,NH2-Ala-Ala-Dhb-Asn-Dhb-Phe-D Ala-Leu-Ala-Asp-Tyr-Trp-Gly-Asn-Asn-Gly-Ala-Trp-Ala-Abu-Leu-Abu-His-Glu-Ala-Met-Ala-Trp-Ala-Lys-COOH + Dhb-Pro-Ala-Dhb-Pro-Ala-Ile-D Ala-Ile-Leu-D Ala-Ala-Tyr-Ile-Ala-Thr-Asn-Thr-Ala-Pro-Abu-Thr-Lys-Ala-Abu-Arg-Ala-Ala,50,Not available,Lactococcus lactis,Bacteria,Experimentally validated,hVISA 32681,MIC = 30.9 mg/L,Not available,19561147,Not available,Not available,Not available
AVR/I/SSAP313,Non-clinical,Lacticin 3147,NH2-Ala-Ala-Dhb-Asn-Dhb-Phe-D Ala-Leu-Ala-Asp-Tyr-Trp-Gly-Asn-Asn-Gly-Ala-Trp-Ala-Abu-Leu-Abu-His-Glu-Ala-Met-Ala-Trp-Ala-Lys-COOH + Dhb-Pro-Ala-Dhb-Pro-Ala-Ile-D Ala-Ile-Leu-D Ala-Ala-Tyr-Ile-Ala-Thr-Asn-Thr-Ala-Pro-Abu-Thr-Lys-Ala-Abu-Arg-Ala-Ala,50,Not available,Lactococcus lactis,Bacteria,Experimentally validated,VISA 22783,MIC = 61.8 mg/L,Not available,19561147,Not available,Not available,Not available
AVR/I/SSAP314,Non-clinical,Lacticin 3147,NH2-Ala-Ala-Dhb-Asn-Dhb-Phe-D Ala-Leu-Ala-Asp-Tyr-Trp-Gly-Asn-Asn-Gly-Ala-Trp-Ala-Abu-Leu-Abu-His-Glu-Ala-Met-Ala-Trp-Ala-Lys-COOH + Dhb-Pro-Ala-Dhb-Pro-Ala-Ile-D Ala-Ile-Leu-D Ala-Ala-Tyr-Ile-Ala-Thr-Asn-Thr-Ala-Pro-Abu-Thr-Lys-Ala-Abu-Arg-Ala-Ala,50,Not available,Lactococcus lactis,Bacteria,Experimentally validated,VISA 24764,MIC = 61.8 mg/L,Not available,19561147,Not available,Not available,Not available
AVR/I/SSAP315,Non-clinical,Lacticin 3147,NH2-Ala-Ala-Dhb-Asn-Dhb-Phe-D Ala-Leu-Ala-Asp-Tyr-Trp-Gly-Asn-Asn-Gly-Ala-Trp-Ala-Abu-Leu-Abu-His-Glu-Ala-Met-Ala-Trp-Ala-Lys-COOH + Dhb-Pro-Ala-Dhb-Pro-Ala-Ile-D Ala-Ile-Leu-D Ala-Ala-Tyr-Ile-Ala-Thr-Asn-Thr-Ala-Pro-Abu-Thr-Lys-Ala-Abu-Arg-Ala-Ala,50,Not available,Lactococcus lactis,Bacteria,Experimentally validated,VISA 22796,MIC = 61.8 mg/L,Not available,19561147,Not available,Not available,Not available
AVR/I/SSAP316,Non-clinical,Lacticin 3147,NH2-Ala-Ala-Dhb-Asn-Dhb-Phe-D Ala-Leu-Ala-Asp-Tyr-Trp-Gly-Asn-Asn-Gly-Ala-Trp-Ala-Abu-Leu-Abu-His-Glu-Ala-Met-Ala-Trp-Ala-Lys-COOH + Dhb-Pro-Ala-Dhb-Pro-Ala-Ile-D Ala-Ile-Leu-D Ala-Ala-Tyr-Ile-Ala-Thr-Asn-Thr-Ala-Pro-Abu-Thr-Lys-Ala-Abu-Arg-Ala-Ala,50,Not available,Lactococcus lactis,Bacteria,Experimentally validated,VISA 25949,MIC = 61.8 mg/L,Not available,19561147,Not available,Not available,Not available
AVR/I/SSAP317,Non-clinical,Lacticin 3147,NH2-Ala-Ala-Dhb-Asn-Dhb-Phe-D Ala-Leu-Ala-Asp-Tyr-Trp-Gly-Asn-Asn-Gly-Ala-Trp-Ala-Abu-Leu-Abu-His-Glu-Ala-Met-Ala-Trp-Ala-Lys-COOH + Dhb-Pro-Ala-Dhb-Pro-Ala-Ile-D Ala-Ile-Leu-D Ala-Ala-Tyr-Ile-Ala-Thr-Asn-Thr-Ala-Pro-Abu-Thr-Lys-Ala-Abu-Arg-Ala-Ala,50,Not available,Lactococcus lactis,Bacteria,Experimentally validated,VISA 29369,MIC = 61.8 mg/L,Not available,19561147,Not available,Not available,Not available
AVR/I/SSAP318,Non-clinical,Lacticin 3147,NH2-Ala-Ala-Dhb-Asn-Dhb-Phe-D Ala-Leu-Ala-Asp-Tyr-Trp-Gly-Asn-Asn-Gly-Ala-Trp-Ala-Abu-Leu-Abu-His-Glu-Ala-Met-Ala-Trp-Ala-Lys-COOH + Dhb-Pro-Ala-Dhb-Pro-Ala-Ile-D Ala-Ile-Leu-D Ala-Ala-Tyr-Ile-Ala-Thr-Asn-Thr-Ala-Pro-Abu-Thr-Lys-Ala-Abu-Arg-Ala-Ala,50,Not available,Lactococcus lactis,Bacteria,Experimentally validated,VISA 22797,MIC = 61.8 mg/L,Not available,19561147,Not available,Not available,Not available
AVR/I/SSAP319,Non-clinical,RRIKA,WLRRIKAWLRRIKA,14,Not available,Synthetic peptide,Not available,Experimentally validated,VISA NRS1,MIC = 2 microM,"RRIKA caused minimal hemolysis in human erythrocytes even at 300microM, exhibited no toxicity to HeLa cells up to 32microM (8 times its MIC), and had an EC50 of 64microM against macrophages, showing significantly lower toxicity compared to melittin.",24798285,7YSS_A,Not available,Not available
AVR/I/SSAP320,Non-clinical,RRIKA,WLRRIKAWLRRIKA,14,Not available,Synthetic peptide,Not available,Experimentally validated,VISA NRS19,MIC = 4 microM,"RRIKA caused minimal hemolysis in human erythrocytes even at 300microM, exhibited no toxicity to HeLa cells up to 32microM (8 times its MIC), and had an EC50 of 64microM against macrophages, showing significantly lower toxicity compared to melittin.",24798285,7YSS_A,Not available,Not available
AVR/I/SSAP321,Non-clinical,RRIKA,WLRRIKAWLRRIKA,14,Not available,Synthetic peptide,Not available,Experimentally validated,VISA NRS37,MIC = 2 microM,"RRIKA caused minimal hemolysis in human erythrocytes even at 300microM, exhibited no toxicity to HeLa cells up to 32microM (8 times its MIC), and had an EC50 of 64microM against macrophages, showing significantly lower toxicity compared to melittin.",24798285,7YSS_A,Not available,Not available
AVR/I/SSAP322,Non-clinical,RRIKA,WLRRIKAWLRRIKA,14,Not available,Synthetic peptide,Not available,Experimentally validated,VRSA 1,MIC = 4 microM,"RRIKA caused minimal hemolysis in human erythrocytes even at 300microM, exhibited no toxicity to HeLa cells up to 32microM (8 times its MIC), and had an EC50 of 64microM against macrophages, showing significantly lower toxicity compared to melittin.",24798285,7YSS_A,Not available,Not available
AVR/I/SSAP323,Non-clinical,RRIKA,WLRRIKAWLRRIKA,14,Not available,Synthetic peptide,Not available,Experimentally validated,VRSA 2,MIC = 4 microM,"RRIKA caused minimal hemolysis in human erythrocytes even at 300microM, exhibited no toxicity to HeLa cells up to 32microM (8 times its MIC), and had an EC50 of 64microM against macrophages, showing significantly lower toxicity compared to melittin.",24798285,7YSS_A,Not available,Not available
AVR/I/SSAP324,Non-clinical,RRIKA,WLRRIKAWLRRIKA,14,Not available,Synthetic peptide,Not available,Experimentally validated,VRSA 3a,MIC = 4 microM,"RRIKA caused minimal hemolysis in human erythrocytes even at 300microM, exhibited no toxicity to HeLa cells up to 32microM (8 times its MIC), and had an EC50 of 64microM against macrophages, showing significantly lower toxicity compared to melittin.",24798285,7YSS_A,Not available,Not available
AVR/I/SSAP325,Non-clinical,RRIKA,WLRRIKAWLRRIKA,14,Not available,Synthetic peptide,Not available,Experimentally validated,VRSA 4,MIC = 4 microM,"RRIKA caused minimal hemolysis in human erythrocytes even at 300microM, exhibited no toxicity to HeLa cells up to 32microM (8 times its MIC), and had an EC50 of 64microM against macrophages, showing significantly lower toxicity compared to melittin.",24798285,7YSS_A,Not available,Not available
AVR/I/SSAP326,Non-clinical,RRIKA,WLRRIKAWLRRIKA,14,Not available,Synthetic peptide,Not available,Experimentally validated,VRSA 5,MIC = 4 microM,"RRIKA caused minimal hemolysis in human erythrocytes even at 300microM, exhibited no toxicity to HeLa cells up to 32microM (8 times its MIC), and had an EC50 of 64microM against macrophages, showing significantly lower toxicity compared to melittin.",24798285,7YSS_A,Not available,Not available
AVR/I/SSAP327,Non-clinical,RRIKA,WLRRIKAWLRRIKA,14,Not available,Synthetic peptide,Not available,Experimentally validated,VRSA 6,MIC = 4 microM,"RRIKA caused minimal hemolysis in human erythrocytes even at 300microM, exhibited no toxicity to HeLa cells up to 32microM (8 times its MIC), and had an EC50 of 64microM against macrophages, showing significantly lower toxicity compared to melittin.",24798285,7YSS_A,Not available,Not available
AVR/I/SSAP328,Non-clinical,RRIKA,WLRRIKAWLRRIKA,14,Not available,Synthetic peptide,Not available,Experimentally validated,VRSA 7,MIC = 4 microM,"RRIKA caused minimal hemolysis in human erythrocytes even at 300microM, exhibited no toxicity to HeLa cells up to 32microM (8 times its MIC), and had an EC50 of 64microM against macrophages, showing significantly lower toxicity compared to melittin.",24798285,7YSS_A,Not available,Not available
AVR/I/SSAP329,Non-clinical,RRIKA,WLRRIKAWLRRIKA,14,Not available,Synthetic peptide,Not available,Experimentally validated,VRSA 8,MIC = 4 microM,"RRIKA caused minimal hemolysis in human erythrocytes even at 300microM, exhibited no toxicity to HeLa cells up to 32microM (8 times its MIC), and had an EC50 of 64microM against macrophages, showing significantly lower toxicity compared to melittin.",24798285,7YSS_A,Not available,Not available
AVR/I/SSAP330,Non-clinical,RRIKA,WLRRIKAWLRRIKA,14,Not available,Synthetic peptide,Not available,Experimentally validated,VRSA 9,MIC = 4 microM,"RRIKA caused minimal hemolysis in human erythrocytes even at 300microM, exhibited no toxicity to HeLa cells up to 32microM (8 times its MIC), and had an EC50 of 64microM against macrophages, showing significantly lower toxicity compared to melittin.",24798285,7YSS_A,Not available,Not available
AVR/I/SSAP331,Non-clinical,RRIKA,WLRRIKAWLRRIKA,14,Not available,Synthetic peptide,Not available,Experimentally validated,VRSA 10,MIC = 4 microM,"RRIKA caused minimal hemolysis in human erythrocytes even at 300microM, exhibited no toxicity to HeLa cells up to 32microM (8 times its MIC), and had an EC50 of 64microM against macrophages, showing significantly lower toxicity compared to melittin.",24798285,7YSS_A,Not available,Not available
AVR/I/SSAP332,Non-clinical,RRIKA,WLRRIKAWLRRIKA,14,Not available,Synthetic peptide,Not available,Experimentally validated,VRSA 11b,MIC = 4 microM,"RRIKA caused minimal hemolysis in human erythrocytes even at 300microM, exhibited no toxicity to HeLa cells up to 32microM (8 times its MIC), and had an EC50 of 64microM against macrophages, showing significantly lower toxicity compared to melittin.",24798285,7YSS_A,Not available,Not available
AVR/I/SSAP333,Non-clinical,RRIKA,WLRRIKAWLRRIKA,14,Not available,Synthetic peptide,Not available,Experimentally validated,VRSA 12,MIC = 4 microM,"RRIKA caused minimal hemolysis in human erythrocytes even at 300microM, exhibited no toxicity to HeLa cells up to 32microM (8 times its MIC), and had an EC50 of 64microM against macrophages, showing significantly lower toxicity compared to melittin.",24798285,7YSS_A,Not available,Not available
AVR/I/SSAP334,Non-clinical,RRIKA,WLRRIKAWLRRIKA,14,Not available,Synthetic peptide,Not available,Experimentally validated,VRSA 13,MIC = 4 microM,"RRIKA caused minimal hemolysis in human erythrocytes even at 300microM, exhibited no toxicity to HeLa cells up to 32microM (8 times its MIC), and had an EC50 of 64microM against macrophages, showing significantly lower toxicity compared to melittin.",24798285,7YSS_A,Not available,Not available
AVR/I/SSAP335,Non-clinical,RR,WLRRIKAWLRR,11,Not available,Synthetic peptide,Not available,Experimentally validated,VISA NRS1,MIC = 16 microM,"RR demonstrated minimal toxicity to HeLa cells up to 64microM and low hemolytic activity with a maximum of 10% hemolysis at 300microM, making it a promising antimicrobial agent compared to the highly toxic melittin.",24798285,7YSS_A,Not available,Not available
AVR/I/SSAP336,Non-clinical,RR,WLRRIKAWLRR,11,Not available,Synthetic peptide,Not available,Experimentally validated,VISA NRS19,MIC = 8 microM,"RR demonstrated minimal toxicity to HeLa cells up to 64microM and low hemolytic activity with a maximum of 10% hemolysis at 300microM, making it a promising antimicrobial agent compared to the highly toxic melittin.",24798285,7YSS_A,Not available,Not available
AVR/I/SSAP337,Non-clinical,RR,WLRRIKAWLRR,11,Not available,Synthetic peptide,Not available,Experimentally validated,VISA NRS37,MIC = 8 microM,"RR demonstrated minimal toxicity to HeLa cells up to 64microM and low hemolytic activity with a maximum of 10% hemolysis at 300microM, making it a promising antimicrobial agent compared to the highly toxic melittin.",24798285,7YSS_A,Not available,Not available
AVR/I/SSAP338,Non-clinical,RR,WLRRIKAWLRR,11,Not available,Synthetic peptide,Not available,Experimentally validated,VRSA 1,MIC = 32 microM,"RR demonstrated minimal toxicity to HeLa cells up to 64microM and low hemolytic activity with a maximum of 10% hemolysis at 300microM, making it a promising antimicrobial agent compared to the highly toxic melittin.",24798285,7YSS_A,Not available,Not available
AVR/I/SSAP339,Non-clinical,RR,WLRRIKAWLRR,11,Not available,Synthetic peptide,Not available,Experimentally validated,VRSA 2,MIC = 16 microM,"RR demonstrated minimal toxicity to HeLa cells up to 64microM and low hemolytic activity with a maximum of 10% hemolysis at 300microM, making it a promising antimicrobial agent compared to the highly toxic melittin.",24798285,7YSS_A,Not available,Not available
AVR/I/SSAP340,Non-clinical,RR,WLRRIKAWLRR,11,Not available,Synthetic peptide,Not available,Experimentally validated,VRSA 3a,MIC = 16 microM,"RR demonstrated minimal toxicity to HeLa cells up to 64microM and low hemolytic activity with a maximum of 10% hemolysis at 300microM, making it a promising antimicrobial agent compared to the highly toxic melittin.",24798285,7YSS_A,Not available,Not available
AVR/I/SSAP341,Non-clinical,RR,WLRRIKAWLRR,11,Not available,Synthetic peptide,Not available,Experimentally validated,VRSA 4,MIC = 32 microM,"RR demonstrated minimal toxicity to HeLa cells up to 64microM and low hemolytic activity with a maximum of 10% hemolysis at 300microM, making it a promising antimicrobial agent compared to the highly toxic melittin.",24798285,7YSS_A,Not available,Not available
AVR/I/SSAP342,Non-clinical,RR,WLRRIKAWLRR,11,Not available,Synthetic peptide,Not available,Experimentally validated,VRSA 5,MIC = 32 microM,"RR demonstrated minimal toxicity to HeLa cells up to 64microM and low hemolytic activity with a maximum of 10% hemolysis at 300microM, making it a promising antimicrobial agent compared to the highly toxic melittin.",24798285,7YSS_A,Not available,Not available
AVR/I/SSAP343,Non-clinical,RR,WLRRIKAWLRR,11,Not available,Synthetic peptide,Not available,Experimentally validated,VRSA 6,MIC = 32 microM,"RR demonstrated minimal toxicity to HeLa cells up to 64microM and low hemolytic activity with a maximum of 10% hemolysis at 300microM, making it a promising antimicrobial agent compared to the highly toxic melittin.",24798285,7YSS_A,Not available,Not available
AVR/I/SSAP344,Non-clinical,RR,WLRRIKAWLRR,11,Not available,Synthetic peptide,Not available,Experimentally validated,VRSA 7,MIC = 16 microM,"RR demonstrated minimal toxicity to HeLa cells up to 64microM and low hemolytic activity with a maximum of 10% hemolysis at 300microM, making it a promising antimicrobial agent compared to the highly toxic melittin.",24798285,7YSS_A,Not available,Not available
AVR/I/SSAP345,Non-clinical,RR,WLRRIKAWLRR,11,Not available,Synthetic peptide,Not available,Experimentally validated,VRSA 8,MIC = 16 microM,"RR demonstrated minimal toxicity to HeLa cells up to 64microM and low hemolytic activity with a maximum of 10% hemolysis at 300microM, making it a promising antimicrobial agent compared to the highly toxic melittin.",24798285,7YSS_A,Not available,Not available
AVR/I/SSAP346,Non-clinical,RR,WLRRIKAWLRR,11,Not available,Synthetic peptide,Not available,Experimentally validated,VRSA 9,MIC = 16 microM,"RR demonstrated minimal toxicity to HeLa cells up to 64microM and low hemolytic activity with a maximum of 10% hemolysis at 300microM, making it a promising antimicrobial agent compared to the highly toxic melittin.",24798285,7YSS_A,Not available,Not available
AVR/I/SSAP347,Non-clinical,RR,WLRRIKAWLRR,11,Not available,Synthetic peptide,Not available,Experimentally validated,VRSA 10,MIC = 16 microM,"RR demonstrated minimal toxicity to HeLa cells up to 64microM and low hemolytic activity with a maximum of 10% hemolysis at 300microM, making it a promising antimicrobial agent compared to the highly toxic melittin.",24798285,7YSS_A,Not available,Not available
AVR/I/SSAP348,Non-clinical,RR,WLRRIKAWLRR,11,Not available,Synthetic peptide,Not available,Experimentally validated,VRSA 11b,MIC = 32 microM,"RR demonstrated minimal toxicity to HeLa cells up to 64microM and low hemolytic activity with a maximum of 10% hemolysis at 300microM, making it a promising antimicrobial agent compared to the highly toxic melittin.",24798285,7YSS_A,Not available,Not available
AVR/I/SSAP349,Non-clinical,RR,WLRRIKAWLRR,11,Not available,Synthetic peptide,Not available,Experimentally validated,VRSA 12,MIC = 32 microM,"RR demonstrated minimal toxicity to HeLa cells up to 64microM and low hemolytic activity with a maximum of 10% hemolysis at 300microM, making it a promising antimicrobial agent compared to the highly toxic melittin.",24798285,7YSS_A,Not available,Not available
AVR/I/SSAP350,Non-clinical,RR,WLRRIKAWLRR,11,Not available,Synthetic peptide,Not available,Experimentally validated,VRSA 13,MIC = 16 microM,"RR demonstrated minimal toxicity to HeLa cells up to 64microM and low hemolytic activity with a maximum of 10% hemolysis at 300microM, making it a promising antimicrobial agent compared to the highly toxic melittin.",24798285,7YSS_A,Not available,Not available
AVR/I/SSAP351,Non-clinical,Mersacidin,A-Abu-I-Abu-L-P-C-G-G-G-V-A-Abu-L-Abu-Dha-E-A-I,15,Not available,Bacillus sp,Bacteria,Experimentally validated,VISA-27,MIC = 35 microG/ML,Not available,"18947397, 34360692",Not available,Not available,Not available
AVR/I/SSAP352,Non-clinical,Omiganan (Indolicidin analog),ILRWPWWPWRRK-amide,12,Not available,Synthetic peptide,Not available,Experimentally validated,hVISA,"MIC(50%) = 16 microG/ML, MIC(90%) = 32 microG/ML",Not available,18178361,Not available,Not available,DB06610
AVR/I/SSAP353,Non-clinical,Omiganan (Indolicidin analog),ILRWPWWPWRRK-amide,12,Not available,Synthetic peptide,Not available,Experimentally validated,VISA,"MIC(50%) = 16 microG/ML, MIC(90%) = 32 microG/ML",Not available,18178361,Not available,Not available,DB06610
AVR/I/SSAP354,Non-clinical,Omiganan (Indolicidin analog),ILRWPWWPWRRK-amide,12,Not available,Synthetic peptide,Not available,Experimentally validated,VRSA,"MIC(50%) = 16 microG/ML, MIC(90%) = NIL",Not available,18178361,Not available,Not available,DB06610
AVR/I/SSAP355,Non-clinical,Mutacin 1140,F-K-A-W-Dha-L-A-Abu-P-G-A-A-R-Dhb-G-A-F-N-A-Y-A,18,Not available,Streptococcus mutans,Bacteria,Experimentally validated,VISA,Cmax = 11.0 +- 4.1 microG/ML,Not available,20039385,Not available,Not available,Not available
AVR/I/SSAP356,Non-clinical,Mutacin 1140,F-K-A-W-Dha-L-A-Abu-P-G-A-A-R-Dhb-G-A-F-N-A-Y-A,18,Not available,Streptococcus mutans,Bacteria,Experimentally validated,VISA,Cmax = 21.0 +- 12.6 microG/ML,Not available,20039385,Not available,Not available,Not available
AVR/I/SSAP357,Non-clinical,CSPK14,HYDPGDDSGNTG,12,Skin secretion of the frog species Bacillus amyloliquefaciens subsp. plantarum FZB42(T),Bacillus amyloliquefaciens subsp. plantarum FZB42(T),Bacteria,Experimentally validated,VRSA,MIC = 64 microG/ML,Not available,27787755,Not available,Not available,Not available
AVR/I/SSAP358,Non-clinical,Fusaricidin A/LI-F04a,D-Asn-D-Asn-D-Ser-L-Tyr-L-Asn-L-Asn-D-Asn-L-Asn-D-Ser-L-Thr-L-Gln-D-Asn-D-Asn-D-Ser-L-Tyr-L-Asn-L-Asn-D-Asn-D-Asn,19,Not available,Paenibacillus polymyxa,Bacteria,Experimentally validated,Staphylococcus aureus Mu50 (VRSA) ATCC 700699,MIC =>128 microG/ML,"Depsipeptides 6, 8, and 11 showed hemolytic activity at higher concentrations, correlating with their hydrophobicity, while amide analogues 14–16 had no appreciable hemolytic activity. DMSO presence in the assay may enhance hemolysis due to potential peptide aggregation at higher concentrations. Depsipeptides 4 and 6 were cytotoxic to WRL 68 and HepG2 cell lines at higher concentrations, unlike amide analogue 14, which exhibited much lower cytotoxicity. The lack of cytotoxicity in amide analogue 14 is likely due to its conformational differences and lower hydrophobicity compared to the depsipeptides.",22392790,Not available,Not available,Not available
AVR/I/SSAP359,Non-clinical,Agelaia-MPI,INWLKLGKAIIDAL,14,Venom of Parachartergus fraternus,Parachartergus fraternus,Animalia (Insect),Experimentally validated,S. aureus VRSA,MIC = 4−8 microG/ML,Agelaia-MPI was found to be hemolytic and toxic to cancerous and non-cancerous cell lines. Agelaia-MPI showed hemolytic activity with a hemolytic concentration to lyse 50% of red blood cells (HC50) of 11.5 plusminus 1.1 microM. Agelaia-MPI also exhibited cytotoxic activity against cancerous cells with a CC50 >32 microM and non-cancerous cells with a CC50 >32 microM.,33244888,Not available,P0DRA8,Not available
AVR/I/SSAP360,Non-clinical,NeuroVAL,ILE-PHE-TRP-LEU-PHE-ARG-GLY-LYS-ALA-ASP-VAL-ALA-LEU-NH2,13,Venom of Parachartergus fraternus,Parachartergus fraternus,Animalia (Insect),Experimentally validated,S. aureus VRSA,MIC = 128 microG/ML,Not available,33244888,7JGX_A,Not available,Not available
AVR/I/SSAP361,Non-clinical,Protonectin,ILGTILGLLKGL,12,Venom of Agelaia pallipes pallipes,Agelaia pallipes pallipes,Animalia (Insect),Experimentally validated,S. aureus VRSA,MIC = 16 microG/ML,Protonectin showed cytotoxic activity against both cancerous and non-cancerous cells.,33244888,6N68_A,P0C1R1,Not available
AVR/I/SSAP362,Non-clinical,Protonectin-F,IFGTILGFLKGL,12,Venom of Agelaia pallipes pallipes,Agelaia pallipes pallipes,Animalia (Insect),Experimentally validated,S. aureus VRSA,MIC = 16 microG/ML,"Protonectin-F was found to be toxic to cancerous and non-cancerous cell lines. Specifically, Protonectin-F showed activity against MM96L cells, with a cytotoxic concentration (CC50) close to the concentration necessary to kill the correlated non-cancer cell HaCaT. The cytotoxic concentrations (CC50) of Protonectin-F were also more active toward HCT116, with a CC50 <10microM, and twice the concentration of Protonectin-F was necessary to kill the correlated non-cancer cell HEK293 (CC50 19microM).",33244888,7JHF_A,Not available,Not available
AVR/I/SSAP363,Non-clinical,Fusaricidin A/LI-F04a analogues compound 1,Thr1-D-Val2-Val3-D-Thr4-D-Asn5-D-Ala6,21,Not available,Paenibacillus polymyxa,Bacteria,Experimentally validated,Mu50 (VRSA) ATCC 700699,MIC = 128 microG/ML,"The cytotoxicity of analogues 1-18 was assessed using the MTT assay on WRL 68 and HepG2 cell lines. Lipidated depsipeptide analogues 4 and 6 were cytotoxic at higher concentrations, with analogue 6 being highly cytotoxic at 90 mg/mL. In contrast, amide analogue 14 exhibited much lower cytotoxicity at the same concentrations. Moreover, None of the amide analogues 14-17 nor the linear peptide 18 showed hemolytic activity at concentrations eight times the MIC, indicating that ring opening due to ester bond hydrolysis is not responsible for hemolysis.",22392790,Not available,Not available,Not available
AVR/I/SSAP364,Non-clinical,Fusaricidin A/LI-F04a analogues compound 2,Thr1-D-Val2-Val3-D-aThr4-D-Asn5-D-Ala6,21,Not available,Paenibacillus polymyxa,Bacteria,Experimentally validated,Mu50 (VRSA) ATCC 700699,MIC = 128 microG/ML,"The cytotoxicity of analogues 1-18 was assessed using the MTT assay on WRL 68 and HepG2 cell lines. Lipidated depsipeptide analogues 4 and 6 were cytotoxic at higher concentrations, with analogue 6 being highly cytotoxic at 90 mg/mL. In contrast, amide analogue 14 exhibited much lower cytotoxicity at the same concentrations. Moreover, None of the amide analogues 14-17 nor the linear peptide 18 showed hemolytic activity at concentrations eight times the MIC, indicating that ring opening due to ester bond hydrolysis is not responsible for hemolysis.",22392790,Not available,Not available,Not available
AVR/I/SSAP365,Non-clinical,Fusaricidin A/LI-F04a analogues compound 3,Thr1-D-Val2-Val3-D-Thr4-D-Asn5-D-Ala6,21,Not available,Paenibacillus polymyxa,Bacteria,Experimentally validated,Mu50 (VRSA) ATCC 700699,MIC = 128 microG/ML,"The cytotoxicity of analogues 1-18 was assessed using the MTT assay on WRL 68 and HepG2 cell lines. Lipidated depsipeptide analogues 4 and 6 were cytotoxic at higher concentrations, with analogue 6 being highly cytotoxic at 90 mg/mL. In contrast, amide analogue 14 exhibited much lower cytotoxicity at the same concentrations. Moreover, None of the amide analogues 14-17 nor the linear peptide 18 showed hemolytic activity at concentrations eight times the MIC, indicating that ring opening due to ester bond hydrolysis is not responsible for hemolysis.",22392790,Not available,Not available,Not available
AVR/I/SSAP366,Non-clinical,Fusaricidin A/LI-F04a analogues compound 4,Thr1-D-Val2-Val3-D-aThr4-D-Asn5-D-Ala6,21,Not available,Paenibacillus polymyxa,Bacteria,Experimentally validated,Mu50 (VRSA) ATCC 700699,MIC = 128 microG/ML,"The cytotoxicity of analogues 1-18 was assessed using the MTT assay on WRL 68 and HepG2 cell lines. Lipidated depsipeptide analogues 4 and 6 were cytotoxic at higher concentrations, with analogue 6 being highly cytotoxic at 90 mg/mL. In contrast, amide analogue 14 exhibited much lower cytotoxicity at the same concentrations. Moreover, None of the amide analogues 14-17 nor the linear peptide 18 showed hemolytic activity at concentrations eight times the MIC, indicating that ring opening due to ester bond hydrolysis is not responsible for hemolysis.",22392790,Not available,Not available,Not available
AVR/I/SSAP367,Non-clinical,Fusaricidin A/LI-F04a analogues compound 5,Thr1-D-Val2-Val3-D-Thr4-D-Asn5-D-Ala6,21,Not available,Paenibacillus polymyxa,Bacteria,Experimentally validated,Mu50 (VRSA) ATCC 700699,MIC = 16 microG/ML,"The cytotoxicity of analogues 1-18 was assessed using the MTT assay on WRL 68 and HepG2 cell lines. Lipidated depsipeptide analogues 4 and 6 were cytotoxic at higher concentrations, with analogue 6 being highly cytotoxic at 90 mg/mL. In contrast, amide analogue 14 exhibited much lower cytotoxicity at the same concentrations. Moreover, None of the amide analogues 14-17 nor the linear peptide 18 showed hemolytic activity at concentrations eight times the MIC, indicating that ring opening due to ester bond hydrolysis is not responsible for hemolysis.",22392790,Not available,Not available,Not available
AVR/I/SSAP368,Non-clinical,Fusaricidin A/LI-F04a analogues compound 6,Thr1-D-Val2-Val3-D-aThr4-D-Asn5-D-Ala6,21,Not available,Paenibacillus polymyxa,Bacteria,Experimentally validated,Mu50 (VRSA) ATCC 700699,MIC = 16 microG/ML,"The cytotoxicity of analogues 1-18 was assessed using the MTT assay on WRL 68 and HepG2 cell lines. Lipidated depsipeptide analogues 4 and 6 were cytotoxic at higher concentrations, with analogue 6 being highly cytotoxic at 90 mg/mL. In contrast, amide analogue 14 exhibited much lower cytotoxicity at the same concentrations. Moreover, None of the amide analogues 14-17 nor the linear peptide 18 showed hemolytic activity at concentrations eight times the MIC, indicating that ring opening due to ester bond hydrolysis is not responsible for hemolysis.",22392790,Not available,Not available,Not available
AVR/I/SSAP369,Non-clinical,Fusaricidin A/LI-F04a analogues compound 7,Thr1-D-Val2-Val3-D-Ala4-D-Asn5-D-Ala6,21,Not available,Paenibacillus polymyxa,Bacteria,Experimentally validated,Mu50 (VRSA) ATCC 700699,MIC = 64 microG/ML,"The cytotoxicity of analogues 1-18 was assessed using the MTT assay on WRL 68 and HepG2 cell lines. Lipidated depsipeptide analogues 4 and 6 were cytotoxic at higher concentrations, with analogue 6 being highly cytotoxic at 90 mg/mL. In contrast, amide analogue 14 exhibited much lower cytotoxicity at the same concentrations. Moreover, None of the amide analogues 14-17 nor the linear peptide 18 showed hemolytic activity at concentrations eight times the MIC, indicating that ring opening due to ester bond hydrolysis is not responsible for hemolysis.",22392790,Not available,Not available,Not available
AVR/I/SSAP370,Non-clinical,Fusaricidin A/LI-F04a analogues compound 8,Thr1-D-Val2-Ala3-D-aThr4-D-Asn5-D-Ala6,21,Not available,Paenibacillus polymyxa,Bacteria,Experimentally validated,Mu50 (VRSA) ATCC 700699,MIC = 16 microG/ML,"The cytotoxicity of analogues 1-18 was assessed using the MTT assay on WRL 68 and HepG2 cell lines. Lipidated depsipeptide analogues 4 and 6 were cytotoxic at higher concentrations, with analogue 6 being highly cytotoxic at 90 mg/mL. In contrast, amide analogue 14 exhibited much lower cytotoxicity at the same concentrations. Moreover, None of the amide analogues 14-17 nor the linear peptide 18 showed hemolytic activity at concentrations eight times the MIC, indicating that ring opening due to ester bond hydrolysis is not responsible for hemolysis.",22392790,Not available,Not available,Not available
AVR/I/SSAP371,Non-clinical,Fusaricidin A/LI-F04a analogues compound 9,Thr1-D-Ala2-Val3-D-aThr4-D-Asn5-D-Ala6,21,Not available,Paenibacillus polymyxa,Bacteria,Experimentally validated,Mu50 (VRSA) ATCC 700699,MIC = 64 microG/ML,"The cytotoxicity of analogues 1-18 was assessed using the MTT assay on WRL 68 and HepG2 cell lines. Lipidated depsipeptide analogues 4 and 6 were cytotoxic at higher concentrations, with analogue 6 being highly cytotoxic at 90 mg/mL. In contrast, amide analogue 14 exhibited much lower cytotoxicity at the same concentrations. Moreover, None of the amide analogues 14-17 nor the linear peptide 18 showed hemolytic activity at concentrations eight times the MIC, indicating that ring opening due to ester bond hydrolysis is not responsible for hemolysis.",22392790,Not available,Not available,Not available
AVR/I/SSAP372,Non-clinical,Fusaricidin A/LI-F04a analogues compound 10,Thr1-D-Val2-Val3-D-aThr4-D-Asn5-Gly6,21,Not available,Paenibacillus polymyxa,Bacteria,Experimentally validated,Mu50 (VRSA) ATCC 700699,MIC = 64 microG/ML,"The cytotoxicity of analogues 1-18 was assessed using the MTT assay on WRL 68 and HepG2 cell lines. Lipidated depsipeptide analogues 4 and 6 were cytotoxic at higher concentrations, with analogue 6 being highly cytotoxic at 90 mg/mL. In contrast, amide analogue 14 exhibited much lower cytotoxicity at the same concentrations. Moreover, None of the amide analogues 14-17 nor the linear peptide 18 showed hemolytic activity at concentrations eight times the MIC, indicating that ring opening due to ester bond hydrolysis is not responsible for hemolysis.",22392790,Not available,Not available,Not available
AVR/I/SSAP373,Non-clinical,Fusaricidin A/LI-F04a analogues compound 11,Thr1-D-Val2-Tyr3-D-aThr4-D-Asn5-D-Ala6,21,Not available,Paenibacillus polymyxa,Bacteria,Experimentally validated,Mu50 (VRSA) ATCC 700699,MIC = 16 microG/ML,"The cytotoxicity of analogues 1-18 was assessed using the MTT assay on WRL 68 and HepG2 cell lines. Lipidated depsipeptide analogues 4 and 6 were cytotoxic at higher concentrations, with analogue 6 being highly cytotoxic at 90 mg/mL. In contrast, amide analogue 14 exhibited much lower cytotoxicity at the same concentrations. Moreover, None of the amide analogues 14-17 nor the linear peptide 18 showed hemolytic activity at concentrations eight times the MIC, indicating that ring opening due to ester bond hydrolysis is not responsible for hemolysis.",22392790,Not available,Not available,Not available
AVR/I/SSAP374,Non-clinical,Fusaricidin A/LI-F04a analogues compound 12,Thr1-D-Val2-Phe3-D-aThr4-D-Asn5-D-Ala6,21,Not available,Paenibacillus polymyxa,Bacteria,Experimentally validated,Mu50 (VRSA) ATCC 700699,MIC = Not available,"The cytotoxicity of analogues 1-18 was assessed using the MTT assay on WRL 68 and HepG2 cell lines. Lipidated depsipeptide analogues 4 and 6 were cytotoxic at higher concentrations, with analogue 6 being highly cytotoxic at 90 mg/mL. In contrast, amide analogue 14 exhibited much lower cytotoxicity at the same concentrations. Moreover, None of the amide analogues 14-17 nor the linear peptide 18 showed hemolytic activity at concentrations eight times the MIC, indicating that ring opening due to ester bond hydrolysis is not responsible for hemolysis.",22392790,Not available,Not available,Not available
AVR/I/SSAP375,Non-clinical,Fusaricidin A/LI-F04a analogues compound 13,ELys1-D-Val2-Val3-D-aThr4-D-Asn5,5,Not available,Paenibacillus polymyxa,Bacteria,Experimentally validated,Mu50 (VRSA) ATCC 700699,MIC = 64 microG/ML,"The cytotoxicity of analogues 1-18 was assessed using the MTT assay on WRL 68 and HepG2 cell lines. Lipidated depsipeptide analogues 4 and 6 were cytotoxic at higher concentrations, with analogue 6 being highly cytotoxic at 90 mg/mL. In contrast, amide analogue 14 exhibited much lower cytotoxicity at the same concentrations. Moreover, None of the amide analogues 14-17 nor the linear peptide 18 showed hemolytic activity at concentrations eight times the MIC, indicating that ring opening due to ester bond hydrolysis is not responsible for hemolysis.",22392790,Not available,Not available,Not available
AVR/I/SSAP376,Non-clinical,Fusaricidin A/LI-F04a analogues compound 14,Dap1-D-Val2-Val3-D-aThr4-D-Asn5-D-Ala6,5,Not available,Paenibacillus polymyxa,Bacteria,Experimentally validated,Mu50 (VRSA) ATCC 700699,MIC = 16 microG/ML,"The cytotoxicity of analogues 1-18 was assessed using the MTT assay on WRL 68 and HepG2 cell lines. Lipidated depsipeptide analogues 4 and 6 were cytotoxic at higher concentrations, with analogue 6 being highly cytotoxic at 90 mg/mL. In contrast, amide analogue 14 exhibited much lower cytotoxicity at the same concentrations. Moreover, None of the amide analogues 14-17 nor the linear peptide 18 showed hemolytic activity at concentrations eight times the MIC, indicating that ring opening due to ester bond hydrolysis is not responsible for hemolysis.",22392790,Not available,Not available,Not available
AVR/I/SSAP377,Non-clinical,Fusaricidin A/LI-F04a analogues compound 15,Dap1-D-Val2-Ala3-D-aThr4-D-Asn5-D-Ala6,5,Not available,Paenibacillus polymyxa,Bacteria,Experimentally validated,Mu50 (VRSA) ATCC 700699,MIC = Not available,"The cytotoxicity of analogues 1-18 was assessed using the MTT assay on WRL 68 and HepG2 cell lines. Lipidated depsipeptide analogues 4 and 6 were cytotoxic at higher concentrations, with analogue 6 being highly cytotoxic at 90 mg/mL. In contrast, amide analogue 14 exhibited much lower cytotoxicity at the same concentrations. Moreover, None of the amide analogues 14-17 nor the linear peptide 18 showed hemolytic activity at concentrations eight times the MIC, indicating that ring opening due to ester bond hydrolysis is not responsible for hemolysis.",22392790,Not available,Not available,Not available
AVR/I/SSAP378,Non-clinical,Fusaricidin A/LI-F04a analogues compound 16,Dap1-D-Val2-Phe3-D-aThr4-D-Asn5-D-Ala6,5,Not available,Paenibacillus polymyxa,Bacteria,Experimentally validated,Mu50 (VRSA) ATCC 700699,MIC = Not available,"The cytotoxicity of analogues 1-18 was assessed using the MTT assay on WRL 68 and HepG2 cell lines. Lipidated depsipeptide analogues 4 and 6 were cytotoxic at higher concentrations, with analogue 6 being highly cytotoxic at 90 mg/mL. In contrast, amide analogue 14 exhibited much lower cytotoxicity at the same concentrations. Moreover, None of the amide analogues 14-17 nor the linear peptide 18 showed hemolytic activity at concentrations eight times the MIC, indicating that ring opening due to ester bond hydrolysis is not responsible for hemolysis.",22392790,Not available,Not available,Not available
AVR/I/SSAP379,Non-clinical,Fusaricidin A/LI-F04a analogues compound 17,Dap1-D-Val2-Tyr3-D-aThr4-D-Asn5-D-Ala6,5,Not available,Paenibacillus polymyxa,Bacteria,Experimentally validated,Mu50 (VRSA) ATCC 700699,MIC = Not available,"The cytotoxicity of analogues 1-18 was assessed using the MTT assay on WRL 68 and HepG2 cell lines. Lipidated depsipeptide analogues 4 and 6 were cytotoxic at higher concentrations, with analogue 6 being highly cytotoxic at 90 mg/mL. In contrast, amide analogue 14 exhibited much lower cytotoxicity at the same concentrations. Moreover, None of the amide analogues 14-17 nor the linear peptide 18 showed hemolytic activity at concentrations eight times the MIC, indicating that ring opening due to ester bond hydrolysis is not responsible for hemolysis.",22392790,Not available,Not available,Not available
AVR/I/SSAP380,Non-clinical,Fusaricidin A/LI-F04a analogues compound 18,Thr1-D-Val2-Val3-D-aThr4-D-Asn5-D-Ala6,21,Not available,Paenibacillus polymyxa,Bacteria,Experimentally validated,Mu50 (VRSA) ATCC 700699,MIC = Not available,"The cytotoxicity of analogues 1-18 was assessed using the MTT assay on WRL 68 and HepG2 cell lines. Lipidated depsipeptide analogues 4 and 6 were cytotoxic at higher concentrations, with analogue 6 being highly cytotoxic at 90 mg/mL. In contrast, amide analogue 14 exhibited much lower cytotoxicity at the same concentrations. Moreover, None of the amide analogues 14-17 nor the linear peptide 18 showed hemolytic activity at concentrations eight times the MIC, indicating that ring opening due to ester bond hydrolysis is not responsible for hemolysis.",22392790,Not available,Not available,Not available
AVR/I/SSAP381,Non-clinical,LL-37,LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES,37,cathelicidin found in epithelial cells and neutrophils,Homo sapiens,Animalia (Human),Experimentally validated,VSSA303,MIC = 5 microG/ML,Not available,29927700,2K6O_A,"Q1KLX1, P49913",DB16532
AVR/I/SSAP382,Non-clinical,Polymyxin B,D-Leu-D-Leu-D-Thr-D-Pro-D-Leu-D-Val-D-Val-D-Asp-D-Glu-D-Ile-D-Asn-D-Leu-D-Ala-D-Ala-D-Ala-D-Trp-D-Phe-D-Thr,18,Not available,Bacillus polymyxa [T2],Bacteria,Experimentally validated,VSSA303,MIC = 50 microG/ML,Not available,29927700,Not available,Not available,DB00781
AVR/I/SSAP383,Non-clinical,LL-13,IGKEFKRIVQRIKDFLRNLVPRTES,25,cathelicidin (hCAP18),Homo sapiens,Animalia (Human),Experimentally validated,ATCC 700699(S.aureus strain),MIC = 1024 microG/ML,Not available,30120393,"2FCG_F, 2K6O_A","Q1KLX1, P49913",Not available
AVR/I/SSAP384,Non-clinical,LL-17,FKRIVQRIKDFLR,13,cathelicidin (hCAP19),Homo sapiens,Animalia (Human),Experimentally validated,ATCC 700699(S.aureus strain),MIC = 1024 microG/ML,Not available,30120393,"6S6M_A, 2FBS_N, 8DEW_D, 5XNG_A, 2L5M_A, 2FCG_F, 2K6O_A","Q1KLX2, Q1KLX1, P49913",Not available
AVR/I/SSAP385,Non-clinical,LL-13,IGKEFKRIVQRIKDFLRNLVPRTES,25,cathelicidin (hCAP19),Homo sapiens,Animalia (Human),Experimentally validated,BR-VRSA,MIC = 512 microG/ML,Not available,30120393,"2FCG_F, 2K6O_A","Q1KLX1, P49913",Not available
AVR/I/SSAP386,Non-clinical,LL-17,FKRIVQRIKDFLR,13,cathelicidin (hCAP19),Homo sapiens,Animalia (Human),Experimentally validated,BR-VRSA,MIC = 512 microG/ML,Not available,30120393,"6S6M_A, 2FBS_N, 8DEW_D, 5XNG_A, 2L5M_A, 2FCG_F, 2K6O_A","Q1KLX2, Q1KLX1, P49913",Not available
AVR/I/SSAP387,Non-clinical,LL-13+LL-17+vancomycin,IGKEFKRIVQRIKDFLRNLVPRTES + FKRIVQRIKDFLR,38,cathelicidin (hCAP19),Homo sapiens,Animalia (Human),Experimentally validated,ATCC 700699(S.aureus strain),FIC = 0.06 microG/ML,Not available,30120393,Not available,Not available,Not available
AVR/I/SSAP388,Non-clinical,LL-13+LL-17+vancomycin,IGKEFKRIVQRIKDFLRNLVPRTES + FKRIVQRIKDFLR,38,cathelicidin (hCAP19),Homo sapiens,Animalia (Human),Experimentally validated,ATCC 700699(S.aureus strain),FIC = 1 microG/ML,Not available,30120393,Not available,Not available,Not available
AVR/I/SSAP389,Non-clinical,LL-13+LL-17+vancomycin,IGKEFKRIVQRIKDFLRNLVPRTES + FKRIVQRIKDFLR,38,cathelicidin (hCAP19),Homo sapiens,Animalia (Human),Experimentally validated,BR-VRSA,FIC = 0.13 microG/ML,Not available,30120393,Not available,Not available,Not available
AVR/I/SSAP390,Non-clinical,LL-13+LL-17+vancomycin,IGKEFKRIVQRIKDFLRNLVPRTES + FKRIVQRIKDFLR,38,cathelicidin (hCAP19),Homo sapiens,Animalia (Human),Experimentally validated,BR-VRSA,FIC = 0.13 microG/ML,Not available,30120393,Not available,Not available,Not available
AVR/I/SSAP391,Non-clinical,Hecate(Hec),FALAL-KALKKALKKLKKALKKAL,23,Bee venom,Apis mellifera,Animalia (Insect),Experimentally validated,VRSA,MIC = 80 microM,Not available,30349337,Not available,Not available,Not available
AVR/I/SSAP392,Non-clinical,Cerein 7B(Bacteriocin),N-Gly-Trp-Trp-Asn-Ser-Trp-Gly-Lys ,8,Not available,Bacillus cereus Bc7,Bacteria,Experimentally validated,VRSA,MIC = 20 microG/ML,Not available,37370267,Not available,Not available,Not available
AVR/I/SSAP393,Non-clinical,Cerein 7B(Bacteriocin),N-Gly-Trp-Trp-Asn-Ser-Trp-Gly-Lys ,8,Not available,Bacillus cereus Bc7,Bacteria,Experimentally validated,VISA ,MIC = 20 microG/ML,Not available,37370267,Not available,Not available,Not available
AVR/I/SSAP394,Non-clinical,LL-37,LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES,37,cathelicidin found in epithelial cells and neutrophils,Homo sapiens,Animalia (Human),Experimentally validated,VISA072,MIC = 5 microG/ML,Not available,29927700,2K6O_A,"Q1KLX1, P49913",DB16532
AVR/I/SSAP395,Non-clinical,Polymyxin B,D-Leu-D-Leu-D-Thr-D-Pro-D-Leu-D-Val-D-Val-D-Asp-D-Glu-D-Ile-D-Asn-D-Leu-D-Ala-D-Ala-D-Ala-D-Trp-D-Phe-D-Thr,18,Not available,Bacillus polymyxa [T2],Bacteria,Experimentally validated,VISA072,MIC = 50 microG/ML,Not available,29927700,Not available,Not available,DB00781
AVR/I/SSAP396,Non-clinical,Pexiganan,Gly-Ile-Gly-Lys-Phe-Leu-Lys-Lys-Ala-Lys-Lys-Phe-Gly-Lys-Ala-Phe-Val-Lys-Ile-Leu-Lys-Lys-NH2,21,Skin,African clawed frog,Animalia (Frog),Experimentally validated,VRSA,EC50 = 32 microM,Exhibit low toxicity to mammalian cells.,27405275,Not available,Not available,DB16293
AVR/I/SSAP397,Non-clinical,WR12 + D-1K8,RWWRWWRRWWRR + IRIKIRIK,20,Not available,Synthetic conjugation,Not available,Experimentally validated,VRSA,FIC index of 0.27,Not available,27405275,Not available,Not available,Not available
AVR/I/SSAP398,Non-clinical,MSI-843,G-I-G-K-F-L-K-K-A-K-K-F-G-K-A-F-V-K-I-L-K-K-NH2,22,Not available,Xenopus laevis ,Animalia (Frog),Experimentally validated,VRSA,MIC = 1.6 to 12.5 microM,"MSI-843, has broad-spectrum antimicrobial activity without observable hemolytic activity.",20459377,Not available,Not available,Not available
AVR/I/SSAP399,Non-clinical,YD1,Ala-Pro-Lys-Gly-Val-Gln-Gly-Pro-Asn-Gly ,10,Not available,Bacillus amyloliquefaciens CBSYD1,Bacteria,Experimentally validated,VRSA,MIC = 128 microG/ML,YD1 was not toxic to RAW 264.7 macrophage cells even at a concentration of 120microg/mL. The study demonstrated that YD1 did not exhibit cytotoxicity and showed high cell viability in macrophage cells.,28050849,Not available,Not available,Not available
AVR/I/SSAP400,Non-clinical,NZ2114,Glu-Val-Pro-Trp-Asn-Pro-Ala-Pro-Pro-Pro-Pro-Pro-Pro-Pro-Pro-Pro-Pro,17,Defensin,Pseudoplectania nigrella,Bacteria,Experimentally validated,VRSA 2 (Pennsylvania HIP11983),Emax = 4 mg/L (At pH 7.4),Not available,20534628,Not available,Not available,Not available
AVR/I/SSAP401,Non-clinical,NZ2114,Glu-Val-Pro-Trp-Asn-Pro-Ala-Pro-Pro-Pro-Pro-Pro-Pro-Pro-Pro-Pro-Pro,17,Defensin,Pseudoplectania nigrella,Bacteria,Experimentally validated,VRSA 2 (Pennsylvania HIP11983),Emax = 64 mg/L (At lower acidic pH),Not available,20534628,Not available,Not available,Not available
AVR/I/SSAP402,Non-clinical,Daptomycin,KEDNKVYGN-GTPSTCGTQQPKVGSNNYGKT,30,Soil,Streptomyces roseosporus,Bacteria,Experimentally validated,VRSA 2 (Pennsylvania HIP11983),Emax = 1 mg/L (At pH 7.4),Have a low potential for causing hemolysis.,20534628,Not available,Not available,DB00080
AVR/I/SSAP403,Non-clinical,Daptomycin,KEDNKVYGN-GTPSTCGTQQPKVGSNNYGKT,30,Soil,Streptomyces roseosporus,Bacteria,Experimentally validated,VRSA 2 (Pennsylvania HIP11983),Emax = 16 mg/L (At lower acidic pH),Have a low potential for causing hemolysis.,20534628,Not available,Not available,DB00080
AVR/I/SSAP404,Non-clinical,Ranalexin ,FLGGLIKIVPAMICAVTKKC,20,Not available,Rana catesbeiana,Animalia (Frog),Experimentally validated,VISA 3700.W,log10 CFU/ML = 8.97(0.03),"Ranalexin caused hemolysis and toxicity to Vero cells at concentrations =>50 mg/L, but combining it with lysostaphin did not increase toxicity beyond that of ranalexin alone, with toxic concentrations exceeding those needed for antibacterial activity in human serum.",20206480,Not available,P39084,Not available
AVR/I/SSAP405,Non-clinical,Ranalexin ,FLGGLIKIVPAMICAVTKKC,20,Not available,Rana catesbeiana,Animalia (Frog),Experimentally validated,VISA Mu3,log10 CFU/ML = 9.40(0.09),"Ranalexin caused hemolysis and toxicity to Vero cells at concentrations =>50 mg/L, but combining it with lysostaphin did not increase toxicity beyond that of ranalexin alone, with toxic concentrations exceeding those needed for antibacterial activity in human serum.",20206480,Not available,P39084,Not available
AVR/I/SSAP406,Non-clinical,Ranalexin ,FLGGLIKIVPAMICAVTKKC,20,Not available,Rana catesbeiana,Animalia (Frog),Experimentally validated,VISA Mu50d,log10 CFU/ML = 6.15(0.13),"Ranalexin caused hemolysis and toxicity to Vero cells at concentrations =>50 mg/L, but combining it with lysostaphin did not increase toxicity beyond that of ranalexin alone, with toxic concentrations exceeding those needed for antibacterial activity in human serum.",20206480,Not available,P39084,Not available
AVR/I/SSAP407,Non-clinical,Ranalexin ,FLGGLIKIVPAMICAVTKKC,20,Not available,Rana catesbeiana,Animalia (Frog),Experimentally validated,VISA 3759.V,log10 CFU/ML = 9.80(0.02),"Ranalexin caused hemolysis and toxicity to Vero cells at concentrations =>50 mg/L, but combining it with lysostaphin did not increase toxicity beyond that of ranalexin alone, with toxic concentrations exceeding those needed for antibacterial activity in human serum.",20206480,Not available,P39084,Not available
AVR/I/SSAP408,Non-clinical,Lysostaphin,Not available,13,Not available,Staphylococcus simulans,Bacteria,Experimentally validated,VISA 3700.W,log10 CFU/ML = 9.51(0.19),"Lysostaphin alone showed no haemolysis or effect on Vero cell viability, and when combined with ranalexin, did not increase toxicity beyond ranalexin alone, with toxic concentrations for erythrocytes and Vero cells exceeding those needed for antibacterial efficacy in human serum.",20206480,Not available,Not available,Not available
AVR/I/SSAP409,Non-clinical,Lysostaphin,Not available,13,Not available,Staphylococcus simulans,Bacteria,Experimentally validated,VISA 3759.V ,log10 CFU/ML = 9.90(0.02),"Lysostaphin alone showed no haemolysis or effect on Vero cell viability, and when combined with ranalexin, did not increase toxicity beyond ranalexin alone, with toxic concentrations for erythrocytes and Vero cells exceeding those needed for antibacterial efficacy in human serum.",20206480,Not available,Not available,Not available
AVR/I/SSAP410,Non-clinical,Ranalexin ,FLGGLIKIVPAMICAVTKKC,20,Not available,Rana catesbeiana,Animalia (Frog),Experimentally validated,VISA 5827,log10 CFU/ML = 8.67(0.44),"Ranalexin caused hemolysis and toxicity to Vero cells at concentrations =>50 mg/L, but combining it with lysostaphin did not increase toxicity beyond that of ranalexin alone, with toxic concentrations exceeding those needed for antibacterial activity in human serum.",20206480,Not available,P39084,Not available
AVR/I/SSAP411,Non-clinical,Ranalexin ,FLGGLIKIVPAMICAVTKKC,20,Not available,Rana catesbeiana,Animalia (Frog),Experimentally validated,VISA 5836,log10 CFU/ML = 8.72(0.16),"Ranalexin caused hemolysis and toxicity to Vero cells at concentrations =>50 mg/L, but combining it with lysostaphin did not increase toxicity beyond that of ranalexin alone, with toxic concentrations exceeding those needed for antibacterial activity in human serum.",20206480,Not available,P39084,Not available
AVR/I/SSAP412,Non-clinical,Lysostaphin,Not available,13,Not available,Staphylococcus simulans,Bacteria,Experimentally validated,VISA 5827,log10 CFU/ML = 9.85(0.06),"Lysostaphin alone showed no haemolysis or effect on Vero cell viability, and when combined with ranalexin, did not increase toxicity beyond ranalexin alone, with toxic concentrations for erythrocytes and Vero cells exceeding those needed for antibacterial efficacy in human serum.",20206480,Not available,Not available,Not available
AVR/I/SSAP413,Non-clinical,Lysostaphin,Not available,13,Not available,Staphylococcus simulans,Bacteria,Experimentally validated,VISA 5836,log10 CFU/ML = 9.65(0.07),"Lysostaphin alone showed no haemolysis or effect on Vero cell viability, and when combined with ranalexin, did not increase toxicity beyond ranalexin alone, with toxic concentrations for erythrocytes and Vero cells exceeding those needed for antibacterial efficacy in human serum.",20206480,Not available,Not available,Not available
AVR/I/SSAP414,Non-clinical,Lysostaphin,Not available,13,Not available,Staphylococcus simulans,Bacteria,Experimentally validated,VISA Mu3,log10 CFU/ML = 9.64(0.04),"Lysostaphin alone showed no haemolysis or effect on Vero cell viability, and when combined with ranalexin, did not increase toxicity beyond ranalexin alone, with toxic concentrations for erythrocytes and Vero cells exceeding those needed for antibacterial efficacy in human serum.",20206480,Not available,Not available,Not available
AVR/I/SSAP415,Non-clinical,Lysostaphin,Not available,13,Not available,Staphylococcus simulans,Bacteria,Experimentally validated,VISA Mu50,log10 CFU/ML = 8.48(0.92),"Lysostaphin alone showed no haemolysis or effect on Vero cell viability, and when combined with ranalexin, did not increase toxicity beyond ranalexin alone, with toxic concentrations for erythrocytes and Vero cells exceeding those needed for antibacterial efficacy in human serum.",20206480,Not available,Not available,Not available
AVR/I/SSAP416,Non-clinical,LL-37,LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES,37,cathelicidin found in epithelial cells and neutrophils,Homo sapiens,Animalia (Human),Experimentally validated,ATCC 700699 (VISA),MIC = 64 microM,"Non-specific cytotoxicities (e.g., leukocyte, T-cell, and red blood cell viability).",30120393,2K6O_A,"Q1KLX1, P49913",DB16532
AVR/I/SSAP417,Non-clinical,LL-37,LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES,37,cathelicidin found in epithelial cells and neutrophils,Homo sapiens,Animalia (Human),Experimentally validated,BR-VRSA (VRSA),MIC = 64 microM,"Non-specific cytotoxicities (e.g., leukocyte, T-cell, and red blood cell viability).",30120393,2K6O_A,"Q1KLX1, P49913",DB16532
AVR/I/SSAP418,Non-clinical,LTX-109,Gly-Gly-Glu-Phe-Ile-Lys-Arg-Ile-Lys-Ile-Arg-Gly-Gly,12,Not available,Synthetic peptide,Not available,Experimentally validated,VISA NRS-1,MIC = 4 microG/ML,Non-hemolytic.,22585222,Not available,Not available,DB12711
AVR/I/SSAP419,Non-clinical,LTX-109,Gly-Gly-Glu-Phe-Ile-Lys-Arg-Ile-Lys-Ile-Arg-Gly-Gly,12,Not available,Synthetic peptide,Not available,Experimentally validated,VISA NRS-3,MIC = 2 microG/ML,Non-hemolytic.,22585222,Not available,Not available,DB12711
AVR/I/SSAP420,Non-clinical,LTX-109,Gly-Gly-Glu-Phe-Ile-Lys-Arg-Ile-Lys-Ile-Arg-Gly-Gly,12,Not available,Synthetic peptide,Not available,Experimentally validated,VISA NRS-4,MIC = 2 microG/ML,Non-hemolytic.,22585222,Not available,Not available,DB12711
AVR/I/SSAP421,Non-clinical,LTX-109,Gly-Gly-Glu-Phe-Ile-Lys-Arg-Ile-Lys-Ile-Arg-Gly-Gly,12,Not available,Synthetic peptide,Not available,Experimentally validated,VISA NRS-12,MIC = 4 microG/ML,Non-hemolytic.,22585222,Not available,Not available,DB12711
AVR/I/SSAP422,Non-clinical,LTX-109,Gly-Gly-Glu-Phe-Ile-Lys-Arg-Ile-Lys-Ile-Arg-Gly-Gly,12,Not available,Synthetic peptide,Not available,Experimentally validated,VISA NRS-14,MIC = 4 microG/ML,Non-hemolytic.,22585222,Not available,Not available,DB12711
AVR/I/SSAP423,Non-clinical,LTX-109,Gly-Gly-Glu-Phe-Ile-Lys-Arg-Ile-Lys-Ile-Arg-Gly-Gly,12,Not available,Synthetic peptide,Not available,Experimentally validated,VISA NRS-17,MIC = 2 microG/ML,Non-hemolytic.,22585222,Not available,Not available,DB12711
AVR/I/SSAP424,Non-clinical,LTX-109,Gly-Gly-Glu-Phe-Ile-Lys-Arg-Ile-Lys-Ile-Arg-Gly-Gly,12,Not available,Synthetic peptide,Not available,Experimentally validated,VISA NRS-18,MIC = 2 microG/ML,Non-hemolytic.,22585222,Not available,Not available,DB12711
AVR/I/SSAP425,Non-clinical,LTX-109,Gly-Gly-Glu-Phe-Ile-Lys-Arg-Ile-Lys-Ile-Arg-Gly-Gly,12,Not available,Synthetic peptide,Not available,Experimentally validated,VISA NRS-19,MIC = 2 microG/ML,Non-hemolytic.,22585222,Not available,Not available,DB12711
AVR/I/SSAP426,Non-clinical,LTX-109,Gly-Gly-Glu-Phe-Ile-Lys-Arg-Ile-Lys-Ile-Arg-Gly-Gly,12,Not available,Synthetic peptide,Not available,Experimentally validated,VISA NRS-21,MIC = 4 microG/ML,Non-hemolytic.,22585222,Not available,Not available,DB12711
AVR/I/SSAP427,Non-clinical,LTX-109,Gly-Gly-Glu-Phe-Ile-Lys-Arg-Ile-Lys-Ile-Arg-Gly-Gly,12,Not available,Synthetic peptide,Not available,Experimentally validated,VISA NRS-22,MIC = 2 microG/ML,Non-hemolytic.,22585222,Not available,Not available,DB12711
AVR/I/SSAP428,Non-clinical,LTX-109,Gly-Gly-Glu-Phe-Ile-Lys-Arg-Ile-Lys-Ile-Arg-Gly-Gly,12,Not available,Synthetic peptide,Not available,Experimentally validated,VISA NRS-23,MIC = 2 microG/ML,Non-hemolytic.,22585222,Not available,Not available,DB12711
AVR/I/SSAP429,Non-clinical,LTX-109,Gly-Gly-Glu-Phe-Ile-Lys-Arg-Ile-Lys-Ile-Arg-Gly-Gly,12,Not available,Synthetic peptide,Not available,Experimentally validated,VISA NRS-24,MIC = 2 microG/ML,Non-hemolytic.,22585222,Not available,Not available,DB12711
AVR/I/SSAP430,Non-clinical,LTX-109,Gly-Gly-Glu-Phe-Ile-Lys-Arg-Ile-Lys-Ile-Arg-Gly-Gly,12,Not available,Synthetic peptide,Not available,Experimentally validated,VISA NRS-26,MIC = 4 microG/ML,Non-hemolytic.,22585222,Not available,Not available,DB12711
AVR/I/SSAP431,Non-clinical,LTX-109,Gly-Gly-Glu-Phe-Ile-Lys-Arg-Ile-Lys-Ile-Arg-Gly-Gly,12,Not available,Synthetic peptide,Not available,Experimentally validated,VISA NRS-27,MIC = 2 microG/ML,Non-hemolytic.,22585222,Not available,Not available,DB12711
AVR/I/SSAP432,Non-clinical,LTX-109,Gly-Gly-Glu-Phe-Ile-Lys-Arg-Ile-Lys-Ile-Arg-Gly-Gly,12,Not available,Synthetic peptide,Not available,Experimentally validated,VISA NRS-39,MIC = 4 microG/ML,Non-hemolytic.,22585222,Not available,Not available,DB12711
AVR/I/SSAP433,Non-clinical,LTX-109,Gly-Gly-Glu-Phe-Ile-Lys-Arg-Ile-Lys-Ile-Arg-Gly-Gly,12,Not available,Synthetic peptide,Not available,Experimentally validated,VISA NRS-49,MIC = 4 microG/ML,Non-hemolytic.,22585222,Not available,Not available,DB12711
AVR/I/SSAP434,Non-clinical,LTX-109,Gly-Gly-Glu-Phe-Ile-Lys-Arg-Ile-Lys-Ile-Arg-Gly-Gly,12,Not available,Synthetic peptide,Not available,Experimentally validated,VISA NRS-51,MIC = 2 microG/ML,Non-hemolytic.,22585222,Not available,Not available,DB12711
AVR/I/SSAP435,Non-clinical,LTX-109,Gly-Gly-Glu-Phe-Ile-Lys-Arg-Ile-Lys-Ile-Arg-Gly-Gly,12,Not available,Synthetic peptide,Not available,Experimentally validated,VISA NRS-52,MIC = 4 microG/ML,Non-hemolytic.,22585222,Not available,Not available,DB12711
AVR/I/SSAP436,Non-clinical,LTX-109,Gly-Gly-Glu-Phe-Ile-Lys-Arg-Ile-Lys-Ile-Arg-Gly-Gly,12,Not available,Synthetic peptide,Not available,Experimentally validated,VISA NRS-54,MIC = 4 microG/ML,Non-hemolytic.,22585222,Not available,Not available,DB12711
AVR/I/SSAP437,Non-clinical,LTX-109,Gly-Gly-Glu-Phe-Ile-Lys-Arg-Ile-Lys-Ile-Arg-Gly-Gly,12,Not available,Synthetic peptide,Not available,Experimentally validated,VISA NRS-56,MIC = 4 microG/ML,Non-hemolytic.,22585222,Not available,Not available,DB12711
AVR/I/SSAP438,Non-clinical,LTX-109,Gly-Gly-Glu-Phe-Ile-Lys-Arg-Ile-Lys-Ile-Arg-Gly-Gly,12,Not available,Synthetic peptide,Not available,Experimentally validated,VISA NRS-63,MIC = 4 microG/ML,Non-hemolytic.,22585222,Not available,Not available,DB12711
AVR/I/SSAP439,Non-clinical,LTX-109,Gly-Gly-Glu-Phe-Ile-Lys-Arg-Ile-Lys-Ile-Arg-Gly-Gly,12,Not available,Synthetic peptide,Not available,Experimentally validated,VISA NRS-65,MIC = 4 microG/ML,Non-hemolytic.,22585222,Not available,Not available,DB12711
AVR/I/SSAP440,Non-clinical,LTX-109,Gly-Gly-Glu-Phe-Ile-Lys-Arg-Ile-Lys-Ile-Arg-Gly-Gly,12,Not available,Synthetic peptide,Not available,Experimentally validated,VISA NRS-68,MIC = 2 microG/ML,Non-hemolytic.,22585222,Not available,Not available,DB12711
AVR/I/SSAP441,Non-clinical,LTX-109,Gly-Gly-Glu-Phe-Ile-Lys-Arg-Ile-Lys-Ile-Arg-Gly-Gly,12,Not available,Synthetic peptide,Not available,Experimentally validated,VISA NRS-73,MIC = 2 microG/ML,Non-hemolytic.,22585222,Not available,Not available,DB12711
AVR/I/SSAP442,Non-clinical,LTX-109,Gly-Gly-Glu-Phe-Ile-Lys-Arg-Ile-Lys-Ile-Arg-Gly-Gly,12,Not available,Synthetic peptide,Not available,Experimentally validated,VISA NRS-74,MIC = 4 microG/ML,Non-hemolytic.,22585222,Not available,Not available,DB12711
AVR/I/SSAP443,Non-clinical,LTX-109,Gly-Gly-Glu-Phe-Ile-Lys-Arg-Ile-Lys-Ile-Arg-Gly-Gly,12,Not available,Synthetic peptide,Not available,Experimentally validated,VISA NRS-76,MIC = 4 microG/ML,Non-hemolytic.,22585222,Not available,Not available,DB12711
AVR/I/SSAP444,Non-clinical,LTX-109,Gly-Gly-Glu-Phe-Ile-Lys-Arg-Ile-Lys-Ile-Arg-Gly-Gly,12,Not available,Synthetic peptide,Not available,Experimentally validated,VISA NRS-118,MIC = 4 microG/ML,Non-hemolytic.,22585222,Not available,Not available,DB12711
AVR/I/SSAP445,Non-clinical,LTX-109,Gly-Gly-Glu-Phe-Ile-Lys-Arg-Ile-Lys-Ile-Arg-Gly-Gly,12,Not available,Synthetic peptide,Not available,Experimentally validated,VISA NRS-126,MIC = 4 microG/ML,Non-hemolytic.,22585222,Not available,Not available,DB12711
AVR/I/SSAP446,Non-clinical,LTX-109,Gly-Gly-Glu-Phe-Ile-Lys-Arg-Ile-Lys-Ile-Arg-Gly-Gly,12,Not available,Synthetic peptide,Not available,Experimentally validated,VISA NRS-272,MIC = 2 microG/ML,Non-hemolytic.,22585222,Not available,Not available,DB12711
AVR/I/SSAP447,Non-clinical,LTX-109,Gly-Gly-Glu-Phe-Ile-Lys-Arg-Ile-Lys-Ile-Arg-Gly-Gly,12,Not available,Synthetic peptide,Not available,Experimentally validated,VISA NRS-283,MIC = 4 microG/ML,Non-hemolytic.,22585222,Not available,Not available,DB12711
AVR/I/SSAP448,Non-clinical,LTX-109,Gly-Gly-Glu-Phe-Ile-Lys-Arg-Ile-Lys-Ile-Arg-Gly-Gly,12,Not available,Synthetic peptide,Not available,Experimentally validated,VISA NRS-402,MIC = 2 microG/ML,Non-hemolytic.,22585222,Not available,Not available,DB12711
AVR/I/SSAP449,Non-clinical,LTX-109,Gly-Gly-Glu-Phe-Ile-Lys-Arg-Ile-Lys-Ile-Arg-Gly-Gly,12,Not available,Synthetic peptide,Not available,Experimentally validated,VISA NRS-403,MIC = 2 microG/ML,Non-hemolytic.,22585222,Not available,Not available,DB12711
AVR/I/SSAP450,Non-clinical,LTX-109,Gly-Gly-Glu-Phe-Ile-Lys-Arg-Ile-Lys-Ile-Arg-Gly-Gly,12,Not available,Synthetic peptide,Not available,Experimentally validated,VISA NRS-404,MIC = 4 microG/ML,Non-hemolytic.,22585222,Not available,Not available,DB12711
AVR/I/SSAP451,Non-clinical,LTX-109,Gly-Gly-Glu-Phe-Ile-Lys-Arg-Ile-Lys-Ile-Arg-Gly-Gly,12,Not available,Synthetic peptide,Not available,Experimentally validated,VRSA VRS-1,MIC = 2 microG/ML,Non-hemolytic.,22585222,Not available,Not available,DB12711
AVR/I/SSAP452,Non-clinical,LTX-109,Gly-Gly-Glu-Phe-Ile-Lys-Arg-Ile-Lys-Ile-Arg-Gly-Gly,12,Not available,Synthetic peptide,Not available,Experimentally validated,VRSA VRS-2,MIC = 4 microG/ML,Non-hemolytic.,22585222,Not available,Not available,DB12711
AVR/I/SSAP453,Non-clinical,LTX-109,Gly-Gly-Glu-Phe-Ile-Lys-Arg-Ile-Lys-Ile-Arg-Gly-Gly,12,Not available,Synthetic peptide,Not available,Experimentally validated,VRSA VRS-3a,MIC = 4 microG/ML,Non-hemolytic.,22585222,Not available,Not available,DB12711
AVR/I/SSAP454,Non-clinical,LTX-109,Gly-Gly-Glu-Phe-Ile-Lys-Arg-Ile-Lys-Ile-Arg-Gly-Gly,12,Not available,Synthetic peptide,Not available,Experimentally validated,VRSA VRS-3b,MIC = 4 microG/ML,Non-hemolytic.,22585222,Not available,Not available,DB12711
AVR/I/SSAP455,Non-clinical,LTX-109,Gly-Gly-Glu-Phe-Ile-Lys-Arg-Ile-Lys-Ile-Arg-Gly-Gly,12,Not available,Synthetic peptide,Not available,Experimentally validated,VRSA VRS-4,MIC = 4 microG/ML,Non-hemolytic.,22585222,Not available,Not available,DB12711
AVR/I/SSAP456,Non-clinical,LTX-109,Gly-Gly-Glu-Phe-Ile-Lys-Arg-Ile-Lys-Ile-Arg-Gly-Gly,12,Not available,Synthetic peptide,Not available,Experimentally validated,VRSA VRS-5,MIC = 4 microG/ML,Non-hemolytic.,22585222,Not available,Not available,DB12711
AVR/I/SSAP457,Non-clinical,LTX-109,Gly-Gly-Glu-Phe-Ile-Lys-Arg-Ile-Lys-Ile-Arg-Gly-Gly,12,Not available,Synthetic peptide,Not available,Experimentally validated,VRSA VRS-6,MIC = 4 microG/ML,Non-hemolytic.,22585222,Not available,Not available,DB12711
AVR/I/SSAP458,Non-clinical,LTX-109,Gly-Gly-Glu-Phe-Ile-Lys-Arg-Ile-Lys-Ile-Arg-Gly-Gly,12,Not available,Synthetic peptide,Not available,Experimentally validated,VRSA VRS-7,MIC = 4 microG/ML,Non-hemolytic.,22585222,Not available,Not available,DB12711
AVR/I/SSAP459,Non-clinical,LTX-109,Gly-Gly-Glu-Phe-Ile-Lys-Arg-Ile-Lys-Ile-Arg-Gly-Gly,12,Not available,Synthetic peptide,Not available,Experimentally validated,VRSA VRS-8,MIC = 4 microG/ML,Non-hemolytic.,22585222,Not available,Not available,DB12711
AVR/I/SSAP460,Non-clinical,LTX-109,Gly-Gly-Glu-Phe-Ile-Lys-Arg-Ile-Lys-Ile-Arg-Gly-Gly,12,Not available,Synthetic peptide,Not available,Experimentally validated,VRSA VRS-9,MIC = 4 microG/ML,Non-hemolytic.,22585222,Not available,Not available,DB12711
AVR/I/SSAP461,Non-clinical,LTX-109,Gly-Gly-Glu-Phe-Ile-Lys-Arg-Ile-Lys-Ile-Arg-Gly-Gly,12,Not available,Synthetic peptide,Not available,Experimentally validated,VRSA VRS-10,MIC = 4 microG/ML,Non-hemolytic.,22585222,Not available,Not available,DB12711
AVR/I/SSAP462,Non-clinical,LTX-109,Gly-Gly-Glu-Phe-Ile-Lys-Arg-Ile-Lys-Ile-Arg-Gly-Gly,12,Not available,Synthetic peptide,Not available,Experimentally validated,VRSA VRS-11a,MIC = 4 microG/ML,Non-hemolytic.,22585222,Not available,Not available,DB12711
AVR/I/SSAP463,Non-clinical,LTX-109,Gly-Gly-Glu-Phe-Ile-Lys-Arg-Ile-Lys-Ile-Arg-Gly-Gly,12,Not available,Synthetic peptide,Not available,Experimentally validated,VRSA VRS-11b,MIC = 4 microG/ML,Non-hemolytic.,22585222,Not available,Not available,DB12711
AVR/I/SSAP464,Non-clinical,Gramicidin,VGALAVVVWLWLWLWG,16,Not available,Soil bacterium Bacillus brevis,Bacteria,Experimentally validated,VISA,MIC = Not available,Not available,20654578,Not available,Not available,DB00027
AVR/I/SSAP465,Non-clinical,Polymyxin B,D-Leu-D-Leu-D-Thr-D-Pro-D-Leu-D-Val-D-Val-D-Asp-D-Glu-D-Ile-D-Asn-D-Leu-D-Ala-D-Ala-D-Ala-D-Trp-D-Phe-D-Thr,18,Not available,Bacillus polymyxa,Bacteria,Experimentally validated,VISA,MIC = 10.39 microG/ML,Not available,20654578,Not available,Not available,DB00781
AVR/I/SSAP466,Non-clinical,Colistin,D-Phe-D-Leu-D-Thr-D-Ser-D-Glu-D-Gln-L-Pro-D-Val-D-Val-D-Leu-D-Pro-D-Trp-D-Leu-D-Lys-D-Asn-D-Ala-D-Ala-D-Ala-D-Gly-D-Ser-D-Ser-D-Ala-D-Ala-D-Ala-D-Arg-D-Ser-D-Leu-D-Thr-D-Leu-D-Thr,30,Not available,Bacillus polymyxa,Bacteria,Experimentally validated,VISA,MIC = Not available,Not available,20654578,Not available,Not available,DB00803
AVR/I/SSAP467,Non-clinical,Bacitractin A,L-Asn-D-Asn-D-Ala-L-Ser-D-Asn-L-Gln-D-Val-D-Pro-D-Arg-D-Pro-D-Tyr-D-Thr-D-Phe-L-Thr-D-Pro-L-Thr-D-Thr,17,Not available,Bacillus licheniformis and Bacillus subtilis,Bacteria,Experimentally validated,VISA,MIC = 5.34 microG/ML,Not available,20654578,Not available,Not available,Not available
AVR/I/SSAP468,Non-clinical,Nisin,I-Dhb-A-I-Dhb-I-A-Abu-P-G-A-K-Abu-G-A-L-M-G-A-N-M-K-Abu-A-Abu-A-H-A-S-I-H-V-Dha-K,27,Not available,Lactococcus lactis,Bacteria,Experimentally validated,VISA,MIC = Not available,Not available,20654578,Not available,Not available,Not available
AVR/I/SSAP469,Non-clinical,Hominicin,DmIle-Dhb-Pro-Ala-Dhb-Pro-Phe-Dhb-Pro-Ala-Ile-Thr-Glu-Ile-Dhb-Ala-Ala-Val-Ile-Ala-Dmp,15,Not available,Staphylococcus hominis MBBL 2-9,Bacteria,Experimentally validated,VISA-CCARM 3501,MIC = 3.82 microG/ML,Not available,20654578,Not available,Not available,Not available
AVR/I/SSAP470,Non-clinical,Ranalexin + Lysostaphin,Not available,13,Not available,Conjugate Synthetic Petide,Not available,Experimentally validated,VISA 3700.W,MIC = NIL,"Ranalexin alone caused hemolysis and toxicity to Vero cells at concentrations => 50 mg/L, whereas lysostaphin alone showed no hemolysis or toxicity. The combination of ranalexin and lysostaphin was no more toxic than ranalexin alone and demonstrated non-toxicity and minimal hemolytic activity at antibacterial concentrations.",20206480,Not available,Not available,Not available
AVR/I/SSAP471,Non-clinical,Ranalexin + Lysostaphin,Not available,13,Not available,Conjugate Synthetic Petide,Not available,Experimentally validated,VISA 3759.V,MIC = NIL,"Ranalexin alone caused hemolysis and toxicity to Vero cells at concentrations => 50 mg/L, whereas lysostaphin alone showed no hemolysis or toxicity. The combination of ranalexin and lysostaphin was no more toxic than ranalexin alone and demonstrated non-toxicity and minimal hemolytic activity at antibacterial concentrations.",20206480,Not available,Not available,Not available
AVR/I/SSAP472,Non-clinical,Ranalexin + Lysostaphin,Not available,13,Not available,Conjugate Synthetic Petide,Not available,Experimentally validated,VISA 5827,MIC = NIL,"Ranalexin alone caused hemolysis and toxicity to Vero cells at concentrations => 50 mg/L, whereas lysostaphin alone showed no hemolysis or toxicity. The combination of ranalexin and lysostaphin was no more toxic than ranalexin alone and demonstrated non-toxicity and minimal hemolytic activity at antibacterial concentrations.",20206480,Not available,Not available,Not available
AVR/I/SSAP473,Non-clinical,Ranalexin + Lysostaphin,Not available,13,Not available,Conjugate Synthetic Petide,Not available,Experimentally validated,VISA 5836,MIC = NIL,"Ranalexin alone caused hemolysis and toxicity to Vero cells at concentrations => 50 mg/L, whereas lysostaphin alone showed no hemolysis or toxicity. The combination of ranalexin and lysostaphin was no more toxic than ranalexin alone and demonstrated non-toxicity and minimal hemolytic activity at antibacterial concentrations.",20206480,Not available,Not available,Not available
AVR/I/SSAP474,Non-clinical,Ranalexin + Lysostaphin,Not available,13,Not available,Conjugate Synthetic Petide,Not available,Experimentally validated,VISA Mu3,MIC = NIL,"Ranalexin alone caused hemolysis and toxicity to Vero cells at concentrations => 50 mg/L, whereas lysostaphin alone showed no hemolysis or toxicity. The combination of ranalexin and lysostaphin was no more toxic than ranalexin alone and demonstrated non-toxicity and minimal hemolytic activity at antibacterial concentrations.",20206480,Not available,Not available,Not available
AVR/I/SSAP475,Non-clinical,Ranalexin + Lysostaphin,Not available,13,Not available,Conjugate Synthetic Petide,Not available,Experimentally validated,VISA Mu50,MIC = NIL,"Ranalexin alone caused hemolysis and toxicity to Vero cells at concentrations => 50 mg/L, whereas lysostaphin alone showed no hemolysis or toxicity. The combination of ranalexin and lysostaphin was no more toxic than ranalexin alone and demonstrated non-toxicity and minimal hemolytic activity at antibacterial concentrations.",20206480,Not available,Not available,Not available
AVR/I/SSAP476,Non-clinical,P-113,Ac- A K R His His G Y K R K F His -NH2,12,Not available,Synthetic peptide,Not available,Experimentally validated,VRSA01,MIC = 64 microG/ML,"P-113 exhibited increased toxicity at concentrations greater than 25 microG/mL, causing 10-20% cell death and hemolysis.",32605123,Not available,Not available,DB06763
AVR/I/SSAP477,Non-clinical,P-113,Ac- A K R His His G Y K R K F His -NH2,12,Not available,Synthetic peptide,Not available,Experimentally validated,VRSA02,MIC = 64 microG/ML,"P-113 exhibited increased toxicity at concentrations greater than 25 microG/mL, causing 10-20% cell death and hemolysis.",32605123,Not available,Not available,DB06763
AVR/I/SSAP478,Non-clinical,P-113,Ac- A K R His His G Y K R K F His -NH2,12,Not available,Synthetic peptide,Not available,Experimentally validated,VRSA03,MIC = 64 microG/ML,"P-113 exhibited increased toxicity at concentrations greater than 25 microG/mL, causing 10-20% cell death and hemolysis.",32605123,Not available,Not available,DB06763
AVR/I/SSAP479,Non-clinical,Phe-P-113,Ac- A K R Phe Phe G Y K R K F Phe -NH2,12,Not available,Synthetic peptide,Not available,Experimentally validated,VRSA01,MIC = 64 microG/ML,"Phe-P-113 exhibited low toxicity and hemolytic activity. It caused minimal cell death and hemolysis, indicating a favorable safety profile compared to other peptides with bulkier hydrophobic side chains.",32605123,Not available,Not available,Not available
AVR/I/SSAP480,Non-clinical,Phe-P-113,Ac- A K R Phe Phe G Y K R K F Phe -NH2,12,Not available,Synthetic peptide,Not available,Experimentally validated,VRSA02,MIC = 64 microG/ML,"Phe-P-113 exhibited low toxicity and hemolytic activity. It caused minimal cell death and hemolysis, indicating a favorable safety profile compared to other peptides with bulkier hydrophobic side chains.",32605123,Not available,Not available,Not available
AVR/I/SSAP481,Non-clinical,Phe-P-113,Ac- A K R Phe Phe G Y K R K F Phe -NH2,12,Not available,Synthetic peptide,Not available,Experimentally validated,VRSA03,MIC = 64 microG/ML,"Phe-P-113 exhibited low toxicity and hemolytic activity. It caused minimal cell death and hemolysis, indicating a favorable safety profile compared to other peptides with bulkier hydrophobic side chains.",32605123,Not available,Not available,Not available
AVR/I/SSAP482,Non-clinical,"beta-(4, 4'-biphenyl)alanine (Bip-P-113)",Ac- A K R Bip Bip G Y K R K F Bip -NH2,9,Not available,Synthetic peptide,Not available,Experimentally validated,VRSA01,MIC = 16 microG/ML,"At concentrations higher than 25 microG/mL, Bip-P-113 caused increased toxicity, 10-20% cell death and hemolysis. However, in an in vivo endotoxemia mouse model, no adverse effects were observed at a dose of 10 mg/kg (0.2 mg/mouse).",32605123,Not available,Not available,Not available
AVR/I/SSAP483,Non-clinical,"beta-(4, 4'-biphenyl)alanine (Bip-P-113)",Ac- A K R Bip Bip G Y K R K F Bip -NH2,9,Not available,Synthetic peptide,Not available,Experimentally validated,VRSA02,MIC = 16 microG/ML,"At concentrations higher than 25 microG/mL, Bip-P-113 caused increased toxicity, 10-20% cell death and hemolysis. However, in an in vivo endotoxemia mouse model, no adverse effects were observed at a dose of 10 mg/kg (0.2 mg/mouse).",32605123,Not available,Not available,Not available
AVR/I/SSAP484,Non-clinical,"beta-(4, 4'-biphenyl)alanine (Bip-P-113)",Ac- A K R Bip Bip G Y K R K F Bip -NH2,9,Not available,Synthetic peptide,Not available,Experimentally validated,VRSA03,MIC = 8 microG/ML,"At concentrations higher than 25 microG/mL, Bip-P-113 caused increased toxicity, 10-20% cell death and hemolysis. However, in an in vivo endotoxemia mouse model, no adverse effects were observed at a dose of 10 mg/kg (0.2 mg/mouse).",32605123,Not available,Not available,Not available
AVR/I/SSAP485,Non-clinical,beta-diphenylalanine (Dip-P-113),Ac- A K R Dip Dip G Y K R K F Dip -NH2,9,Not available,Synthetic peptide,Not available,Experimentally validated,VRSA01,MIC = 32 microG/ML,"Dip-P-113 with bulky hydrophobic side chains caused 10-20% cell death and hemolysis at concentrations above 25microg/mL, but no adverse effects were observed in an in vivo endotoxemia mouse model treated with 10 mg/kg of Dip-P-113.",32605123,Not available,Not available,Not available
AVR/I/SSAP486,Non-clinical,beta-diphenylalanine (Dip-P-113),Ac- A K R Dip Dip G Y K R K F Dip -NH2,9,Not available,Synthetic peptide,Not available,Experimentally validated,VRSA02,MIC = 32 microG/ML,"Dip-P-113 with bulky hydrophobic side chains caused 10-20% cell death and hemolysis at concentrations above 25microg/mL, but no adverse effects were observed in an in vivo endotoxemia mouse model treated with 10 mg/kg of Dip-P-113.",32605123,Not available,Not available,Not available
AVR/I/SSAP487,Non-clinical,beta-diphenylalanine (Dip-P-113),Ac- A K R Dip Dip G Y K R K F Dip -NH2,9,Not available,Synthetic peptide,Not available,Experimentally validated,VRSA03,MIC = 32 microG/ML,"Dip-P-113 with bulky hydrophobic side chains caused 10-20% cell death and hemolysis at concentrations above 25microg/mL, but no adverse effects were observed in an in vivo endotoxemia mouse model treated with 10 mg/kg of Dip-P-113.",32605123,Not available,Not available,Not available
AVR/I/SSAP488,Non-clinical,beta-naphthylalanine (Nal-P-113),Ac- A K R Nal Nal G Y K R K F Nal -NH2,9,Not available,Synthetic peptide,Not available,Experimentally validated,VRSA01,MIC = 32 microG/ML,"Nal-P-113, a peptide with bulky hydrophobic side chains, exhibited increased cell toxicity and hemolytic activity at higher concentrations (> 25 microG/mL), causing 10-20% cell death and hemolysis. This was in comparison to controls, indicating a potential concern for toxicity at elevated doses.",32605123,Not available,Not available,Not available
AVR/I/SSAP489,Non-clinical,beta-naphthylalanine (Nal-P-113),Ac- A K R Nal Nal G Y K R K F Nal -NH2,9,Not available,Synthetic peptide,Not available,Experimentally validated,VRSA02,MIC = 32 microG/ML,"Nal-P-113, a peptide with bulky hydrophobic side chains, exhibited increased cell toxicity and hemolytic activity at higher concentrations (> 25 microG/mL), causing 10-20% cell death and hemolysis. This was in comparison to controls, indicating a potential concern for toxicity at elevated doses.",32605123,Not available,Not available,Not available
AVR/I/SSAP490,Non-clinical,beta-naphthylalanine (Nal-P-113),Ac- A K R Nal Nal G Y K R K F Nal -NH2,9,Not available,Synthetic peptide,Not available,Experimentally validated,VRSA03,MIC = 32 microG/ML,"Nal-P-113, a peptide with bulky hydrophobic side chains, exhibited increased cell toxicity and hemolytic activity at higher concentrations (> 25 microG/mL), causing 10-20% cell death and hemolysis. This was in comparison to controls, indicating a potential concern for toxicity at elevated doses.",32605123,Not available,Not available,Not available
AVR/I/SSAP491,Non-clinical,P138C,Gly-Leu-Glu-Glu-Thr-Val-Tyr-Ile-Tyr-Gly-Ala-Asn-Met-X-Ser,14,Not available,Bacillus subtilis CSB138,Bacteria,Experimentally validated,VRSA,MIC = 20 microG/ML ,Not available,28581021,Not available,Not available,Not available
